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ABSTRACT 
RhoJ is an endothelial expressed Rho GTPase, and its knock-down impairs endothelial cell 
(EC) migration and tubulogenesis, increases stress fibre (SF) and focal adhesion (FA) 
numbers. This work aimed to determine the intracellular localisation of RhoJ, identify its 
binding partners, test how it is activated and further explore its function in ECs. 
Endogenous RhoJ localised to FAs and overexpression of its active mutant (daRhoJ) 
promoted EC migration, and diminished FA and SF numbers. In addition to FAs, 
overexpressed RhoJ localised also to endosomes and RhoJ knock-down slightly delayed 
transferrin recycling. Vascular endothelial growth factor (VEGF), fibroblast growth factor 2 
(FGF-2) and thrombin activated RhoJ in ECs. PAK-interacting exchange factor β (βPIX) and 
G protein-coupled receptor kinase-interacting target 1 (GIT1), which promote FA 
disassembly, were identified as RhoJ-binding partners. RhoJ co-localised with these proteins 
in ECs, and βPIX knock-down and to a lesser extent GIT1 knock-down reduced RhoJ 
localisation to FAs. Overexpression of daRhoJ increased the amount of GIT1 and βPIX in 
FAs, and increased the total amount of the βPIX protein in ECs.  
In conclusion, RhoJ localises to FAs, promotes EC migration, regulates FA and SF numbers, 
interacts with βPIX and GIT1 and is activated by pro-angiogenic factors. 
 
 
 
 ii 
 
ACKNOWLEDGEMENTS 
Firstly and foremost, I would like to express my sincere gratitude to my supervisor, Dr 
Victoria Heath. Thank you for all your friendship, support, advice, love to the science and 
invaluable experience that you shared with me. Huge thanks for your patience in convincing 
me that the glass is half full and not half empty. It was a great honour to be your student.  
I would like to thank to my second supervisor, Prof. Roy Bicknell. I extremely appreciate all 
your help, guidance and support given to me during these studies. It was a great pleasure and 
a privilege to work in your team. Huge thanks go also to all the members of The Molecular 
Angiogenesis Group, both present and past. Thank you for the great time we spent together in 
the lab and for lots of joy during the lunch-time cross-word sessions. I extremely enjoyed 
working with all of you. Thank you to Sarah, Ana and Roman for the English support during 
this thesis writing. 
Sincere thanks goes to all the members of Prof. John Heath’s, Dr Neil Hotchin’s, Dr Mike 
Tomlinson’s and Dr Josh Rappoport’s groups from the School of Biosciences. I truly enjoyed 
our common lab meetings, thank you for all your help and advice. Particularly, I would like to 
acknowledge Prof. John Heath for offering the collaboration on the mass spec project. This 
extremely raised the value of the results that I achieved during these studies and helped to 
take my work forward. My special thank you goes also to Dr Neil Hotchin for his invaluable 
advices.  
I also thank to my parents, for their love and support. Huge thanks to Paula and Piotr for their 
friendship and time that we spent together. And finally, I would like to thank to my husband, 
Mirek, for his presence, support and endless optimism. I dedicate this thesis to you. 
 iii 
 
TABLE OF CONTENTS 
ABSTRACT ......................................................................................................................................................... I 
ACKNOWLEDGEMENTS .................................................................................................................................... II 
TABLE OF CONTENTS ....................................................................................................................................... III 
LIST OF FIGURES .............................................................................................................................................. VI 
LIST OF TABLES .............................................................................................................................................. VII 
ABBREVIATIONS ........................................................................................................................................... VIII 
1. INTRODUCTION ...................................................................................................................................... 1 
1.1. ENDOTHELIAL CELLS IN ANGIOGENESIS ........................................................................................................... 2 
1.2. RHO GTPASE FAMILY ................................................................................................................................. 5 
1.2.1. Structure of Rho GTPases ................................................................................................................ 5 
1.2.2. Regulation of Rho GTPase activation cycle ...................................................................................... 8 
1.2.2.1. GEFs ........................................................................................................................................................ 8 
1.2.2.2. GAPs ..................................................................................................................................................... 12 
1.2.2.3. GDIs ...................................................................................................................................................... 13 
1.2.3. General functions of Rho GTPases ................................................................................................. 13 
1.2.4. Main effectors of Rho GTPases ...................................................................................................... 17 
1.2.5. Role of Rho GTPases in angiogenesis ............................................................................................. 20 
1.2.5.1. Rho GTPases in vascular permeability .................................................................................................. 20 
1.2.5.2. Rho GTPases in ECM remodelling ........................................................................................................ 21 
1.2.5.3. Rho GTPases in endothelial cell migration ........................................................................................... 22 
1.2.5.4. Rho GTPases and endothelial cell proliferation ................................................................................... 23 
1.2.5.5. Rho GTPases in stabilisation and survival of newly formed capillaries ................................................ 23 
1.2.6. RhoJ ............................................................................................................................................... 25 
1.2.6.1. RhoJ in endothelial cells ....................................................................................................................... 27 
1.3. ACTIN CYTOSKELETON AND FOCAL ADHESIONS IN CELLS ................................................................................... 28 
1.3.1. Actin cytoskeleton .......................................................................................................................... 28 
1.3.2. Focal adhesions ............................................................................................................................. 30 
1.3.3. Actomyosin contractility and focal adhesion turnover – involvement of Rho GTPases ................. 34 
1.3.4. Focal adhesions and stress fibres in endothelial cells in vivo ......................................................... 35 
1.4. ENDOCYTOSIS ......................................................................................................................................... 36 
1.5. THE GIT/PIX COMPLEX ............................................................................................................................ 38 
1.5.1. Domain organisation of PIX proteins ............................................................................................. 38 
1.5.1. Domain organisation of GIT proteins ............................................................................................. 39 
1.5.2. Functions of PIX and GIT ................................................................................................................ 41 
1.5.3. The GIT/PIX complex in endothelial cells ....................................................................................... 44 
1.6. AIM OF THE STUDY ................................................................................................................................... 46 
2. MATERIALS AND METHODS ................................................................................................................... 46 
2.1. REAGENTS AND EQUIPMENT ...................................................................................................................... 47 
2.2. COMMON BUFFERS .................................................................................................................................. 47 
2.3. ANTIBODIES ........................................................................................................................................... 50 
2.4. DNA OLIGONUCLEOTIDES ......................................................................................................................... 53 
2.5. PLASMIDS .............................................................................................................................................. 56 
2.6. SIRNA DUPLEXES ..................................................................................................................................... 59 
2.7. MAMMALIAN CELL CULTURE ...................................................................................................................... 60 
2.7.1. Mammalian cells and media.......................................................................................................... 60 
2.7.2. Passaging cells ............................................................................................................................... 61 
2.7.3. Counting cells ................................................................................................................................. 61 
2.7.4. Freezing and storing cells .............................................................................................................. 62 
2.8. BACTERIA STRAINS, MEDIA AND ANTIBIOTICS ................................................................................................. 62 
2.9. MANIPULATION OF DNA MATERIAL ............................................................................................................ 62 
2.9.1. Cloning ........................................................................................................................................... 62 
2.9.1.1. Production and purification of plasmids .............................................................................................. 64 
 iv 
 
2.9.1.2. Amplification of insert by PCR .............................................................................................................. 64 
2.9.1.3. PCR quick DNA purification .................................................................................................................. 64 
2.9.1.4. Digestion of DNA with restriction enzymes .......................................................................................... 64 
2.9.1.5. DNA gel electrophoresis ....................................................................................................................... 65 
2.9.1.6. DNA gel purification ............................................................................................................................. 65 
2.9.1.7. DNA ligations ........................................................................................................................................ 65 
2.9.1.8. Heat-shock transformation of bacteria ................................................................................................ 65 
2.9.1.9. Colony- PCR screen .............................................................................................................................. 66 
2.9.1.10. Sequencing and storing of plasmids ..................................................................................................... 66 
2.9.2. Site-directed mutagenesis ............................................................................................................. 66 
2.10. ANALYSIS OF PROTEINS ............................................................................................................................. 67 
2.10.1. Protein production and purification .......................................................................................... 67 
2.10.2. Preparation of mammalian cell lysates .................................................................................... 69 
2.10.3. Protein quantification ............................................................................................................... 69 
2.10.4. SDS-PAGE .................................................................................................................................. 70 
2.10.5. Western blotting ....................................................................................................................... 70 
2.10.6. Comparing the protein levels of endogenous Rho GTPases in HUVECs .................................... 71 
2.11. PULL-DOWN AND IDENTIFICATION OF RHOJ-BINDING PARTNERS ....................................................................... 73 
2.11.1. Pull-down of RhoJ-binding partners from cellular lysates ......................................................... 73 
2.11.2. Preparation of samples for mass spectrometry ........................................................................ 74 
2.11.3. Mass spectrometry ................................................................................................................... 75 
2.12. YEAST-TWO-HYBRID ................................................................................................................................. 76 
2.12.1. Yeast strain and media ............................................................................................................. 76 
2.12.2. Yeast-two-hybrid method ......................................................................................................... 77 
2.12.3. Yeast transformation ................................................................................................................ 78 
2.13. DEVELOPMENT OF RHOJ POLYCLONAL ANTIBODIES ......................................................................................... 79 
2.13.1. Production of polyclonal RhoJ antibodies in rabbits ................................................................. 79 
2.13.2. Purification of polyclonal RhoJ antibodies from rabbit antiserum ............................................ 79 
2.14. PLASMID TRANSFECTIONS OF MAMMALIAN CELLS ........................................................................................... 81 
2.14.1. Calcium-phosphate transfection of HEK 293Ts ......................................................................... 81 
2.14.2. TransPass D2 transfection of HUVECs ....................................................................................... 81 
2.15. LENTIVIRUS INFECTIONS OF HUVECS .......................................................................................................... 82 
2.15.1. Production of lentivirus ............................................................................................................. 82 
2.15.2. Infection of HUVECs .................................................................................................................. 82 
2.16. KNOCK-DOWN OF GENES USING SIRNA ....................................................................................................... 83 
2.17. ENDOCYTOSIS ASSAYS ............................................................................................................................... 83 
2.17.1. Trafficking of transferrin receptor in HUVECs ........................................................................... 83 
2.17.2. Testing the surface levels of VEGFR2 in HUVECs ....................................................................... 84 
2.18. IMMUNOFLUORESCENCE ........................................................................................................................... 85 
2.19. TESTING THE FUNCTIONS OF ENDOTHELIAL CELLS EXPRESSING DOMINANT ACTIVE RHOJ ......................................... 87 
2.19.1. Scratch wound assay ................................................................................................................. 87 
2.19.2. Analysis of focal adhesions and stress fibres ............................................................................ 88 
2.19.3. Organotypic tube forming assay ............................................................................................... 88 
2.20. EXAMINING THE LOCALISATION OF RHOJ, GIT1 AND ΒPIX TO FOCAL ADHESIONS ................................................. 89 
2.21. RHOJ ACTIVATION ASSAY ........................................................................................................................... 89 
2.21.1. Optimisation of RhoJ-GTP pull-down ........................................................................................ 89 
2.21.1.1. Preparation of cellular lysate for GTP/GDP loading on Rho GTPases ................................................... 89 
2.21.1.2. Preparation of GST-CRIB beads ............................................................................................................ 90 
2.21.1.3. GTP/GDP loading on Rho GTPases and pull-down ............................................................................... 90 
2.21.2. Measuring RhoJ activation after VEGFA, FGF-2 and thrombin stimulation .............................. 91 
2.22. STATISTICAL ANALYSES .............................................................................................................................. 92 
2.23. PREPARATION OF FIGURES ......................................................................................................................... 92 
3. INTRACELLULAR LOCALISATION AND FUNCTION OF RHOJ IN ENDOTHELIAL CELLS ................................ 93 
3.1. INTRA-CELLULAR LOCALISATION, EXPRESSION AND KNOWN FUNCTIONS OF RHOJ .................................................. 94 
3.2. COMPARISON OF RHOJ, CDC42 AND RAC1 PROTEINS IN HUVECS.................................................................... 97 
3.3. PRODUCTION AND PURIFICATION OF RHOJ POLYCLONAL ANTIBODIES ................................................................. 99 
 v 
 
3.3.1. Testing the specificity of RhoJ antibodies in western blotting ....................................................... 99 
3.3.2. Testing the purified polyclonal rabbit RhoJ antibody for immunofluorescence ........................... 101 
3.4. LOCALISATION OF ENDOGENOUS RHOJ TO FAS ............................................................................................ 103 
3.5. LOCALISATION OF OVEREXPRESSED RHOJ TO VESICLES AND FAS ...................................................................... 106 
3.6. TESTING THE ROLE OF DOMINANT ACTIVE RHOJ IN ENDOTHELIAL CELL MOTILITY ................................................. 109 
3.6.1. Dominant active RhoJ promotes endothelial cell tube branching ............................................... 112 
3.6.2. Dominant active RhoJ increases cell migration ........................................................................... 114 
3.6.3. Dominant active RhoJ decreases the numbers of FAs and SFs in migrating cells ........................ 114 
3.7. THE ROLE OF RHOJ IN AN ENDOCYTOSIS OF TRANSFERRIN RECEPTOR IN ENDOTHELIAL CELLS .................................. 117 
3.8. TESTING AN INFLUENCE OF RHOJ KNOCK-DOWN ON THE SURFACE LEVELS OF VEGFR2 IN HUVECS ...................... 119 
3.9. DISCUSSION ......................................................................................................................................... 121 
4. IDENTIFICATION OF RHOJ BINDING PARTNERS IN ENDOTHELIAL CELLS ............................................... 126 
4.1. RHOJ BINDING PARTNERS ........................................................................................................................ 127 
4.2. PULL-DOWN OF RHOJ BINDING PARTNERS AND THEIR IDENTIFICATION BY MASS SPECTROMETRY ............................ 129 
4.3. CONFIRMATION OF THE INTERACTIONS BETWEEN RHOJ AND PULLED-DOWN PROTEINS ........................................ 133 
4.4. FURTHER INVESTIGATION OF RHOJ INTERACTIONS WITH GIT1 AND ΒPIX PROTEINS ............................................. 138 
4.4.1. Mapping the GIT1 domain that interacts with RhoJ .................................................................... 138 
4.4.2. Testing co-localisation of RhoJ with βPix and GIT1 in HUVECs .................................................... 140 
4.4.3. Testing the interdependence in the localisation of RhoJ, βPIX and GIT1 to FAs .......................... 140 
4.5. DISCUSSION ......................................................................................................................................... 159 
5. RHOJ ACTIVATION IN ENDOTHELIAL CELLS........................................................................................... 164 
5.1. RHOJ ACTIVATION ................................................................................................................................. 165 
5.2. OPTIMISATION OF AN ASSAY FOR THE PULL-DOWN OF ACTIVE RHOJ IN ECS ....................................................... 167 
5.3. RHOJ ACTIVATION BY PRO-ANGIOGENIC STIMULI .......................................................................................... 171 
5.4. DISCUSSION ......................................................................................................................................... 177 
6. GENERAL DISCUSSION ......................................................................................................................... 180 
LIST OF REFERENCES ..................................................................................................................................... 190 
APPENDIX: RE-PRINT OF THE THESIS-RELATED PUBLICATION ....................................................................... 205 
 
 vi 
 
LIST OF FIGURES 
FIG. 1.1 STAGES OF ANGIOGENESIS.   ................................................................................................................................. 3
FIG. 1.2 RHOJ IS A MEMBER OF RHO GTPASE FAMILY.   ........................................................................................................ 6
FIG. 1.3 DOMAIN ORGANISATION OF RHO GTPASES.   .......................................................................................................... 7
FIG. 1.4 CONFORMATIONAL CHANGES OF RAS AS A RESULT OF BINDING WITH GTP OR GDP.  ...................................................... 9
FIG. 1.5 MODE OF ACTIVATION OF TYPICAL RHO GTPASES.   ................................................................................................ 10
FIG. 1.6 MAIN EFFECTORS OF RHO GTPASES.   .................................................................................................................. 19
FIG. 1.7 REGULATION OF THE ACTOMYSOIN CYTOSKELETON AND FOCAL ADHESIONS DURING CELL MIGRATION.   ............................. 31
FIG. 1.8 MAIN COMPONENTS OF FOCAL ADHESIONS AND THEIR CONNECTION TO THE ACTOMYOSIN FILAMENTS.   ........................... 32
FIG. 1.9 DOMAIN ORGANISATION OF GIT AND PIX PROTEINS.   ............................................................................................ 40
FIG. 2.1 CLONING PROCESS.   ......................................................................................................................................... 63
FIG. 3.1 QUANTITATION OF RHOJ, CDC42 AND RAC1 PROTEIN LEVELS IN HUVEC.   ................................................................ 98
FIG. 3.2 TESTING THE SPECIFICITY OF RHOJ ANTIBODIES AND SIRNA DUPLEXES.   ................................................................... 100
FIG. 3.3 TESTING THE PURIFIED POLYCLONAL RHOJ ANTIBODY IN IMMUNOFLUORESCENCE.   ..................................................... 102
FIG. 3.4 RHOJ LOCALISES TO FOCAL ADHESIONS, CO-LOCALISING WITH VINCULIN, TALIN AND PFAK IN HUVECS CULTURED ON 
GELATIN-COATED COVERSLIPS.   ........................................................................................................................... 104
FIG. 3.5 RHOJ LOCALISES TO FOCAL ADHESIONS, CO-LOCALISING WITH VINCULIN, TALIN AND PFAK IN HUVECS CULTURED ON 
MATRIGEL-COATED COVERSLIPS.   ........................................................................................................................ 105
FIG. 3.6 OVEREXPRESSED GFP-RHOJ LOCALISES TO ENDOSOMES AND LYSOSOMES IN HUVECS.   ............................................. 107
FIG. 3.7 OVEREXPRESSED MYC-RHOJ LOCALISES TO ENDOSOMES AND LYSOSOMES IN HUVECS.   .............................................. 108
FIG. 3.8 STABLE EXPRESSION OF GFP-WTRHOJ AND GFP-DARHOJ IN HUVECS.   ................................................................. 110
FIG. 3.9 LENTIVIRALLY TRANSDUCED GFP-RHOJ LOCALISES TO VESICLES AND FOCAL ADHESIONS IN HUVECS.   ............................ 111
FIG. 3.10 DOMINANT ACTIVE RHOJ CHANGES HUVECS MORPHOLOGY AND PROMOTES ENDOTHELIAL TUBE BRANCHING.   ............ 113
FIG. 3.11 DOMINANT ACTIVE RHOJ PROMOTES HUVECS MIGRATION IN THE SCRATCH WOUND ASSAY.   .................................... 115
FIG. 3.12 DOMINANT ACTIVE RHOJ DECREASES THE NUMBERS OF FOCAL ADHESIONS AND STRESS FIBRES IN MIGRATING ENDOTHELIAL 
CELLS.   ........................................................................................................................................................... 116
FIG. 3.13 RHOJ SIRNA SILENCING DELAYS TF RELEASE IN HUVECS.   .................................................................................. 118
FIG. 3.14 RHOJ SIRNA SILENCING DOES NOT AFFECT THE VEGFR2 SURFACE DISTRIBUTION IN HUVECS.   ................................. 120
FIG. 4.1 PULL-DOWN OF GAPS, GEFS AND EFFECTORS OF RHOJ.   ...................................................................................... 130
FIG. 4.2 COMPARISON OF THE INTERACTIONS BETWEEN RHOJ AND CANDIDATE PROTEINS.   ..................................................... 135
FIG. 4.3 WESTERN BLOT CONFIRMING THE PULL-DOWN OF GIT1 AND ΒPIX WITH GST-DARHOJ.   ............................................ 137
FIG. 4.4 MAPPING OF THE GIT1 DOMAIN THAT INTERACTS WITH RHOJ.   ............................................................................. 139
FIG. 4.5 GFP-RHOJ CO-LOCALISES WITH ΒPIX IN HUVECS.   ............................................................................................. 141
FIG. 4.6 GFP-RHOJ CO-LOCALISES WITH GIT1 IN HUVECS.   ............................................................................................ 142
FIG. 4.7 DOMINANT ACTIVE RHOJ INCREASES THE LEVEL OF ΒPIX PROTEIN.   .......................................................................... 143
FIG. 4.8 WESTERN BLOTS SHOWING SIRNA KNOCK-DOWNS OF ΒPIX, GIT1 AND RHOJ.   ........................................................ 145
FIG. 4.9 THE INFLUENCE OF ΒPIX- OR GIT1-SIRNA SILENCING ON THE LOCALISATION OF RHOJ TO FOCAL ADHESIONS.   ................ 146
FIG. 4.10 THE INFLUENCE OF RHOJ- OR GIT1-SIRNA SILENCING ON THE LOCALISATION OF ΒPIX TO FOCAL ADHESIONS.   .............. 150
FIG. 4.11 THE INFLUENCE OF RHOJ- OR ΒPIX-SIRNA SILENCING ON THE LOCALISATION OF GIT1 TO FOCAL ADHESIONS.   .............. 154
FIG. 5.1 OPTIMISATION OF GTP/GDP LOADING ON RHOJ.   .............................................................................................. 168
FIG. 5.2 COMPARISON OF PULL-DOWN OF GTP-LOADED RHOJ, CDC42 AND RAC1 FROM HUVEC LYSATES BY CRIB DOMAINS FROM 
WASP AND PAK.   ........................................................................................................................................... 169
FIG. 5.3 GTP/GDP LOADING ON ENDOGENOUS RHOJ IN HMEC-1 AND ON HA-RHOJ EXPRESSED IN HEK 293TS.   .................... 170
FIG. 5.4 TESTING THE LEVELS OF BASAL ACTIVE RHOJ AND CDC42 IN HUVECS.   ................................................................... 172
FIG. 5.5 ACTIVATION OF RHOJ AND CDC42 BY VEGF-A IN HUVECS.   ................................................................................ 174
FIG. 5.6 ACTIVATION OF RHOJ AND CDC42 BY FGF-2 IN HUVECS.   .................................................................................. 175
FIG. 5.7 ACTIVATION OF RHOJ AND CDC42 BY THROMBIN IN HUVECS.   ............................................................................. 176
FIG. 6.1 LOCALISATION AND FUNCTION OF RHOJ IN ECS.   ................................................................................................. 182
 
 vii 
 
LIST OF TABLES 
TAB. 2.1 COMMON BUFFERS……………………………………………………….…………………..…………………………………48 
TAB. 2.2 PRIMARY ANTIBODIES……………………………………………………………………………………………………….....50 
TAB. 2.3 SECONDARY ANTIBODIES…………………………………………………………………………………………………..….52 
TAB. 2.4 DNA OLIGONUCLEOTIDES USED FOR CLONING, SEQUENCING OR MUTAGENESIS…………………….....53 
TAB. 2.5 CLONED DNA CONSTRUCTS……………………………………………….………………………………………………...56 
TAB. 2.6 OTHER PLASMIDS…………………………………………………………………….…………………………………………..58 
TAB. 2.7 SIRNA DUPLEXES………………………………………………………………….……………………………………………...59 
TAB. 4.1 MASS SPECTROMETRY RESULTS SHOWING POTENTIAL RHOJ-BINDING PROTEINS………….…………..131 
TAB. 4.2 RHOJ-BINDING PROTEIN CANDIDATES TESTED IN THE Y2H ASSAY…………………………………………...133 
TAB. 4.3 SUMMARY OF THE EFFECT OF RHOJ, ΒPIX OR GIT1 KNOCK-DOWN AND OVEREXPRESSION OF    
DARHOJ ON RECRUITMENT OF THESE PROTEINS TO FAS…………………………………………………..………………….158 
 
 viii 
 
ABBREVIATIONS 
aa – amino acids 
Amp - ampicillin 
Arp2/3 – a seven subunit complex comprising actin-related proteins 2 and 3  
BSA – bovine serum albumin 
CC – coiled-coil region 
Chloramph – chloramphenicol  
CRIB domain – Cdc42/Rac1-interacting binding domain 
da – dominant active 
DH – Dbl homology domain 
DMEM – Dulbecco’s Modified Eagle’s Medium 
dn – dominant negative  
E. coli – Escherichia coli 
EC(s) – endothelial cell(s) 
ECM – extracellular matrix 
EE/ES – early/sorting endosomes 
ERK1/2 – extracellular signal-regulated kinase 1/2 
FACS – fluorescence activated cell sorting 
F-actin – filamentous actin 
FAH – focal adhesion targeting homology domain 
FAK – focal adhesion kinase 
FA(s) – focal adhesion(s) 
FCS – fetal calf serum 
FGF-2 – fibroblast growth factor 2; also called basic FGF (bFGF)  
FITC – fluorescein-5-isothiocyanate 
G-actin – globular actin 
GAP(s) – GTPase activating protein(s) 
GDI(s) – guanine nucleotide dissociation inhibitor(s) 
GDP – guanosine-5'-biphosphate   
GEF(s) – guanine nucleotide exchange factor(s) 
GIT1– G protein-coupled receptor kinase-interacting target 1 
GPCR(s) – G protein-coupled receptor(s) 
GST – glutathione-S-transferase 
GTP – guanosine-5'-triphosphate 
H – hour  
HBS – HEPES-buffered saline 
HEK 293T(s) - human embryonic kidney 293T cell(s) 
HMEC-1 – human microvascular endothelial cell line-1 
HRP – horseradish peroxidase 
HUVEC(s) – human umbilical vein endothelial cell(s) 
IF – immunofluorescence  
IRSp53 – insulin receptor tyrosine kinase substrate p53 
Kan – kanamycin 
LB broth/agar– Luria Bertani broth/agar 
LIMK – LIM motif containing protein kinase 
MBP – maltose binding protein 
 ix 
 
mDia – mammalian Diaphanous formin 
MLC – myosin light chain 
MLCK – myosin light chain kinase 
MLCP – myosin light chain phosphatase 
MMP – matrix-metalloproteinase 
MRCK, A or B – myotonic dystrophy kinase-related Cdc42-binding kinase A or B 
NM II – non-muscle myosin II 
N-WASP – neural-Wiskott-Aldrich syndrome protein 
PAK – p21-activated kinase 
PBS – phosphate-buffered saline 
PCR – polymerase chain reaction 
PH – pleckstrin homology domain 
PIX, α or β – PAK-interacting exchange factor α or β 
PI3K – phosphatidylinositol 3-kinase  
pMLC – phosphorylated myosin light chain 
ROCK – Rho-associated coiled coil kinase 
RTK(s) – receptor tyrosine kinase(s) 
SDS-PAGE – sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
SF(s) – stress fibre(s) 
SHD – yeast Spa2 homology domain 
SH3 – Src homology 3 domain  
TBS – tris-buffered saline 
TBST – tris-buffered saline tween 
Tf – transferrin 
TNF-α – tumor necrosis factor-α 
VEGF – vascular endothelial growth factor  
VEGFR – vascular endothelial growth factor receptor 
WASP – Wiskott-Aldrich syndrome protein  
WAVE – Wiskott-Aldrich syndrome protein-family verprolin homologous protein 
WB – western blotting 
wt – wild type 
w/v – weight per volume 
v/v – volume per volume 
Y2H – yeast-two-hybrid 
 1 
 
 
 
1. INTRODUCTION 
 
     1. INTRODUCTION 
2 
 
1.1. Endothelial cells in angiogenesis 
Endothelial cells (ECs) line the inner wall of blood and lymphatic vessels. Both circulation 
systems are important for homeostasis in the healthy organism as they mediate an exchange of 
gases, liquids and nutrients to the adjacent tissues as well as transportation of various cells 
within the organism (Adams and Alitalo 2007). Disruption of vascular or lymphatic systems 
leads to severe pathologies such as tissue ischemia or oedema (Carmeliet 2003; Alitalo, 
Tammela et al. 2005). The initial formation of blood vessels is called vasculogenesis and 
occurs in developing embryo when endothelial progenitor cells assemble into so called blood 
islands which then develop into vascular plexus (Flamme, Frolich et al. 1997; Patan 2004). In 
the later stages of development, new blood vessels are formed from the pre-existing 
vasculature and this process is called angiogenesis. Angiogenesis takes place not only during 
development but also in conditions such as wound healing or the female menstrual cycle. 
Neovascularisation also contributes to the pathogenesis of many diseases such as psoriasis, 
diabetic retinopathy, rheumatoid arthritis, heart diseases and cancer (Carmeliet 2003; 
Milkiewicz, Ispanovic et al. 2006; Adams and Alitalo 2007). 
As indicated in the Fig. 1.1, angiogenesis is a multi-step process (Adams and Alitalo 2007). 
Firstly, blood vessels are stimulated with pro-angiogenic factors and become more permeable. 
This induces ECs to secrete matrix metalloproteinases, which then degrade the surrounding 
basement membrane. Some cells from the endothelial wall start to migrate toward the gradient 
of angiogenic stimuli. The column of cells extends as they migrate and proliferate. 
Subsequently, a sprouting tube merges with another already established or newly forming 
vessel and a lumen is formed. Eventually the vessel maturates and is stabilised by the 
recruitment of pericytes. Then a newly formed and fully functional capillary can supply 
nutrients to the adjacent tissue (Carmeliet 2003; Jain 2003). During vessel formation ECs  
     1. INTRODUCTION 
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Fig. 1.1 Stages of angiogenesis.  
Blood vessels are permeabilised by stimulation with pro-angiogenic factors (1) and endothelial cells 
(ECs) activate matrix metalloproteinases to degrade the basement membrane (2). Then ECs proliferate 
(3) and migrate (4) towards the gradient of stimuli and after joining with another vessel the lumen 
forms (5). Finally blood vessels are stabilised by recruitment of other cells such as pericytes (6). 
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which are at the front of a migrating sprout are called tip cells, and the ones that follow behind 
are called stalk cells (Carmeliet, De Smet et al. 2009; De Smet, Segura et al. 2009; Jakobsson, 
Franco et al. 2010). The gene expression in tip and stalk cells is different, resulting in the 
differences in phenotypes of these cells (Hellstrom, Phng et al. 2007b; Del Toro, Prahst et al. 
2010). Tip cells are highly motile and invasive, while stalk cells have increased proliferation 
(Hellstrom, Phng et al. 2007a; Hellstrom, Phng et al. 2007b). 
Various molecules or mechanical forces can induce the formation of blood vessels (Adams 
and Alitalo 2007). These include growth factors, cytokines, components of extracellular 
matrix (ECM), hypoxia, blood flow and shear stress. Vascular endothelial growth factor 
(VEGF) A is one of the most potent pro-angiogenic stimuli and it belongs to the larger family 
of proteins which comprises VEGFA, -B, -C, -D, -E and placental growth factors (PlGF1 and 
2) (Gerhardt, Golding et al. 2003; Olsson, Dimberg et al. 2006). VEGF ligands induce various 
signalling pathways by binding to their cognate vascular endothelial growth factor receptors 
(VEGFR) 1-3, which belong to a larger family of receptor tyrosine kinases (RTKs). VEGFR2 
(also known as KDR or FLK1) is the most active mediator of the angiogenic signal, and upon 
VEGFA binding undergoes autophosphorylation and then activates other associated proteins. 
VEGFR1 (also known as FLT1) has a higher affinity to VEGFA, but a weak tyrosine-kinase 
activity. When expressed in a soluble, catalytically inactive form it can trap VEGF and 
decrease the angiogenic signal. VEGFR3 (also known as FLT4) acts mainly as a receptor in 
lymphangiogenesis (Olsson, Dimberg et al. 2006). Different splice variants of VEGFA exist 
and can control various processes in angiogenesis. VEGFA165 has a heparan sulphate binding 
region and mediates a polarised extension of the tip-cell filopodia, while a shorter form of this 
growth factor, VEGFA121, does not bind heparan sulphate and is not able to promote EC 
branching; rather it acts to activate cell proliferation. Other molecules important in 
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development of blood vessels include basic fibroblast growth factor (bFGF, also known as 
FGF-2), platelet derived growth factors (PDGF), integrins, SLITs/ROBO4, angiopoietins and 
many other proteins (Adams and Alitalo 2007).  
1.2. Rho GTPase family 
1.2.1. Structure of Rho GTPases 
Rho GTPases belong to the large superfamily of Ras-like small G proteins and comprise eight 
subgroups: RhoA-like group one (RhoA, RhoB, RhoC), Rac1-like group two (Rac1, Rac2, 
Rac3, RhoG), Cdc42-like group three (Cdc42, TC10/RhoQ, TCL/RhoJ), group four 
(Wrch1/RhoU, Chp/Wrch2/RhoV), Rnd-like group five (Rnd1/Rho6, Rnd2/RhoN, 
Rnd3/RhoE), group six (RhoD, Rif/RhoF), RhoBTB-like group seven (RhoBTB1, 
RhoBTB2/DBC2) and RhoH/TTF (Boureux, Vignal et al. 2007; Heasman and Ridley 2008). 
Fig. 1.2 illustrates the relationship between these family members.  
The structure of Rho GTPases is highly conserved and the presence of the Rho-specific insert 
domain distinguishes them from other small G proteins (Madaule and Axel 1985; Jaffe and 
Hall 2005). Fig. 1.3 shows the protein sequence alignments of the Cdc42-like subfamily 
members obtained with the ClustalW 2.0.8 program (Chenna, Sugawara et al. 2003) and also 
the conserved domains of Rho GTPases. All Rho GTPases contain the effector domain and 
some possess a so-called CAAX box (C- cysteine, A- aliphatic amino acid, X- any amino 
acid) on the c-terminal tail. The CAAX box is a potential substrate for geranyl-geranyl- or 
farnesyltransferases (Foster, Hu et al. 1996; Liang, Ko et al. 2002). These enzymes catalyse a 
lipidation of the CAAX box, which facilitates protein anchoring in the membrane. A 
hypervariable region is situated upstream of the CAAX box and in some Rho GTPases this 
contains a polybasic sequence. The polybasic sequence varies in the number and order of  
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Fig. 1.2 RhoJ is a member of Rho GTPase family.  
The family comprises the RhoA-like, Rac1-like, Cdc42-like, Wrch, Rnd-like, RhoBTB-like, RhoD/Rif 
and TTF subgroups. An unrooted phylogenetic tree of the human small Rho GTPases. Alternative 
names are given in brackets. The figure was adapted from Chardin (2006). 
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Fig. 1.3 Domain organisation of Rho GTPases. 
A, ClustalW 2.0.8 alignment of RhoJ, TC10 and Cdc42 showing similarities in their amino acid (aa) 
sequences. Similarity in amino acid substitutions is encoded by “*” for identical aa, “:” for conserved 
aa substitutions, “.” for semi-conserved aa substitutions according to Chenna et al. (2003). B, Regions 
of Rho GTPases marked by colour-coded frames are described in the legend box. The corresponding 
aa sequences of these regions are marked for the Cdc42-like subfamily members as shown in A. 
Organisation of domains was drawn on the basis of those shown in reviews by Vega and Ridley 
(2008) and Johnson (1999). 
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lysines and arginines and can determine the localisation of particular Rho GTPases to 
different cell compartments (Jack, Madine et al. 2008). 
1.2.2. Regulation of Rho GTPase activation cycle 
The characteristic feature of many Rho GTPases is their ability to bind the guanine 
nucleotides, namely guanosine-5'-triphosphate or guanosine-5'-biphosphate (GTP or GDP, 
respectively) (Nobes and Hall 1994). Rho GTPases act as molecular switches: binding of GTP 
or GDP determines the conformation of the so-called Switch I and Switch II regions (Fig. 
1.4), and this regulates their interactions with various downstream proteins (Nobes and Hall 
1994; Paduch, Jelen et al. 2001). When inactive (GDP-bound), some Rho GTPases can be 
stabilised by guanine nucleotide dissociation inhibitors (GDIs) (Olofsson 1999). Upon cell 
activation, the GDI is released and GDP exchanged into GTP by guanine nucleotide exchange 
factors (GEFs) (Cherfils and Chardin 1999). The active Rho GTPases are then able to bind to 
effector proteins and propagate signals in the cell (Bishop and Hall 2000). Inactivation of Rho 
GTPases occurs when they interact with GTPase activating proteins (GAPs). These promote 
the intrinsic hydrolytic activity of Rho GTPases to hydrolyse GTP to GDP (Moon and Zheng 
2003). Fig. 1.5 summarises the activation cycle of typical Rho GTPases such as RhoA-like, 
Rac-like, Cdc42-like, RhoF and RhoD. Other Rho GTPases including RhoBTB-like, Rnd-
like, Wrch1, Wrch2 and TTF are atypical since their activity is regulated in ways other than 
GDP/GTP exchange (Aspenstrom, Ruusala et al. 2007). 
1.2.2.1. GEFs 
Rho GTPases can be activated by various stimuli such as hormones, cytokines, growth 
factors, mechanical forces, interactions with neighbouring cells and ECM (Kjoller and Hall 
1999). These signals lead to the activation of GEFs, which then “turn on” Rho GTPases, by 
mediating an exchange of GDP to GTP and therefore inducing conformational changes  
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Fig. 1.4 Conformational changes of Ras as a result of binding with GTP or GDP. 
Conformational changes caused by nucleotide binding are similar in different small G proteins 
(Paduch et al. 2001), and here are demonstrated in Ras GTPase. Both nucleotides (GTP in A or GDP 
in B) are locked within the protein in the presence of a magnesium ion. The presence of a GDP or 
GTP nucleotide determines the conformation of the Switch I and II regions of small G proteins and 
enables their interaction with other proteins. Adapted from Paduch et al. (2001).  
 
     1. INTRODUCTION 
10 
 
 
Fig. 1.5 Mode of activation of typical Rho GTPases. 
Typical Rho GTPases cycle between active GTP-bound and inactive GDP-bound forms. These 
transitions are regulated by three families of proteins: guanine nucleotide exchange factors (GEFs) 
which mediate GDP to GTP exchange; GTPase activating proteins (GAPs) which promote the 
enzymatic activity of Rho proteins leading to hydrolysis of GTP to GDP; guanine nucleotide 
dissociation inhibitors (GDIs) which stabilise some Rho GTPases in their inactive form. 
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(Paduch, Jelen et al. 2001). The GDP-GTP exchange occurs in several stages (Cherfils and 
Chardin 1999). Firstly, the GEF binds with a low-affinity to the GDP-Rho GTPase complex 
and this leads to the dissociation of GDP. The GEF then stabilises a nucleotide-free Rho 
GTPase, by forming a high affinity complex, which is then dissociated by GTP. Magnesium 
ions coordinate binding of the guanine nucleotides to the Rho GTPases. The regions in small 
G proteins responsible for binding to a guanine nucleotide and magnesium ion include the p-
loop and two regions called Switch I and Switch II. The p-loop mediates the interaction with 
GDP while the Switch regions coordinate the binding of the γ-phosphate group of GTP. Thus 
GEFs interact with p-loop to cause a dissociation of GDP and then their binding to small G 
proteins is stabilised by switch I and II regions (Cherfils and Chardin 1999). 
Most GEFs have several domains; these may be involved in their dimerisation, their binding 
to membranes or other proteins in addition to the region required for activation of small G 
proteins (Cherfils and Chardin 1999; Schmidt and Hall 2002; Rossman, Der et al. 2005; 
Garcia-Mata and Burridge 2007). The catalytic GEF-domains include the Dbl-homology 
domain (DH) very often followed by the pleckstrin homology domain (PH). The latter one 
enhances the main GEF activity of the DH domain (Liu, Wang et al. 1998; Rossman and 
Campbell 2000), but also it can act as a membrane targeting domain (Chen, Corbalan-Garcia 
et al. 1997; Michiels, Stam et al. 1997; Stam, Sander et al. 1997; Snyder, Rossman et al. 
2001). Some GEFs need to undergo additional modifications (such as phosphorylation) to 
become catalytically active. The GEF βPIX contains a T1 inhibitory insert located after the 
PH domain; this insert requires phosphorylation by Src for full GEF activity of βPIX (Feng, 
Albeck et al. 2002; Baird, Feng et al. 2005). Another group of GEF-activity domains includes 
Dock homology regions. These GEFs are called Dock180-related or CZH after the “CDM and 
Zizimin homology” (Cote and Vuori 2002; Meller, Merlot et al. 2005). In general, more than 
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70 GEFs had been found in the human genome, which can activate about 20 Rho GTPases. 
Some of the best studied ones include Vav (1-3), Sos, Tiam1, Dock1, Larg and Trio 
(Rossman, Der et al. 2005). It was found that one GEF can serve as an activator for several 
Rho GTPases, while one Rho GTPase can be triggered by multiple GEFs. This may lead to 
crosstalk between different Rho proteins (Garcia-Mata and Burridge 2007). 
1.2.2.2. GAPs 
RhoGAPs are negative regulators of Rho GTPase activity. They bind to activated Rho 
proteins and induce their enzymatic activity which mediates hydrolysis of GTP to GDP 
(Lamarche and Hall 1994; Moon and Zheng 2003). More precisely, RhoGAPs interact with p-
loop, Switch I and Switch II regions of Rho GTPases that hold GTP. This leads to the 
conformational change in a small G protein’s structure and induction of their hydrolytic 
activity (Li, Zhang et al. 1997; Nassar, Hoffman et al. 1998). Analysis of human genome 
revealed the existence of around 80 RhoGAPs, which is again several fold more than the 
number of Rho GTPases. It has been suggested that expression of some GAPs is tissue 
specific. As an example, p73RhoGAP is expressed in the blood vessels where it regulates 
angiogenesis (Su, Hahn et al. 2004), while the brain-specific GAP Grit (GTPase regulator 
interacting with TrkA) regulates neuritogenesis (Nakamura, Komiya et al. 2002).  
As with GEFs, the activity of some RhoGAPs may be regulated by modifications such as 
phosphorylation or lipidation (Moon and Zheng 2003). As an example, the activity of 
p190RhoGAP is increased after its phosphorylation by Src (Hu and Settleman 1997; Roof, 
Haskell et al. 1998). On the other hand, the Rac-specific GAP chimaerin is regulated by a 
phospholipid modification (Moon and Zheng 2003). Due to their multi-domain structure, 
many GAPs can also serve as scaffold proteins, which mediate the cross-talk between various 
signalling pathways (Tcherkezian and Lamarche-Vane 2007). 
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1.2.2.3. GDIs 
GDIs stabilise Rho proteins in a GDP-bound form and often cause their translocation from the 
membrane to cytosol (Olofsson 1999). Thus GDIs sequester inactive Rho GTPases in a 
soluble fraction which then can be switched back on upon the stimulation with an appropriate 
signal. Another role of GDIs is to deliver and withdraw Rho GTPases from their site of 
action, which is often located at membranes (Dransart, Olofsson et al. 2005). While numbers 
of RhoGAPs and RhoGEFs are rather large, only three RhoGDIs have been characterised 
(Fukumoto, Kaibuchi et al. 1990; Leonard, Hart et al. 1992; Lelias, Adra et al. 1993; 
Zalcman, Closson et al. 1996; Adra, Iyengar et al. 1998; Gorvel, Chang et al. 1998; Brunet, 
Morin et al. 2002).  
1.2.3. General functions of Rho GTPases 
Rho GTPases were originally characterised as regulators of actin dynamics. The three most 
studied ones RhoA, Rac1 and Cdc42 were found to have a major role in formation of stress 
fibres (SFs), lamellipodia and filopodia, respectively (Nobes and Hall 1995). SFs are 
comprised of actin and myosin bundles, which generate the tension and contraction in the cell 
while lamellipodia and filopodia are sheet-like and finger-like protrusions (respectively) 
generated in spreading or migrating cells (Ridley, Schwartz et al. 2003). Since the first Rho 
GTPase RhoA was identified in 1985 (Madaule and Axel 1985), there had been a great 
interest in discovering other family members. Numerous studies revealed that Rho GTPases 
control cellular processes such as cell migration, proliferation, cytoskeleton rearrangements, 
vesicle transport, phagocytosis, cell division, gene expression, cell-cell and cell-matrix 
adhesion (Jaffe and Hall 2005; Heasman and Ridley 2008). Many of these discoveries were 
based on studies using dominant active or dominant negative mutant forms of Rho GTPases 
created by single amino acid changes. The most typical mutants include GTP-bound active 
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(G12V or Q61L in Rac1), nucleotide-free inactive (G15A in Rac1) or GDP-bound inactive 
(T17N in Rac1) forms based on their analogy to known Ras mutations (Garcia-Mata, 
Wennerberg et al. 2006), with T to N mutations being mostly nucleotide-free in cells. 
Moreover, the availability of knock-out mice for several Rho GTPases provided further 
information about their function (Heasman and Ridley 2008). The paragraphs below list some 
of the main functions of various Rho GTPases. A detailed description of the role of Rho 
GTPases in cytoskeletal reorganisation and focal adhesion (FA) turnover is included in the 
section 1.3.3. 
All members of RhoA-like subfamily activate acto-myosin contractility, induce SF and FA 
formation, regulate cytokinesis, gene transcription and cell migration (Wheeler and Ridley 
2004). RhoB is involved in endocytic trafficking of growth factor receptors such as epidermal 
growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR-β) 
(Gampel, Parker et al. 1999; Huang, Duhadaway et al. 2007). Global RhoB and RhoC knock-
out mice were created, which implicated distinct roles for these two Rho GTPases (Heasman 
and Ridley 2008). RhoB was shown to regulate EC survival during vascular development 
(Adini, Rabinovitz et al. 2003). Mice lacking RhoB disclosed increased susceptibility to skin 
cancer (Liu, Rane et al. 2001).  In many tumours RhoB expression was reduced and this 
GTPase was proposed to be a tumor suppressor since its overexpression inhibited cell growth, 
survival, invasion and metastasis (Huang and Prendergast 2006). In contrast, mice lacking 
RhoC had inhibited tumour cell motility and metastasis (Hakem, Sanchez-Sweatman et al. 
2005). Numerous studies showed promotion of cancer cell invasion and metastasis by RhoC 
(Clark, Golub et al. 2000; Simpson, Dugan et al. 2004; Wu, Wu et al. 2004; Yao, Dashner et 
al. 2006; Liu, Zhang et al. 2007). 
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Rac1-like GTPases are known to regulate lamellipodia and focal complexes formation, 
membrane ruffling, cell migration, cell growth, cell survival, transcription, phagocytosis and 
endocytosis (Wennerberg and Der 2004; Heasman and Ridley 2008; Palamidessi, Frittoli et 
al. 2008; Bosco, Mulloy et al. 2009). Global knockout of Rac1 was embryonic lethal 
(Sugihara, Nakatsuji et al. 1998), while generation of various tissue specific Rac1 deletions in 
mice indicated its importance in many processes. These include neutrophil chemotaxis 
(Glogauer, Marchal et al. 2003), B-cell development (Walmsley, Ooi et al. 2003), 
hematopoietic stem/progenitor cell engraftment in the bone marrow (Gu, Filippi et al. 2003), 
hair follicle formation (Benitah, Frye et al. 2005; Chrostek, Wu et al. 2006), NADPH oxidase 
activity (Satoh, Ogita et al. 2006) regulation of Schwann cell biology (Benninger, Thurnherr 
et al. 2007; Nodari, Zambroni et al. 2007), lamellipodia formation and proliferation in mouse 
embryonic fibroblasts (Vidali, Chen et al. 2006), brain development and axon guidance 
(Chen, Liao et al. 2007) and vascular development (Tan, Palmby et al. 2008). Rac2, Rac3 and 
RhoG global knockouts resulted in viable mice but they had abnormalities in neutrophil 
functioning, behaviour, and lymphocyte responsiveness to antigen, respectively (Vincent, 
Jeanteur et al. 1992; Roberts, Kim et al. 1999; Vigorito, Bell et al. 2004; Cho, Zhang et al. 
2005; Corbetta, Gualdoni et al. 2005). 
Cdc42-like GTPases include Cdc42, TC10 and RhoJ (Heasman and Ridley 2008) and are 
involved in the actin reorganisation and formation of filopodia (Johnson 1999; Wennerberg 
and Der 2004). Cdc42-null mice die during embryonic developments, with defects in the 
primary ectoderm formation (Chen, Ma et al. 2000). Cell-type specific Cdc42 knock-out 
mouse models showed the importance of this GTPase in hematopoietic stem cell quiescence 
(Yang, Wang et al. 2007), fate determination of apical neural progenitor cells (Cappello, 
Attardo et al. 2006), cell polarity (Chen, Liao et al. 2006), axonogenesis (Garvalov, Flynn et 
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al. 2007), Schwann cell biology (Benninger, Thurnherr et al. 2007) and hepatocellular 
carcinogenesis (van Hengel, D'Hooge et al. 2008).  
TC10 was implicated in the regulation of the insulin-induced glucose transporter trafficking 
(Ridley 2006), control of myofibril organisation (Coisy-Quivy, Touzet et al. 2009), adipocyte 
differentiation (JeBailey, Rudich et al. 2004) and also in gene transcription and NIH3T3 
fibroblast cell transformation (Murphy, Solski et al. 1999). The role of RhoJ is described in 
detail in section 1.2.6. 
RhoD and Rif GTPases are involved in actin cytoskeleton rearrangements. RhoD regulates 
actin-dependent transport of early endosomes and promotes FA and SF disassembly (Murphy, 
Saffrich et al. 1996; Murphy, Saffrich et al. 2001). Rif GTPase regulates the formation of 
filopodia and increase of SFs (Ellis and Mellor 2000; Aspenstrom, Fransson et al. 2004). 
Rnd-like proteins are atypical Rho GTPases, which exist permanently in a GTP-bound form 
and their activity is regulated by expression levels, localisation and phosphorylation (Chardin 
2006). Rnd1 and Rnd3 have opposite effects to RhoA as they reduce SFs and cause cell 
rounding (Guasch, Scambler et al. 1998; Nobes, Lauritzen et al. 1998). This was suggested to 
occur via activation of p190RhoGAP, which would lead to inactivation of RhoA 
(Wennerberg, Forget et al. 2003) or by direct binding and inactivation of Rho-associated 
coiled coil kinase I (ROCK I), a known effector of Rho-like proteins (Riento, Guasch et al. 
2003). Rnd proteins were implicated in the function of neurons by regulating the actin 
cytoskeleton, axon guidance, neurite outgrowth and cytokinesis (Chardin 2006). Rnd3 was 
additionally shown to have a role in cancer progression (Vega and Ridley 2008). Other 
atypical Rho GTPases Wrch1 and Wrch2 induce filopodia formation (Aronheim, Broder et al. 
1998; Tao, Pennica et al. 2001). In HeLaS3 cells Wrch-1 localised to FAs and its knock-down 
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with siRNA resulted in increased numbers of FAs and impaired cell migration (Chuang, 
Valster et al. 2007). In another study, activated Wrch-1 was shown to disrupt epithelial cell 
tight junctions and epithelial morphogenesis (Brady, Alan et al. 2009). On the other hand, 
Wrch-2, overexpression in T-cells caused inhibition of cell migration and triggered Pak1 
ubiquitination and degradation (Weisz Hubsman, Volinsky et al. 2007). This Rho GTPase was 
also found to promote cell transformation (Chenette, Mitin et al. 2006). RhoBTB2 and 
RhoBTB1 were proposed as tumour suppressor genes (Wilkins, Ping et al. 2004; Berthold, 
Schenkova et al. 2008). RhoH, another atypical Rho GTPase, was found to inhibit Rac1, 
RhoA and Cdc42 signalling in T cells (Li, Bu et al. 2002). The global knock-out of RhoH 
gene in mice showed the importance of this Rho GTPase in T-cell differentiation and T-cell 
receptor signalling (Gu, Chae et al. 2006; Dorn, Kuhn et al. 2007). 
1.2.4. Main effectors of Rho GTPases 
Although members of Rho GTPase family are quite homologous in their structure 
(Wennerberg and Der 2004), the selectivity in their binding of different effector proteins is 
remarkable (Bishop and Hall 2000). Rho GTPases can interact with a whole range of 
structurally different proteins; these include various scaffold proteins, serine/threonine 
kinases, tyrosine kinases, lipid kinases, lipases and oxidases (Jaffe and Hall 2005). Through 
binding to effector proteins Rho GTPases regulate different cellular processes such as actin 
polymerisation, generation of actomyosin contractility, cell migration, FA turnover, cell 
polarity, cell-cell interactions, cell-cycle progression, enzymatic activities, vesicular 
trafficking, microtubule dynamics and gene expression (Bishop and Hall 2000; Etienne-
Manneville and Hall 2002; Schwartz 2004; Jaffe and Hall 2005; Ridley 2006; Heasman and 
Ridley 2008; Spiering and Hodgson 2011). Examples of interactions between Rho proteins 
and their effectors that regulate these processes are depicted in the Fig. 1.6. 
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Some effector proteins contain conserved domains that are recognised selectively by activated 
Rho GTPases. The Cdc42/Rac-interacting binding (CRIB) domain, which is present in 
proteins such as Wiskott–Aldrich syndrome protein (WASP) or p21-activated kinases 
(PAKs), can be recognised by activated Rac1, Rac2, Cdc42, TC10 and RhoJ (Sander, van 
Delft et al. 1998; Benard, Bohl et al. 1999; Vignal, De Toledo et al. 2000; Haddad, Zugaza et 
al. 2001; Benard and Bokoch 2002; Chiang, Hou et al. 2002; Tong, Liss et al. 2007). The 
RhoA-binding domain (RBD) from rhotekin can interact with activated RhoA, RhoB and 
RhoC (Ren, Kiosses et al. 1999; Ren and Schwartz 2000; Arthur, Ellerbroek et al. 2002; 
Gampel and Mellor 2002; Bellovin, Simpson et al. 2006). 
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Fig. 1.6 Main effectors of Rho GTPases. 
Rho GTPases regulate many cellular processes including cytoskeletal rearrangements, cell migration, 
vesicular trafficking, focal adhesion dynamics, cell-cycle progression, cell polarity or gene expression 
(Jaffe and Hall 2005). The scheme shows some main effectors of Rho GTPases which play a crucial 
role in the regulation of cytoskeletal dynamics. The green boxes indicate direct effectors of Rho 
GTPases. Abbreviations: mDia, mammalian Diaphanous formin; ROCK, Rho-associated coiled coil 
kinase; PAK, p21-activated kinase; IRSp53, insulin receptor tyrosine kinase substrate p53; MRCK, 
myotonic dystrophy kinase-related Cdc42-binding kinase; MLC, myosin light chain; p, 
phosphorylated; LIMK, LIM motif containing protein kinase; MLCK,  myosin light chain kinase; 
MLCP, myosin light chain phosphatase; WASP, Wiskott-Aldrich syndrome protein; N-WASP, 
neuronal-Wiskott-Aldrich syndrome protein; WAVE, Wiskott-Aldrich syndrome protein-family 
verprolin homologous protein; Arp2/3, a seven subunit complex comprising actin-related proteins 2 
and 3. 
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Regulation of effector proteins by Rho GTPases may vary. Some effectors are folded in an 
auto-inhibitory form which is relieved upon binding to small GTPase (Bishop and Hall 2000). 
This is exampled by group I of PAKs (PAK1-3). These kinases contain the CRIB domain, 
which partially overlaps with an auto-inhibitory domain (AID). The latter binds to and 
inhibits a kinase domain present at the C-terminus of PAK. Binding of activated Rho GTPase 
to the CRIB domain destabilises the AID domain. This leads to the release of a C-terminal 
kinase domain, subsequent autophosphorylation of PAK and its full activation (Zhao, Manser 
et al. 1998; Lei, Lu et al. 2000). Alternatively, Rho GTPases may activate their target proteins 
by bringing them to specific complexes or locations in the cell (Jaffe and Hall 2005). 
1.2.5. Role of Rho GTPases in angiogenesis 
1.2.5.1. Rho GTPases in vascular permeability 
ECs that line blood vessels are inter-connected by adherens and tight junctions (Bazzoni and 
Dejana 2004). These connections are disrupted when angiogenic stimuli such as VEGF or 
thrombin permeabilise an EC wall resulting in the formation of intercellular gaps (Mehta and 
Malik 2006). It is well known that RhoA, Rac1 and Cdc42 can regulate the EC permeability 
(Beckers, van Hinsbergh et al. 2010; Spindler, Schlegel et al. 2010). Stimulation by thrombin 
activates the RhoA-ROCK signalling cascade which leads to myosin light chain (MLC) 
phosphorylation, increased cell contractility and permeability of endothelial wall. Activation 
of RhoA is likely to be mediated by p115RhoGEF (Holinstat, Mehta et al. 2003), GEFH1 
(Birukova, Adyshev et al. 2006) and inhibition of RhoGDI (Mehta, Rahman et al. 2001). On 
the other hand, RhoA mediated permeability can be antagonised by Rac1 and Cdc42. These 
GTPases activate PAK leading to the stabilisation of junctional complexes including 
cadherin/catenin/actin and integrity of cell-cell contacts (Waschke, Baumgartner et al. 2004; 
Seebach, Madler et al. 2005; Waschke, Burger et al. 2006). Moreover, activation of focal 
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adhesion kinase (FAK) can lead to the phosphorylation of p190RhoGAP, which inhibits 
RhoA activity and eventually restores the integrity of EC barrier (Holinstat, Knezevic et al. 
2006). Thus different Rho GTPases can both inhibit or promote a vascular permeability and 
this appears to be regulated temporarily, depending on the signal that leads to their activation 
or inhibition (Beckers, van Hinsbergh et al. 2010; Spindler, Schlegel et al. 2010). 
1.2.5.2. Rho GTPases in ECM remodelling 
ECs which are selected to initiate sprouting, need to change their morphology and become 
highly motile and invasive (Adams and Alitalo 2007). These cells are required to activate 
secreted or cell surface anchored proteases to degrade surrounding endothelial basement 
membranes and invade adjacent tissues. An important matrix-metalloproteinase (MMP) 
expressed in ECs is MMP-9 (Qian, Wang et al. 1997). Some studies showed that 
overexpression of dominant active RhoA in ECs up-regulated the transcription of MMP-9 and 
promoted cell invasion into a 3D matrix-protein gel (Abecassis, Olofsson et al. 2003). In this 
case MMP-9 colocalised with RhoA at the forefront of advancing lamellipodia in migrating 
ECs. Other studies showed that RhoA and Cdc42 were differently regulating some other 
matrix metalloproteinases (Ispanovic, Serio et al. 2008). Expression of dominant active Cdc42 
increased the localisation of a membrane type 1 (MT1)-MMP to the cell surface and activated 
MMP-2 in ECs. A similar effect was seen upon inhibition of ROCK, an effector of RhoA. 
Moreover, expression of dominant active Cdc42 or dominant negative RhoA increased EC 
sprouting in a 3D collagen matrix and inhibition of Cdc42 was sufficient to reduce VEGF-
dependent activation of MMP-2 (Ispanovic, Serio et al. 2008). Thus Rho GTPases are 
important in the regulation of expression and activity of MMPs and thereby in remodelling of 
ECM. 
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1.2.5.3. Rho GTPases in endothelial cell migration 
After successful degradation of the basement membrane, a sprouting endothelial tip cell 
migrates into surrounding tissue (Adams and Alitalo 2007). As described in detail in section 
1.3, the turnover of both the actin cytoskeleton and FAs facilitates cell migration  (Nobes and 
Hall 1995; Raftopoulou and Hall 2004; Parsons, Horwitz et al. 2010). In ECs similar events 
occur and these are accompanied by spatio-temporal activation of Rho GTPases (Cascone, 
Giraudo et al. 2003; Fryer and Field 2005). Activated by pro-migratory stimuli, RhoA and 
Rac1 translocate from the cytosol to the SF-associated perinuclear region and F-actin at 
leading edge, respectively. There they regulate actin polymerisation, actomyosin contraction 
and FA turnover (Bryan and D'Amore 2007). Multiple studies suggested that disruption of 
Rho GTPases-mediated signalling in ECs inhibits cytoskeleton rearrangements and results in 
impaired cell migration (Okamoto, Yatomi et al. 2000; Paik, Chae et al. 2001; Fryer and Field 
2005; Lee and Kay 2006; Bryan, Dennstedt et al. 2010; Del Valle-Perez, Martinez et al. 2010; 
Enciso, Konecny et al. 2010; Liebl, Weitensteiner et al. 2010). During the sprouting of ECs 
the levels of phosphorylated MLC (pMLC) are being reduced and Rac1 activity is induced 
(Mavria, Vercoulen et al. 2006; Abraham, Yeo et al. 2009). Regulation of PAK activity, 
which acts downstream of Rac1 and Cdc42, was shown to be critical in the regulation of EC 
migration (Kiosses, Daniels et al. 1999). Kiosses and colleagues showed that overexpression 
of dominant active or dominant negative PAK mutants significantly decreased EC migration. 
Another group showed that Rac1 was essential for the matrix-induced morphological changes 
of EC and promoted their migration acting through PAK (Connolly, Simpson et al. 2002). 
Garret and colleagues showed that in VEGF-induced EC migration Rac1 was activated by its 
GEF Vav2 (Garrett, Van Buul et al. 2007). This signalling pathway was also dependent on the 
activation of Src (Gavard and Gutkind 2006). Many other studies exist which demonstrate the 
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importance of Rho GTPases in EC migration, however a description of all of these is beyond 
the scope of this introduction. 
1.2.5.4. Rho GTPases and endothelial cell proliferation 
Proliferation of ECs contributes to angiogenesis and enables the extension of newly sprouting 
capillaries. Different signalling pathways are involved in this process (Bryan and D'Amore 
2007). VEGFR2-dependent activation of PLCγ leads to the induction of extracellular signal-
regulated kinase 1/2 (ERK1/2) signalling and subsequent proliferation of ECs (Pages, 
Milanini et al. 2000; Takahashi, Yamaguchi et al. 2001). Moreover the VEGF-induced 
activation of phosphatidylinositol 3-kinase (PI3K) leads to the activation of its downstream 
target, the serine/threonine kinase AKT/PKB, which promotes EC proliferation and survival 
(Fujio and Walsh 1999; Dayanir, Meyer et al. 2001). Some studies showed that Rho GTPases 
also promote EC proliferation by regulation of cell-cycle progression (Bryan and D'Amore 
2007). Stimulation of human umbilical vein endothelial cells (HUVECs) by estradiol, a 
hormone that acts via estrogen receptors, induced the RhoA/ROCK signalling cascade which 
led to the increased expression of cell-cycle related proteins and enhanced EC migration and 
proliferation (Oviedo, Sobrino et al. 2010). In some other studies Rac induced the expression 
of tumor endothelial marker 5, which in turn mediated contact inhibition of proliferation in 
ECs (Vallon, Rohde et al. 2010). 
1.2.5.5. Rho GTPases in stabilisation and survival of newly formed 
capillaries 
When a sprouting column of ECs joins with another vessel the lumen is formed to enable the 
blood flow. This process appears to be complex and is not fully understood yet. The existing 
data suggested a mechanism dependent on interaction of ECs with components of the ECM 
(Adams and Alitalo 2007). This involves integrin-mediated signalling, which leads to the 
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activation of Rac and Cdc42. These GTPases are then involved in the vacuole formation and 
coalescence (Davis, Koh et al. 2007). It was shown that in growing inter-segmental vessels in 
zebrafish the lumen forms firstly by intracellular and then inter-cellular fusion or large 
vacuoles, which are positive for Cdc42 (Kamei, Saunders et al. 2006). Some other studies 
tested lumen formation in 3 dimensional matrices by ECs treated with Clostridium difficle 
toxin B or C3 transferase (Bayless and Davis 2002). The former toxin inhibits RhoA, Rac1 
and Cdc42 GTPases, while the latter one blocks RhoA, RhoB and RhoC. It was found that C3 
transferase did not inhibit the lumen formation as opposed to toxin B treatment. Thus it was 
concluded that Cdc42 and Rac1, but not RhoA play a major role in the lumen formation 
(Bayless and Davis 2002). It was proposed that downstream effectors of Rac and Cdc42 such 
as Pak and WASP are likely to mediate this process (Bryan and D'Amore 2007). 
To stabilise newly forming vasculature, the regulation of EC survival is very important 
(Adams and Alitalo 2007). The blood flow in vessels stabilises connections between cells 
while the supply of oxygen lowers the local expression of VEGFA, resulting in reduction of 
EC proliferation. Then the ECM is formed and other cells such as pericytes are recruited to 
cover the vessel (Jain 2003; Adams and Alitalo 2007). Rho GTPases were shown to play a 
role in EC survival. Inhibition of RhoA but not Rac1 or Cdc42 induced apoptosis in HUVECs 
(Hippenstiel, Schmeck et al. 2002; Li, Liu et al. 2002). Moreover, apoptosis in the newly 
forming retinal vasculature was observed in RhoB knock-out mice (Adini, Rabinovitz et al. 
2003). Pharmacological depletion of RhoB or its dominant negative mutant resulted in 
apoptosis in ECs and reduced EC tube sprouting. This was thought to be due to the 
elimination of Akt from the nucleus and its degradation (Adini, Rabinovitz et al. 2003). On 
the contrary, other studies showed that a dominant negative RhoA or pharmacological 
inhibition of ROCK decreased tumor necrosis factor-α (TNF-α)-induced apoptosis of bovine 
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ECs (Petrache, Crow et al. 2003), which may suggest that Rho-mediated survival/apoptosis 
might be cell type dependent.  
1.2.6. RhoJ 
RhoJ is a member of the Cdc42-like subfamily of Rho GTPases, and it is also called TCL or 
TC10-like due to its highest similarity to other small Rho GTPase TC10 (Vignal, De Toledo 
et al. 2000). RhoJ is encoded by five exons, which span over 85 kilo bases on human 
chromosome 14. Vignal et al. showed that RhoJ very rapidly exchanges GDP into GTP and 
when activated, it binds to the CRIB domain of PAK and WASP (Vignal, De Toledo et al. 
2000). In addition, Aspenstrom et al. performed a yeast-two-hybrid (Y2H) study in which 
they showed that the dominant active RhoJ mutant interacted with known effectors of Cdc42 
such as WASP, neural WASP (N-WASP), Cdc42-interacting protein 4 (CIP4), partitioning 
defective 6 (Par6), p50RhoGAP, PAK1B and PAK4 (Aspenstrom, Fransson et al. 2004). 
However there is a lack of data showing the physiological relevance of these interactions in 
mammalian cells. 
Ectopically expressed RhoJ localised to the dorsal cell membrane and was associated with 
large intra-cytoplasmic vesicles in REF-52 fibroblasts (Vignal, De Toledo et al. 2000). In 
these cells, an active mutant of RhoJ caused the production of large and dynamic F-actin 
ruffles on the dorsal membrane. This phenotype was blocked by dominant negative Rac1 and 
Cdc42 mutants, suggesting that these three GTPases may share similar GEFs.  In another 
study, constitutively active RhoJ caused the formation of lamellipodia and FA-like assemblies 
at the cell periphery of porcine aortic ECs stably expressing the human platelet-derived 
growth factor β-receptor (Aspenstrom, Fransson et al. 2004). Moreover, Billottet and 
colleagues showed that an overexpressed active mutant of RhoJ induced the formation of 
podosomes in ECs (Billottet, Rottiers et al. 2008). Podosomes are another type of cellular 
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adhesions formed by a central actin core surrounded by a ring of integrins and other proteins; 
they play a role in highly motile, invasive cells (Albiges-Rizo, Destaing et al. 2009). 
Some other studies indicated a role for RhoJ in early endocytosis of the transferrin (Tf) 
receptor (de Toledo, Senic-Matuglia et al. 2003). De Toledo et al. showed localisation of 
ectopically expressed myc-tagged RhoJ to the plasma membrane and early/sorting endosomes 
(EE/ES) in HeLa cells. The knock-down of RhoJ with siRNA perturbed Tf release while the 
overexpression of constitutively active RhoJ (daRhoJ) promoted the accumulation of Tf in the 
EE/ES. In addition daRhoJ blocked the movement of Tf to perinuclear recycling endosomes 
resulting in Tf recycling to the plasma membrane directly from the EE/ES  (de Toledo, Senic-
Matuglia et al. 2003). 
Several studies have suggested a role for RhoJ both in adipocytes and adipogenesis. The 
mouse ortholog of RhoJ (called in this study TC10β), when transfected into 3T3-L1 
adipocytes was activated by insulin stimulation (Chiang, Hou et al. 2002). This activation was 
CAP/Cbl/CrkII/C3G pathway dependent. Another group demonstrated increased RhoJ 
(TC10β-long) expression in 3T3-L1 cells induced to differentiate into adipocytes (Nishizuka, 
Arimoto et al. 2003).  This differentiation was inhibited upon antisense mediated knock-down 
of RhoJ. Moreover, the constitutive expression of RhoJ in NIH-3T3 fibroblasts, which do not 
spontaneously differentiate into adipocytes, caused the accumulation of oil droplets and 
adipogenic markers (Nishizuka, Arimoto et al. 2003). Subsequent studies by this group 
revealed that RhoJ regulated the differentiation of mouse adipocytes by controlling mitotic 
clonal expansion (MCE) and this regulatory effect was closely linked to the expression of 
C/EBPβ and C/EBPδ genes (Kawaji, Nishizuka et al. 2010). 
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1.2.6.1. RhoJ in endothelial cells 
Work performed by members of our laboratory showed that RhoJ is a Rho GTPase that may 
play a special role in the vasculature. Herbert et al. initially found that in publicly available 
human expression libraries RhoJ was present only in EC libraries (Herbert, Stekel et al. 2008). 
This bioinformatic prediction was supported by examining RNA expression using reverse 
transcription and quantitative polymerase chain reaction (qPCR), where among several cell 
types tested (fibroblasts, hepatocytes, lymphocytes, keratinocytes, endothelial and epithelial 
cells) RhoJ was present only in the cDNA of ECs (Herbert, Stekel et al. 2008). More recently, 
in situ hybridisation studies in both developing mouse embryo at embryonic day 9.5 (when 
the angiogenesis occurs) and in human tissue sections showed that RhoJ gene was expressed 
in the blood vessels (Kaur, Leszczynska et al. 2011). More specifically, RhoJ expression was 
detected in the blood vessels of the heart, adrenal gland, lymph node, muscle, pancreas, 
placenta, liver, lung, bladder cancer, bone cancer and ovarian cancer but not in the vessels of 
testis, brain, kidney, stomach, colon or rectal cancer. The presence of RhoJ in human smooth 
muscle cells and pericytes was also detected (both RNA and protein) but at a very low level 
when compared to ECs (Kaur, Leszczynska et al. 2011). 
Since RhoJ was expressed in endothelium, a series of experiments aimed to determine its 
function in this tissue (Kaur, Leszczynska et al. 2011). Firstly, silencing of RhoJ using siRNA 
significantly decreased the migration of ECs. This was demonstrated in chemotaxis and 
chemokinesis assays. In the former RhoJ knock-down significantly impaired a movement of 
cells towards serum and FGF-2. In the latter silencing of RhoJ slowed down the migration of 
cells in a scratch wound assay. Another set of experiments tested the effect of silencing RhoJ 
on tubulogenesis in vitro. When plated on Matrigel, which is a solubilised basement 
membrane extract, ECs were induced to form a two dimensional network of tubes and RhoJ 
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knock-down significantly inhibited this process. Similarly, silencing of RhoJ significantly 
impaired tubulogenesis by ECs co-cultured on a monolayer of fibroblasts. In this assay human 
dermal fibroblasts (HDFs) grown to a monolayer produce their own ECM and secrete VEGF. 
These conditions, together with the exogenously added FGF-2 provide an appropriate 
environment for ECs to form tubules with lumens, which are highly reminiscent of those 
present in vivo (Bishop, Bell et al. 1999).   
Sukhbir Kaur in our laboratory also showed that lowering RhoJ expression significantly 
increased a number of FAs and SFs in HUVECs. This effect was most prominent in migrating 
ECs such as those present at the edge of a wounded monolayer. Interestingly, RhoJ knock-
down did not affect FAs and SFs in ECs situated within the monolayer, suggesting that RhoJ 
plays a particular role in regulating these structures in motile cells. Moreover, a general 
increase in EC contractility was observed in the absence of RhoJ. This was detected by 
increased MLC phosphorylation and increased contraction of the type I collagen (Kaur, 
Leszczynska et al. 2011).  
Subsequently, Sukhbir Kaur showed that the pharmacological inhibition of ROCK with 
Y27632 or direct inhibition of MLC phosphorylation with blebbistatin reversed the migrating 
and tube forming defects of RhoJ-knocked-down cells Thus, it was concluded the RhoJ plays 
important role in the regulation of motility, actomyosin contractility and FA turnover in ECs. 
1.3. Actin cytoskeleton and focal adhesions in cells 
1.3.1. Actin cytoskeleton 
The actin cytoskeleton is a dynamic scaffold, which determines the shape and mediates 
motility of cells (Lee and Dominguez 2010). The actin filaments (filamentous actin, F-actin) 
are formed from monomeric units of globular actin (G-actin), and formation of filaments 
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requires energy from hydrolysis of ATP to ADP. On the growing end of the actin filament 
(the barbed end) ATP-bound G-actin monomers are added while in the actin disassembling 
end (the pointed end) ADP-bound actin monomers dissociate, and this process is called actin 
filament treadmilling (Lee and Dominguez 2010). Various proteins can bind to actin and 
mediate the nucleation, elongation, branching, crosslinking or disassembly of its filaments. 
Formins can nucleate and elongate linear actin filaments, while the Arp2/3 complex (a seven-
subunit complex comprising actin-related proteins 2 and 3) is a regulator of filament 
branching (Campellone and Welch 2010). Cofilin/ADF can lead to the dissociation of actin 
filaments into globular monomers (Bamburg 1999). Actin filaments are crosslinked by 
various proteins including α-actinin and non-muscle myosin II (NM II) (Vicente-Manzanares, 
Ma et al. 2009). NM II is a dimer which comprises two identical units connected via their α-
helical coiled-coil rod domains. Each of the two NM II units contains a globular head domain 
with Mg2+-ATPase activity, regulatory and essential myosin light chains (MLC). NM II can 
act with and connect actin filaments and this is known as actomyosin. Upon phosphorylation 
of the regulatory MLC, NM II moves the antiparallel actin filaments and causes actomyosin 
contraction (Vicente-Manzanares, Ma et al. 2009). Bundles of actomyosin filaments can 
assemble into thicker structures, SFs, which provide tension and contraction in the cells 
(Amano, Chihara et al. 1997; Hotulainen and Lappalainen 2006; Pellegrin and Mellor 2007). 
The alignment of actin filaments varies in different cellular regions. In the lamellipodium of 
migrating cells actin filaments are highly branched, while in the following lamellum they are 
organised as parallel bundles (Pollard and Borisy 2003; Nicholson-Dykstra, Higgs et al. 
2005). Some actin filaments are linked to the ECM via FAs (Lauffenburger and Horwitz 
1996; Webb, Parsons et al. 2002). Fig. 1.7 shows a typical organisation of cytoskeletal 
filaments and FAs in the migrating cell. 
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1.3.2. Focal adhesions 
FAs are dynamic, multiprotein complexes which connect the actin cytoskeleton with the ECM 
and therefore allow cells to attach to the underlying surface (Dubash, Menold et al. 2009). In 
the lamellipodium small nascent adhesions are being formed, some of which assemble and 
disassemble quickly. Other adhesions maturate and gradually “move” to the rear while the 
cell is shifting its body forward (Fig. 1.7). Eventually the rear FAs disassemble as the cell 
migrates (Webb, Parsons et al. 2002; Parsons, Horwitz et al. 2010).   
The components of FAs vary but the most common ones include: integrins, talin, vinculin, α-
actinin, paxillin, FAK, Src, Arp2/3 (Parsons, Horwitz et al. 2010). The Fig. 1.8 shows a 
connection between actomyosin filaments and the typical proteins which form FAs. Integrins 
are crucial elements of FAs as they link the cell directly with the ECM and mediate 
bidirectional signalling between the cell and its environment (Dubash, Menold et al. 2009; 
Shattil, Kim et al. 2010). In so called “inside-out” signalling various proteins can activate 
integrins by binding to the β-integrin tails inside the cell. This leads to conformational 
changes of integrins and increases their affinity for extracellular ligands. Using this signalling, 
cells can modulate their ability to bind and remodel the ECM. On the other hand, extracellular 
ligands can bind to integrins and signal to the cell via integrin activation in a so-called 
“outside-in” way. This induces conformational changes in integrins and their clustering. As a 
result integrins transmit the signal into the cell and induce processes such as cell proliferation, 
cytoskeletal rearrangements or gene expression (Shattil, Kim et al. 2010).  
There are two models describing FAs assembly (Parsons, Horwitz et al. 2010). The first 
suggests that integrins bind to the components of ECM such as collagen or fibronectin. This 
leads to the activation of their cytoplasmic tails and results in their clustering. The 
cytoplasmic tail of β-integrins recruits initially talin followed by other FA proteins which
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Fig. 1.7 Regulation of the actomysoin cytoskeleton and focal adhesions during cell migration. 
During migration cells polarise and extend protrusions such as spike-like filopodia and sheet-like 
lamellipodia towards the pro-migratory factors. These protrusions comprise actin filaments and are 
stabilised by nascent focal adhesions, which connect the actin filaments to the extracellular matrix. 
Attached to the underlying surface, cells use the actomyosin contractility to move forwards and 
subsequently focal adhesions at the rear are disassembled. Thus a constant turnover of focal adhesions 
and actomyosin cytoskeleton occurs during cell migration. The picture was adapted from Parsons et al. 
(2010). 
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Fig. 1.8 Main components of focal adhesions and their connection to the actomyosin filaments. 
The scheme shows typical proteins which are recruited to focal adhesion complexes. Firstly, integrins 
bind to the components of extracellular matrix (ECM) such as collagen or fibronectin and this leads to 
the activation of cytoplasmic tails of integrins which then recruit talin, vinculin and other proteins to 
form an adhesion complex. NM II, non-muscle myosin II. The picture was adapted from 
Vicente‑Manzanares et al. (2010). 
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form an adhesion complex, and this complex eventually joins with the actin filaments. 
Another model suggests that proteins such as vinculin or pFAK bind firstly to the Arp2/3 
complex associated with actin filaments. Then subsequent binding of this complex to integrins 
stabilises formation of a FA (Parsons, Horwitz et al. 2010). Some proteins when recruited to 
FAs become activated by phosphorylation (e.g. paxillin or FAK) (Tomar and Schlaepfer 
2009) and this determines the recruitment of other proteins. On the other hand, some 
components of FAs need mechanical tension to be applied to enable their activation. For 
example, talin binds to integrins in an autoinhibitory form. Then its tail connects to actin 
filaments and the actomyosin contraction generates a tension which causes conformational 
changes in talin and reveals its binding site for vinculin (del Rio, Perez-Jimenez et al. 2009). 
This again leads to the recruitment of other proteins and FA maturation (Humphries, Wang et 
al. 2007). 
It is not completely understood how FAs are disassembled. Clearly, dispersion of FAs is 
required for rearrangement of F-actin (Parsons, Horwitz et al. 2010). Some studies showed 
that FAK and Src kinases are very important for FAs disassembly as loss of these proteins 
significantly deacreases a disassembly rate in cells (Ilic, Furuta et al. 1995; Webb, Donais et 
al. 2004). Similarly the activity of mitogen-activated protein kinases is important for this 
process as overexpression of dominant negative mutant of MEK impaires FA disassembly 
(Sieg, Hauck et al. 1999; Webb, Donais et al. 2004). Other studies showed that calpain, which 
is a calcium dependent protease, cleaves talin and cytoplasmic tail of β3 integrin leading to a 
FA disassembly (Franco and Huttenlocher 2005). In addition, phosphorylation of some FA 
components may lead to disassembly of these structures. Some data suggested that 
phosphorylation of paxillin and its interaction with the PAK/PIX/GIT1 complex promotes 
FAs turnover (described in details in the section 1.5) (Zhao, Manser et al. 2000; Nayal, Webb 
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et al. 2006). FA disassembly also largely depends on the dynamics of microtubules and 
related endocytic recycling of FA components. As an example, after FA disassembly integrins 
are transported through the endocytic pathway from the rear of the cell to its front (Ezratty, 
Partridge et al. 2005; Caswell, Vadrevu et al. 2009).  
1.3.3. Actomyosin contractility and focal adhesion turnover – 
involvement of Rho GTPases 
The dynamics of FA and actin cytoskeleton turnover are interdependent (Parsons, Horwitz et 
al. 2010). When cells move forward some actin protrusions grow in the front while other 
retract in the rear and this is accompanied by assembly and disassembly of FAs (Raftopoulou 
and Hall 2004). These processes are highly dependent on the activity of Rho GTPases (Fig. 
1.6) (Nobes and Hall 1995; Pollard and Borisy 2003; Machacek, Hodgson et al. 2009). Firstly, 
Cdc42 and Rac1 induce their downstream effectors such as WASP and WASP-family 
verprolin homologue (WAVE), respectively (Raftopoulou and Hall 2004). These proteins 
activate the Arp2/3 complex, which initiates the branching and nucleation of actin filaments 
(Nicholson-Dykstra, Higgs et al. 2005). Rac1 and Cdc42 also stabilise actin filaments by 
activating PAK. This kinase phosphorylates LIM kinase which then inactivates cofilin – a 
protein that disassembles actin filaments (Yang, Higuchi et al. 1998; Wang, Eddy et al. 2007). 
As a result, the actin filaments extend and are stabilised. RhoA, on the other hand, activates 
the formin mammalian Diaphanous (mDia) at the front of the cell to perform a linear 
elongation of actin filaments (Kurokawa and Matsuda 2005; Pertz, Hodgson et al. 2006; 
Chesarone, DuPage et al. 2010). Moreover RhoA activates ROCK, which then leads to the 
phosphorylation of MLC. This generates tension forces which enable retraction of the rear of 
cell body during migration (Vicente-Manzanares, Koach et al. 2008). As the actin nucleation 
proceeds, the FAs are being assembled in the front and simultaneous actomyosin retraction in 
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the rear is accompanied by disassembly of the rear FAs (Raftopoulou and Hall 2004). Thus it 
is important during cell migration that the balance between constant turnover of the actin 
cytoskeleton and FAs is preserved, and for example excessive formation of SFs and FAs 
induced by RhoA signalling may inhibit cell migration (Raftopoulou and Hall 2004; Parsons, 
Horwitz et al. 2010). 
Interestingly, RhoGAPs and RhoGEFs are very often recruited to FAs where they spatio-
temporally control the activation of certain Rho GTPases. Rac1 can activate p190RhoGAP, 
which then inactivates RhoA leading to a decrease of cellular tension and a more continuous 
extension of protrusions (Arthur and Burridge 2001; Nimnual, Taylor et al. 2003). Some other 
evidence suggests that RhoA may lead to the inactivation of Rac1 via the GAP ARHGAP22 
(Katsumi, Milanini et al. 2002; Sanz-Moreno, Gadea et al. 2008), thus suggesting that these 
GTPases can reciprocally regulate their activity and influence dynamics of actomyosin 
contraction and FA turnover. 
1.3.4. Focal adhesions and stress fibres in endothelial cells in vivo 
Although FAs and SFs form most prominently in many cells grown on plastic tissue culture 
dishes, the formation of similar structures may be observed in some cell types in vivo, 
including smooth muscle cells, myofibroblasts or endothelial cells (Dubash, Menold et al. 
2009). In vitro studies allowed to establish that the size and quantity of FAs in cells largely 
depend on the elasticity and stiffnes of a substratum, to which these cells are attached 
(Dubash, Menold et al. 2009). In quiescent ECs that line blood vessels, FAs are thought to 
play a role in connecting the endothelial wall and basement membrane, while formation of 
SFs and contractility induced by RhoA signalling leads to increased cell permeability 
(Bogatcheva and Verin 2008). Some studies suggest that  EC migration which happens during 
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vascular remodelling and angiogenesis is likely to be accompanied by turnover of FAs and 
cytoskeletal rearrangements (Li, Huang et al. 2005).  
1.4. Endocytosis 
Endocytosis is a process in which the extracellular or membrane-bound material is transported 
to the intracellular compartments. This serves to mediate nutrient uptake, drug delivery, 
signalling, cell migration, adhesion, polarity, growth, differentiation, mitosis or pathogen 
entry. It also regulates the availabilty of various receptors and other membrane-bound 
signalling proteins on the cell surface (Doherty and McMahon 2009; Grant and Donaldson 
2009; Sorkin and von Zastrow 2009). During endocytosis portions of the plasma membrane 
are being engulfed into the cell body in the form of vesicles. Various transmembrane proteins 
with bound ligands and extracellular liquid are internalised with these vesicles and join early 
endosomes (EE). Cargo delivered to EE is subsequently transported to sorting endosomes 
(ES), from where different cargos are trafficked to different cellular destinations. Internalised 
material can be passed to recycling endosomes and back to the plasma membrane, or 
alternatively, it can be sent to late endosomes and eventually to lysosomes for degradation 
(Doherty and McMahon 2009). Some endosomes may be associated with microtubules which 
regulate their trafficking (Grant and Donaldson 2009). The pH of the lumen in different 
endosomes varies from mildly acidic in EE/ES to more acidic in late endosomes and 
lysosomes. Upon these pH changes some internalised receptors release their cargo and recycle 
back to the plasma membrane or are directed into a degradative pathway (Sorkin and von 
Zastrow 2009). Endosomes and lysosomes also take part in trafficking of macromolecules 
biosynthesised by the cell (Luzio, Rous et al. 2000; Gould and Lippincott-Schwartz 2009). 
Different types of endocytosis have been described including phagocytosis, macropinocytosis, 
and caveaole or clathrin-mediated endocytosis; endocytosis may also be classified as clathrin-
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dependent or clathrin-independent (Doherty and McMahon 2009). Phagocytosis mediates the 
internalisation of larger material such as cell debris or microorganisms (Greenberg and 
Grinstein 2002), while macropinocytosis is the uptake of extracellular liquid and solutes 
(Falcone, Cocucci et al. 2006). Caveolae are small vesicles regulated by proteins called 
caveolins and their membranes are enriched in cholesterol and glycosphingolipids (Parton and 
Simons 2007). Another type of membrane budding is controlled by clathrin (Higgins and 
McMahon 2002). Clathrin is a protein which covers inner portions of the plasma membrane 
called clathrin-coated pits. When these pits are internalised into the cell body, vesicles are 
being formed which are coated with clathrin on their cytoplasmic side. With the assistance of 
other proteins, such as dynein or adaptin, clathrin mediates budding of the vesicle and also 
takes part in the selection of a cargo to be internalised. Shortly after internalisation, the 
clathrin coat is discarded and the vesicle fuses with EEs. Clathrin-coated pits are involved in 
the internalisation of various receptors together with their ligands such as low density 
lipoprotein, Tf, antibodies or growth factors (Ungewickell and Hinrichsen 2007). 
One of the most well-defined pathways in endocytosis is the trafficking of Tf receptor. Tf is a 
glycoprotein which delivers iron ions to the cells. Tf receptors present on the cell surface can 
bind, internalise and deliver the Tf-iron complex into endosomes, where low pH causes a 
dissociation of the iron ion. Subsequently, Tf can be recycled back by its receptor to the 
plasma membrane and released  in order to bind more iron ions (Macedo and de Sousa 2008). 
Endocytosis also mediates the internalisation of many other receptors (Sorkin and von 
Zastrow 2009). In ECs, VEGFR2 traffics between the plasma membrane and endosomes and 
a proportion of this protein is sent to lysosomes for degradation (Scott and Mellor 2009). This 
trafficking may regulate the surface levels of VEGFR2 and therefore the sensitivity of ECs to 
VEGF signalling. 
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Many studies have shown the importance of Rho GTPases in various types of endocytosis and 
other intracellular vesicular trafficking (Ellis and Mellor 2000; Ridley 2001; Qualmann and 
Mellor 2003; Symons and Rusk 2003). Rac1-dependent recruitment of PAK to membrane 
ruffles and pinocytic vesicles can stimulate pinocytosis (Dharmawardhane, Schurmann et al. 
2000). Insulin-stimulated activation of TC10 increases glucose uptake by recruitment of 
GLUT4 transporter to the plasma membrane (Chiang, Baumann et al. 2001). RhoD and RhoJ 
were shown to regulate the early endocytosis pathway (Murphy, Saffrich et al. 2001; de 
Toledo, Senic-Matuglia et al. 2003; Gasman, Kalaidzidis et al. 2003), while RhoB is involved 
in the regulation of receptor trafficking from EE to late endosomes (Gampel, Parker et al. 
1999; Huang, Duhadaway et al. 2007). Cdc42 and its effector N-WASP were shown to 
control the transport of proteins from Golgi to endoplasmic reticulum (Luna, Matas et al. 
2002), while RhoG was found to play a role in lysosomal dynamics (Vignal, Blangy et al. 
2001). The activity of Rac1 and RhoA may affect the clathrin-dependent and -independent 
internalisation of various receptors (Lamaze, Chuang et al. 1996; Lamaze, Dujeancourt et al. 
2001). 
1.5. The GIT/PIX complex 
1.5.1. Domain organisation of PIX proteins 
The family of PIX proteins (discovered as PAK-interacting exchange factors) comprises αPIX 
(Cool-2) and βPIX (Cool-1), which are encoded by ARHGEF6 and ARHGEF7 genes, 
respectively (Bagrodia, Taylor et al. 1998; Manser, Loo et al. 1998). These PIX proteins are 
homologous in multiple domains as described in Fig. 1.9. αPIX contains an additional N-
terminal calponin homology (CH) domain, which is absent in most splice variants of βPIX 
and determines an interaction of αPIX with the FA protein β-parvin/affixin. βPIX on the other 
hand contains a ZB domain at the C-terminus, which can bind with the PDZ motif in proteins 
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such as scribble and shank (Park, Na et al. 2003; Audebert, Navarro et al. 2004). Both PIX 
proteins contain a Src homology 3 (SH3) domain and thus are able bind to proline-rich 
sequences such as those present in PAK, c-Cbl ubiquitin ligase and Rac1 (Bagrodia, Taylor et 
al. 1998; Manser, Loo et al. 1998; Flanders, Feng et al. 2003; ten Klooster, Jaffer et al. 2006). 
The DH and PH domains regulate the GEF activity, which is inhibited by T1 insert present in 
βPIX forms only (Feng, Albeck et al. 2002). The GEF activity of βPIX can be restored upon 
Y442 phosphorylation by Src (Feng, Baird et al. 2006). The common domains of αPIX and 
most βPIX splice variants include a proline-rich (PR) region which determines interactions 
with POPX1 and POPX2 phosphatases (Koh, Tan et al. 2002); a GIT-binding domain (GBD) 
(Bagrodia, Bailey et al. 1999; Turner, Brown et al. 1999; Zhao, Manser et al. 2000), and a 
coiled-coil (CC) motif responsible for homo- and heterodimerisation (Kim, Lee et al. 2001; 
Koh, Manser et al. 2001). SH3, PH and DH domains additionally mediate an interaction with 
the protease Calpain 4 (Rosenberger, Gal et al. 2005). 
1.5.1. Domain organisation of GIT proteins 
GITs were discovered as G protein-coupled receptor (GPCR) kinase-interacting targets 
binding to β2-adrenergic receptors (Premont, Claing et al. 1998; Claing, Perry et al. 2000). 
The family comprises GIT1 and GIT2. GIT1 and/or GIT2 are also known as CAT (Cool-
associated tyrosine phosphorylated protein), PKL (paxillin-kinase linker) and p95-APP 
(ArfGAP-putative, PIX-interacting, paxillin-interacting protein) (Bagrodia, Bailey et al. 1999; 
Turner, Brown et al. 1999; Di Cesare, Paris et al. 2000). GIT proteins contain multiple 
domains (Fig. 1.9). These include: an N-terminal GAP domain which specifically binds Arf 
GTPases (Vitale, Patton et al. 2000); the ankyrin repeats responsible for intramolecular 
folding of GIT1 and its targeting to endosomes (Di Cesare, Paris et al. 2000; Paris, Za et al. 
2002; Totaro, Paris et al. 2007); a Spa2 homology domain (SHD) 
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Fig. 1.9 Domain organisation of GIT and PIX proteins. 
GIT and PIX proteins have multiple domains, which are responsible for interactions with various 
proteins. The figure illustrates domain organisation of GIT1, the predominant form of GIT2 (long), 
αPIX and predominant form of βPIX. Abbreviations: GAP, GTPase-activating protein domain; PBS, 
paxillin binding sequence; ANK, ankyrin repeats; SHD, yeast Spa2 homology domain; CC, coiled-coil 
region; FAH, focal adhesion targeting homology domain; SLD, synaptic localisation signal; CH, 
calponin homology domain; SH3, Src homology 3 domain; DH, Dbl homology domain; PH, pleckstrin 
homology domain; T1, GEF inhibitory T1 insert; PR, proline-rich region; GBD, GIT-binding domain; 
ZB, PDZ domain binding motif. 
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involved in interactions with PIX, FAK, MEK, Piccolo  and PLCγ (Kim, Ko et al. 2003; 
Premont, Perry et al. 2004; Yin, Haendeler et al. 2004; Zhao and Manser 2005; Jones and 
Katan 2007); a coiled-coil region, which together with the SHD domain mediates homo- and 
heterodimerisation of GIT (Paris, Longhi et al. 2003); and a focal adhesion targeting 
homology domain (FAH) which binds to paxillin (Turner, Brown et al. 1999; Zhao, Manser et 
al. 2000). The middle region of GIT1 including the CC motif spans a synaptic localisation 
domain responsible for its targeting to dendritic protrusions (Zhang, Webb et al. 2003). In 
addition, stimulation with thrombin, epidermal growth factor or angiotensin II can lead to the 
phosphorylation of GIT1 and this is normally mediated by Src and FAK kinases (Bagrodia, 
Bailey et al. 1999; Kawachi, Fujikawa et al. 2001; Haendeler, Yin et al. 2003; van Nieuw 
Amerongen, Natarajan et al. 2004; Yin, Haendeler et al. 2004; Webb, Mayhew et al. 2006; 
Wang, Taba et al. 2009). A protein tyrosine phosphatase PTPζ was shown to dephosphorylate 
GIT1 (Kawachi, Fujikawa et al. 2001). 
1.5.2. Functions of PIX and GIT 
Both PIX proteins have a GEF activity towards Rac1 and Cdc42 in vitro, with αPIX being a 
stronger GEF than βPIX (Bagrodia, Taylor et al. 1998; Manser, Loo et al. 1998; Koh, Manser 
et al. 2001; Feng, Albeck et al. 2002; ten Klooster, Jaffer et al. 2006). The GEF activity of 
αPIX towards particular Rho GTPases may be regulated by dimerisation. Feng and colleagues 
showed that monomeric αPIX was a GEF for both Rac1 and Cdc42 while as a dimer αPIX 
activated only Rac1 (Feng, Baird et al. 2004). Usually GEFs bind inactive small GTPases and 
mediate their activation (Cherfils and Chardin 1999). Interestingly, studies by Baird et al. 
showed that activated Rho GTPases can also bind to αPIX (Baird, Feng et al. 2005). They 
demonstrated that active Cdc42 bound to the αPIX dimer and induced its GEF activity 
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towards Rac1. In addition they found that activated Rac1 also bound to αPIX but this reduced 
its Rac-specific GEF activity thus providing a negative feedback loop. 
PIX and GIT proteins form tight complexes, which may be homo- or heterodimers (Bagrodia, 
Bailey et al. 1999; Zhao, Manser et al. 2000). A model was proposed in which these 
complexes form larger assemblies as they were found as large aggregates in cells (Paris, 
Longhi et al. 2003; Premont, Perry et al. 2004; Hoefen and Berk 2006). GIT and PIX have 
multiple domains and their complexes often serve as scaffolds to bring into close proximity 
various proteins (Hoefen and Berk 2006; Frank and Hansen 2008). The C-terminus of GIT1 
binds to paxillin, which is associated with FAs usually via binding to FAK (Turner, Brown et 
al. 1999). Then PIX, which is bound to GIT, concomitantly associates with PAK and drives 
its recruitment to FAs (Manser, Loo et al. 1998; Zhao, Manser et al. 2000). Thus the 
FAK/paxillin/GIT/PIX/PAK complex localises to FA where its particular components play 
specific functions. PIX as a GEF can activate Rho GTPases Rac1 and Cdc42, which in turn 
activate PAK inducing membrane ruffling and cytoskeletal reorganisation (Manser, Loo et al. 
1998; Obermeier, Ahmed et al. 1998). Some studies suggested that GIT can also bind directly 
to PAK to induce its autophosphorylation and activation (Loo, Ng et al. 2004), however there 
is greater evidence to suggest that PAK is recruited to this complex via direct interaction with 
the SH3 domain of PIX. The whole complex may play a role in FA turnover (Zhao, Manser et 
al. 2000). Moreover, Zhao et al. proposed that GIT may occur in an autoinhibited form and its 
interaction with PIX unmasks its C-terminal domain thus enabling its binding to paxillin. 
Interaction of GIT with paxillin initiates phosphorylation of paxillin which promotes its 
dissociation from FAs and hence their disassembly (Zhao, Manser et al. 2000). More recent 
studies showed that FA disassembly can be regulated by phosphorylation of βPIX (Feng, 
Baird et al. 2010). Feng and colleagues demonstrated that Src can phosphorylate βPIX on the 
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tyrosine 442 which causes dissociation of βPIX from GIT1. This in turn increases interaction 
between GIT1 and paxillin and facilitates FA disassembly. Consistently, inhibition of the 
phosphorylation of βPIX restores its interaction with GIT1 and promotes FA formation (Feng, 
Baird et al. 2010).  
In addition to FAs, the GIT/PIX complex can also localise to the plasma membrane and 
intracellular vesicles (Di Cesare, Paris et al. 2000; Matafora, Paris et al. 2001; Manabe, 
Kovalenko et al. 2002; Rosenberger and Kutsche 2006; Frank and Hansen 2008). Trafficking 
to these distinct compartments is likely to be dependent on Arf GTPases, which regulate a 
transport between the plasma membrane and endosomes (Nie, Hirsch et al. 2003). GIT 
proteins are GAPs for Arf GTPases and can strongly bind to them (Premont, Claing et al. 
1998; Vitale, Patton et al. 2000). It was proposed that after the FA disassembly components of 
the paxillin/GIT/PIX/PAK complex can cycle to endosomes or other intracellular vesicles and 
from there they can move back to the leading edge of the cell to join with nascent FAs  (Di 
Cesare, Paris et al. 2000; Matafora, Paris et al. 2001; Manabe, Kovalenko et al. 2002; 
Rosenberger and Kutsche 2006).  
Some other studies suggested that PIX proteins can localise to FAs via other 
mechanisms. Filipenko et al. showed that αPIX can be recruited to FAs via the β-
parvin/integrins-linked kinase complex and regulate cell spreading via activation of Rac1 and 
Cdc42 (Filipenko, Attwell et al. 2005). Moreover, αPIX can also interact with calpain 4. This 
calcium-dependent protease may cleave some components of FA such as α-actinin and 
spectrin leading to FA disassembly (Glading, Lauffenburger et al. 2002; Rosenberger, Gal et 
al. 2005; Rosenberger and Kutsche 2006).  
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GIT1 and βPIX also play a role at the cell periphery where they regulate directional cell 
migration (Frank and Hansen 2008). GIT1 acting as a GAP reduces active levels of Arf 
GTPases which leads to the inhibition of prolonged Rac1 activity and prevents random 
formation of lamellipodia (West, Zhang et al. 2001; Nishiya, Kiosses et al. 2005). In addition, 
during directional cell migration the actin cytoskeleton is rearranged and Golgi apparatus is 
relocated to the front of the nuclei, which is controlled by activation of Cdc42 (Osmani, Vitale 
et al. 2006). To enable this, scribble binds and targets βPIX to the leading edge of migrating 
cells where βPIX activates Cdc42. This induces the reorientation of the Golgi apparatus and 
perturbation of the PIX/scribble interaction blocks the reorientation of Golgi apparatus and 
thus disrupts directional cell migration (Audebert, Navarro et al. 2004; Osmani, Vitale et al. 
2006; Dow, Kauffman et al. 2007). Scribble is also important for a polarised distribution of 
the PAK/PIX complex to the front of motile cells and for activation of Rac1 during 
chemoattractant-induced directional cell migration (Nola, Sebbagh et al. 2008). GIT may also 
play a role in forming connections between neurons since it localises to pre- and postsynaptic 
regions where it regulates formation of synapses formed along dendrites (Kim, Ko et al. 2003; 
Ko, Kim et al. 2003; Zhang, Webb et al. 2003).  
1.5.3. The GIT/PIX complex in endothelial cells  
Some studies indicated a role for GIT and PIX proteins in ECs. Shikata and colleagues 
showed that GIT1 and GIT2 were involved in the regulation of FA turnover in ECs. In the 
sphingosine-1 phosphate or thrombin stimulated ECs GIT1 promoted FA disassembly while 
GIT2 redistributed paxillin from the cytoplasmic pool to the nascent FAs (Shikata, Birukov et 
al. 2003a; Shikata, Birukov et al. 2003b). In other studies GIT1 was shown to regulate EC 
permeability, where stimulation of ECs with thrombin increased localisation of GIT1 to FAs. 
This process was mediated by activation of RhoA/ROCK pathway and inhibition of GIT1 in 
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HUVECs increased thrombin induced cell rounding, contraction and FA formation (van 
Nieuw Amerongen, Natarajan et al. 2004). Using microarray technology Slevin et al. showed 
up-regulation of GIT1 in ECs isolated from the places of arterial carotid plaques where 
increased haemorrhages and tissue ulceration occurs (Slevin, Elasbali et al. 2006). In other 
studies the integrity of the PAK/PIX/GIT1 complex was necessary for the activation of 
ERK1/2 in induction of vascular permeability by lipopolysaccharide (Stockton, Reutershan et 
al. 2007). A global knock-out of GIT1 gene in mice led to 60 % perinatal mortality and this 
phenotype was caused by the severe impairment of lung development significantly reducing 
the numbers of pulmonary blood vessels and increasing alveolar spaces (Pang, Hoefen et al. 
2009). This study also showed that GIT1 regulated pulmonary vascular development by 
mediation of VEGF-induced PLCγ and ERK1/2 activation. Another study showed that GIT1 
was involved in the regulation of VEGF-induced EC migration and podosome formation 
(Wang, Taba et al. 2009). 
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1.6. Aim of the study 
Our group has shown that RhoJ is expressed predominantly in ECs and lowering of its 
expression by siRNA impairs EC migration, tube formation, proliferation but also increases 
actomyosin contractility and the number of FAs (Kaur, Leszczynska et al. 2011). However, 
little was known about signals and proteins which regulate the function of RhoJ in ECs. 
Therefore these PhD studies aimed to explore the role of RhoJ in ECs by studying its 
intracellular localisation and function, determining its binding partners, and testing its 
activation by pro-angiogenic stimuli. 
1. Determine the localisation of endogenous RhoJ.  
One of the goals of these PhD studies was to examine the localisation of RhoJ in ECs and 
then further explore its function (chapter 3). It was important to establish the intracellular 
localisation of endogenous RhoJ, since overexpression of some proteins may drive their 
aberrant localisation. A polyclonal rabbit RhoJ antibody was made, purified and validated for 
immunofluorescence, which enabled a comparison of localisation of endogenous and 
overexpressed RhoJ in ECs.  
2. Characterise the role of daRhoJ in ECs.  
In order to further examine the function of RhoJ in ECs, the daRhoJ mutant was stably 
overexpressed in HUVECs and its role in cell migration, and regulation of the number of SFs 
and FAs was tested (chapter 3).  
3. Explore the role of RhoJ in endocytosis in ECs.  
Another group had shown that RhoJ played a role in the early endocytosis pathway in HeLa 
cells (de Toledo, Senic-Matuglia et al. 2003), thus some experiments were performed to test 
this function of RhoJ in HUVECs (chapter 3).  
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4. Determine RhoJ binding partners.  
Another goal of these studies was to determine RhoJ-binding partners in ECs (chapter 4). An 
approach was taken, which involved a pull-down of RhoJ-binding proteins from cellular 
lysates using constitutively active or inactive mutants of RhoJ fused with glutathione-S-
transferase (GST). The pulled-down RhoJ-binding candidates were then identified by mass 
spectrometry and the most interesting hits, such as these involved in cell migration, CRIB 
domain-containing proteins, GAPs or GEFs were further tested for direct interactions with 
RhoJ in a Y2H assay. Mass spectrometry indicated that RhoJ pulled-down the GIT1/βPIX 
complex and the Y2H experiment proved direct interaction between RhoJ and GIT1. Both 
RhoJ and the GIT1/βPIX complex were implicated in the regulation of cell motility and FA 
dynamics, thus further experiments aimed to examine the interaction of RhoJ with this 
complex in ECs. Firstly, the co-localisation of RhoJ with GIT1 and βPIX proteins was 
verified. Then siRNA knock-downs of RhoJ, GIT1 and βPIX were performed to test the 
interdependence of these proteins on their localisation to FAs. In addition, the role of a 
dominant active RhoJ mutant in the localisation of GIT1 and βPIX proteins in ECs was 
determined.  
5. Identify fators which activate RhoJ.  
Another series of experiments aimed to test RhoJ activation by pro-angiogenic stimuli 
(chapter 5). Firstly, an assay was optimised to detect active RhoJ in ECs and it was 
subsequently used to measure the levels of active RhoJ in ECs treated with VEGFA, FGF-2 
and thrombin. 
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2.1. Reagents and equipment 
Reagents and chemicals used in methods were purchased from Sigma-Aldrich (Gillingham, 
UK), unless otherwise stated.  
Centrifuges used with different speed ranges were as follows:  
- Biofuge Pico Heraeus centrifuge for 1.5 ml microfuge tubes with up to 16060 x g 
(Kendro Laboratory Products GmbH, Langenselbold, Germany);  
- Hettich Mikro 22R refrigerated centrifuge for 1.5 ml microfuge tubes with up to 
21910 x g (Andreas Hettich GmbH, Tuttlingen, Germany),  
- Biofuge Primo Heraeus centrifuge for up to 50 ml tubes with up to 2576 x g (Thermo 
Electron Corporation, Waltham, USA),  
- AvantiTM J-20XP refrigerated centrifuge for up to 500 ml bottles with up to 26000 x g, 
JLA-10.5 or JA-25.5 rotors used (Beckman Coulter, Brea, CA, USA).  
The names and suppliers of other equipment are stated throughout the method sections. 
2.2. Common buffers 
Common buffers and their contents are listed in Table 2.1. These were used in various 
methods described in the subsequent sections. 
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Tab. 2.1 Common buffers.  
 
Buffer name Contents 
Rho-assay lysis buffer 
 
1 % (v/v) Igepal 
1 % (w/v) N-octyl-β-D-glucopyranoside  
25 mM HEPES pH 7.5 
30 mM MgCl2 a) 
150 mM NaCl a) 
Nucleotide-loading lysis buffer 1 % (v/v) Igepal  
1 % (w/v) N-octyl-β-D-glucopyranoside 
25 mM HEPES pH 7.5 
10 mM MgCl2 a) 
150 mM NaCl a) 
E. coli lysis buffer 
 
50 mM Tris-HCl, pH 7.5 a)  
50 mM NaCl a) 
5 mM MgCl2 a)  
1 mM dithiothreitol (DTT, added fresh) 
1 mM phenylmethylsulfonyl fluoride          
(PMSF, dissolved in methanol and added fresh) 
E. coli washing buffer 50 mM Tris-HCl, pH 7.5 a) 
50 mM NaCl a) 
5 mM MgCl2 a) 
PBS (Phosphate-Buffered Saline) a) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.76 mM KH2PO4  
pH 7.4 
PBST (PBS Tween) PBS a) as above 
0.1 % (v/v) Tween-20 
TBS (Tris-Buffered Saline) 20 mM Tris-Cl, pH 7.5 a) 
150 mM NaCl a) 
TBST (TBS Tween) TBS as above 
0.1 % (v/v) Tween-20 
High salt TBST 20 mM Tris-Cl, pH 7.5 a) 
650 mM NaCl a) 
0.1 % (v/v) Tween-20 
HBS (HEPES-Buffered Saline) 20 mM HEPES, pH 7.5 
150 mM NaCl a) 
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TAE buffer a) 40 mM Tris-base 
18 mM glacial acetic acid 
1 mM EDTA a) 
6x sample loading buffer 30 % (v/v) glycerol a) 
0.25 % (w/v) bromophenol blue  
0.25 % (w/v) xylene cyanol FF 
2x SDS-PAGE  sample-loading 
buffer 
100 mM Tris-Cl, pH 6.8 
20% (v/v) β-mercaptoethanol  
4% (w/v) SDS 
0.2% (w/v) bromophenol blue  
20% (v/v) glycerol a) 
SDS-PAGE running buffer  25 mM Tris-base b) 
250 mM glycine b)  
0.1 % (w/v) SDS 
Transfer buffer  6 mM Tris-base b)  
47.6 mM glycine b)  
20 % (v/v) methanol b), pH 8.3 
Coomassie staining buffer 40 % (v/v) methanol b) 
10 % (v/v) acetic acid 
0.2 g Coomassie Briliant Blue dye 
Coomassie de-staining buffer 10 % (v/v) acetic acid 
12.5 % (v/v) isopropanol  
 
a) reagents purchased from Cancer Research UK (CRUK) Central Services (Clare Hall, UK); 
b) reagents purchased from Fisher Scientific (Loughborough, UK)  
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2.3. Antibodies 
Tab. 2.2 Primary antibodies.  
Abbreviations: mAb, monoclonal antibody; polycl., polyclonal; aa, amino acids; WB, western 
blotting; IF, immunofluorescence; FACS, fluorescence activated cell sorting. 
 
Antibody  Clone 
number, 
isotype 
Immunogen Working 
concentration 
μg/ml 
Supplier 
Mouse mAb 
anti-human 
RhoJ 
ab57584,  
IgG1 
Full-length 
human RhoJ 
1 μg/ml (WB) Abcam, Cambridge, 
UK 
Mouse mAb 
anti-human 
Cdc42 
44, 
IgG1 
1-191 aa of 
human Cdc42 
1 μg/ml (WB) BD Biosciences, 
Oxford, UK 
Mouse mAb 
anti-human 
RhoA 
26C4, 
IgG1 
120-150 aa of 
human RhoA 
0.4 μg/ml (WB) 
 
Santa Cruz 
Biotechnology, 
Santa Cruz, USA 
Mouse mAb 
anti-human 
Rac1 
23A8,  
IgG2b 
Full-length 
human Rac1 
1 μg/ml (WB) Millipore, 
Livingstone, UK 
Mouse mAb 
anti-HA 
12CA5, 
IgG2b 
HA epitope 0.8 μg/ml (WB), 
1.6 μg/ml (IF) 
CRUK Central 
Services 
Mouse mAb 
anti-myc 
9E10,  
IgG1 
408-432 aa of 
human c-myc 
1 μg/ml (WB), 
10 μg/ml (IF) 
CRUK Central 
Services 
Rabbit mAb 
anti-myc 
71D10,  
IgG 
410-419 aa of 
human c-myc 
1:500 (IF), stock 
conc. not known 
Cell Signalling 
Technology, 
Danvers, USA 
Mouse mAb 
anti-flag 
M2,  
IgG 
Flag epitope 2.25 μg/ml (WB) 
 
Sigma-Aldrich 
Mouse mAb 
anti-human 
EEA1 
14,  
IgG1 
3-281 aa of 
human EEA1 
1.25 μg/ml (IF) BD Biosciences 
Rabbit polycl. 
anti-human 
Rab 5A 
Code  
s-19 
 
C-terminal region 
of human Rab 5A 
1.33 μg/ml (IF) Santa Cruz 
Biotechnology 
Rabbit polycl. 
anti-human 
Rab11 
Code  
71-5300 
C-terminal region 
of human Rab11a 
10 μg/ml (IF) Invitrogen, Paisley, 
UK 
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Mouse mAb 
anti-human 
Lamp1 
H4A3,  
IgG1 
Human Lamp1 0.4 μg/ml (IF) Abcam 
Rabbit polycl. 
anti-mouse or 
human β-Pix  
Code  
07-1450  
 
GST fusion of 
SH3 domain of 
βPIX 
1 μg/ml (WB), 
10 μg/ml (IF) 
Millipore 
Mouse mAb 
anti-rat GIT1, 
recognises 
human GIT1 
13, 
IgG2a 
C-terminal 664-
770 aa of rat 
GIT1 
1.25 μg/ml (WB) BD Biosciences 
Rabbit polycl. 
anti-human 
GIT1 
Code        
H-170 
471-640 aa of 
human GIT1 
2 μg/ml (IF) Santa Cruz 
Biotechnology 
Mouse mAb 
anti-chicken 
talin, recogn. 
human talin 
8D4,  
IgG1 
Talin purified 
from chicken 
gizzard 
1:200 
(stock as ascites 
fluid) 
Sigma-Aldrich 
Mouse mAb 
anti-human 
vinculin 
hVIN-1,  
IgG1 
Human vinculin 
from uterus 
20 μg/ml (IF) Sigma-Aldrich 
Mouse mAb 
anti-human 
pFAK (Y397) 
14,  
IgG1 
Human FAK 
(pY397) Peptide 
1.25 μg/ml (IF) BD Biosciences 
Goat polycl. 
anti-human 
VEGFR2 
AF357 Human VEGFR2 
extracellular 
domain 
2 μg/ml (FACS) R&D Systems, 
Minneapolis, USA 
Mouse mAb 
anti-chicken 
tubulin, 
recognises 
human tubulin 
DM1A, 
IgG1 
Chick brain α-
tubulin 
0.1 μg/ml (WB) Sigma-Aldrich 
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Tab. 2.3 Secondary antibodies.  
Abbreviations: HRP, horseradish peroxidise; FITC, fluorescein-5-isothiocyanate; WB, 
western blotting; IF, immunofluorescence; FACS, fluorescence activated cell sorting 
 
Antibody 
against 
Conjugation Host 
species 
Working 
concentration 
Supplier 
Mouse IgG HRP Goat 1 μg/ml (WB) Dako, Ely, UK 
Rabbit IgG HRP Donkey 0.056 μg/ml (WB) GE Healthcare, Chalfont 
St Giles, UK 
Goat IgG FITC Donkey 15 μg/ml (FACS) Stratech Scientific, 
Newmarket, UK 
Mouse IgG Alexa488 Goat 4 μg/ml (IF) Invitrogen 
Mouse IgG Alexa546 Goat 4 μg/ml (IF) Invitrogen 
Rabbit IgG Alexa488 Donkey 4 μg/ml (IF) Invitrogen 
Rabbit IgG Alexa546 Goat 4 μg/ml (IF) Invitrogen 
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2.4. DNA oligonucleotides 
Tab. 2.4 DNA oligonucleotides used for cloning, sequencing or mutagenesis.  
All DNA primers were purchased from Eurogentec (Southampton, UK) and were designed to 
amplify sequences of human genes, unless otherwise stated. For the sequencing primers in the 
brackets are given the spans of bases in the open reading frame of indicated genes. 
Abbreviations: fw, forward; rv, reverse; aa, amino acids; seq, sequencing. 
 
Primer  Primer sequence (5’-3’) Primer application 
SH01 tagtagggatccatgaactgcaaagagggaactg Fw RhoJ, cloning 
VH05 cacgtttggtggtggcgacc Fw pGEX, seq. 
VH266 tagtagaagcttgaattctcagataattgaacagcagctgtg Rv RhoJ, cloning 
VH274 tagtagaagctttcagctgtgaccctcagaacagcg Rv RhoJ (-CAAX), cloning        
VH292 ccgggagctgcatgtgtcagagg Rv pGEX, seq. 
KB1 cagcaggcaggttttcgccacggcgccgtcccccaccaccac Fw G33A RhoJ, mutagenesis 
KB2 gtggtggtgggggacggcgccgtggcgaaaacctgcctgctg Rv G33A RhoJ, mutagenesis 
KB3 tagtagggatccaactgcaaagagggaactg Fw RhoJ (-ATG), cloning 
KB4 cgccaccatggaacaaaaactcatctcagaagaggatctgg Fw Kozak-myc, cloning 
KB5 gatcccagatcctcttctgagatgagtttttgttccatggtggcggtac Rv Kozak-myc, cloning 
KB6 tagtaggaattcatgaactgcaaagagggaactg Fw RhoJ, cloning 
KB7 tagtagggatcctcagctgtgaccctcagaacagcgttt Rv RhoJ (-CAAX), cloning        
KB12 tagtagggatccttatgtcaaataacggcttagacgtc Fw CRIB, cloning 
KB13 tagtaggaattctcagatctcctcatcagacatttctgg Rv CRIB, cloning 
KB14 tagtagggatccttatgtctggagaagtgcgtttgaggcagttg Fw MRCKA, cloning 
KB15 tagtagctcgagtcacgggtcccagctcccgcggtcagtgct Rv MRCKA, cloning 
KB16 tagtagggatccttatgctcaagtgcatcccgctgtggcgc Fw scribble, cloning 
KB18 tagtaggaattcctaggagggcacagggcccaggccacggcg Rv scribble, cloning 
KB19 tagtaggaattcttatgaatccagaagaacaaatcgtgaca Fw αPIX, cloning 
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KB20 tagtagctcgagttatggaagaattgaggtcttgctact Rv αPIX, cloning 
KB23 tagtaggaattcttatgtcccgaaaggggccgcgagcggaggtg Fw GIT1, cloning 
KB24 tagtaggaattctcactgcttcttctctcgggtggtgatggt Rv GIT1, cloning 
KB26 tagtagctcgaggaatgtccgccgcagacgaggttgacgggctg Fw IQGAP1, cloning 
KB27 tagtagctcgagttacttcccgtagaactttttgttgagaag Rv IQGAP1, cloning      
KB28 gagtagtaacaaaggtcaaagaca Fw pGBT9, insert seq. 
KB29 gagtcactttaaaatttgtatacac Rv pGBT9, insert seq. 
KB30 aataccactacaatggatgatgta Fw pACT2, insert seq. 
KB34 gcaaatttgaagatagattgcc Fw MRCKA, seq. (500-521) 
KB35 catcgaattttgatgtagatgatg Fw MRCKA, seq. (1103-1126) 
KB36 cgcacactgtcagaggaaactgg Fw MRCKA, seq. (1701-1723) 
KB37 ctgacgagtgaacttgataagc Fw MRCKA, seq. (2235-2356) 
KB38 ctggatcaatttgaaactgtagac Fw MRCKA, seq. (2890-2913) 
KB39 gctagcagacactgagaatgag Fw MRCKA, seq. (3504-3525) 
KB40 ctaagataccccttgaatggag Fw MRCKA, seq. (4102-4123) 
KB41 caagattcaactttaagcagac Fw αPIX, seq. (500-521) 
KB42 cattttaacaacaaacctcagc Fw αPIX, seq. (1101-1122) 
KB43 gcaccacacctctgcacgtggc Fw GIT1, seq. (500-521) 
KB44 gagcctgagcagccccacagac Fw GIT1, seq. (1101-1122) 
KB45 gcgtccctgtcatttctggtcaagc Fw scribble, seq. (502-526) 
KB46 ccgcctgcagagtctgccgttcg Fw scribble, seq. (1104-1126) 
KB47 ccacggtgcatttcgcagaggacg Fw scribble, seq. (1700-1726) 
KB48 gccctgcggcccgggctggagtc Fw scribble, seq. (2300-2322) 
KB49 ccgctgctgttgccaccaccagc Fw scribble, seq.(2897-2919) 
KB50 gcctgacgcacggcgaggcggtg Fw scribble, seq. (3500-3522) 
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KB51 gaggatgcccctgcccagcccccc Fw scribble, seq. (4000-4023) 
KB52 cctcagattcaagacctatatgg Fw IQGAP1, seq. (496-518) 
KB53 ctgcagtctggagtggatgctgc Fw IQGAP1, seq. (1111-1133) 
KB54 gaaatccaggatgagtcagctgtg Fw IQGAP1, seq. (1777-1800) 
KB55 ggcatatcaagatcggttagct Fw IQGAP1, seq. (2379-2400) 
KB56 ccaccaagttcatggactctgtaatc Fw IQGAP1, seq. (2993-3018) 
KB57 gttgctcctgatgcctttgacatc Fw IQGAP1, seq. (3601-3624) 
KB58 ggagagaccttgactgaaatcc Fw IQGAP1, seq. (4201-4222) 
KB63 gtttttcagtatctacgattc Rv pACT2, insert seq. 
KB64 tagtaggaattcctatagattggtctcatcccaagcagg Rv rat βPIX, cloning 
KB67 tagtaggaattcttatgactgataacgccaacagccaactg Fw rat βPIX, cloning 
KB68 accgctcatcctgggactggcaga Rv rat βPIX, seq. (1000-1023) 
KB69 ttttggcagcagctttttcatggt Rv rat βPIX, seq. (1501-1524) 
KB71 tagtagaagctttgatgaactgcaaagagggaactgac Fw RhoJ, cloning 
KB72 tagtagggatccgccaccatggtgagcaagggc Fw Kozak-GFP, cloning 
KB73 gggattggggggtacagtgcaggg Fw pWPXL, seq. (3361-3384) 
KB77 tagtaggaattctcagtctgtggggctgctcaggctctt Rv GIT1…-378aa , cloning 
KB80 cccatggcgccaggcgggagcaca Fw GIT1, seq. (1501-1524) 
KB81 tagtagggatcctttctcggcaaaagtgcatgtctcag Fw GIT1255aa-… , cloning 
KB82 tagtaggaattctcaggcactgcgctctgtcaccagagt Rv GIT1…-320aa , cloning 
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2.5. Plasmids 
DNA constructs were generated according to cloning or mutagenesis procedures, as described 
in 2.9.1 or 2.9.2, respectively. These are listed in Table 2.5. The DNA constructs provided by 
other scientists and used for transfections or as templates for cloning are listed in Table 2.6. 
Tab. 2.5 Cloned DNA constructs.  
The amplified inserts contain sequences of human genes, unless otherwise stated. 
 
Construct Cloning details 
pGEX-4T2-wtRhoJ    
(lacking CAAX box) 
wtRhoJ-CAAX was amplified with the SH01 & VH274 
primers (BamHI-blunt insert digest) and cloned into the 
BamHI-SmaI restriction sites of pGEX-4T2. 
pGEX-4T2-daRhoJ (Q79L) 
(lacking CAAX box) 
daRhoJ-CAAX was amplified with the SH01 & VH274 
primers (BamHI-blunt insert digest) and cloned into the 
BamHI-SmaI restriction sites of pGEX-4T2. 
pGEX-4T2-dnRhoJ (T35N) 
(lacking CAAX box) 
dnRhoJ-CAAX was amplified with the SH01 & VH274 
primers (BamHI-blunt insert digest) and cloned into the 
BamHI-SmaI restriction sites of pGEX-4T2. 
pGEX-4T2-dnRhoJ (G33A) 
(lacking CAAX box) 
Created by mutagenesis of pGEX-4T2-wtRhoJ-CAAX 
construct with primers KB1 & KB2. 
pMAL-2CE-wtRhoJ  
(lacking CAAX box) 
wtRhoJ-CAAX was amplified with the SH01 & VH274 
primers and cloned into the BamHI-HindIII restriction sites 
of pMAL-2CE. 
pEF6A-myc-wtRhoJ Kozak-myc sequence was generated by annealing of KB4 
& KB5 primers and digested with KpnI-BamHI. wtRhoJ (-
ATG) was amplified with the KB3 & VH266 and digested 
with BamHI-EcoRI. Kozak-myc and wtRhoJ inserts were 
cloned into the KpnI-EcoRI restriction sites of pEF6A. 
pWPXL-GFP-wtRhoJ wtRhoJ was amplified with the KB71 & VH266 primers 
and cloned into the HindIII-EcoRI restriction sites of 
pEGFP-C1. GFP-wtRhoJ insert was then amplified from 
pEGFP-C1-wtRhoJ with the KB72 & VH266 primers and 
cloned into the BamHI-EcoRI restrictions sites of pWPXL, 
replacing the existing EGFP insert. 
pWPXL-GFP-daRhoJ 
(Q79L) 
daRhoJ was amplified with the KB71 & VH266 primers 
and cloned into the HindIII-EcoRI restriction sites of 
pEGFP-C1. GFP-daRhoJ insert was then amplified from 
pEGFP-C1-daRhoJ with the KB72 & VH266 primers and 
cloned into the BamHI-EcoRI restrictions sites of pWPXL, 
replacing the existing EGFP insert. 
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pGBT9-wtRhoJ          
(lacking CAAX box) 
wtRhoJ-CAAX was amplified with the KB6 & KB7 
primers and cloned into the EcoRI-BamHI restriction sites 
of pGBT9. 
pGBT9-daRhoJ (Q79L) 
(lacking CAAX box) 
daRhoJ-CAAX was amplified with the KB6 & KB7 
primers and cloned into the EcoRI-BamHI restriction sites 
of pGBT9. 
pGBT9-dnRhoJ (T35N) 
(lacking CAAX box) 
dnRhoJ-CAAX was amplified with the KB6 & KB7 
primers and cloned into the EcoRI-BamHI restriction sites 
of pGBT9. 
pACT2-CRIB                      
(1-252 aa of rat PAK1 which 
encompasses the CRIB 
domain) 
The CRIB domain was amplified with the KB12 & KB13 
primers and cloned into the BamHI-EcoRI restriction sites 
of pACT2. 
pACT2-MRCKA MRCKA was amplified with the KB14 & KB15 primers 
and cloned into the BamHI-XhoI restriction sites of 
pACT2. 
pACT2-GIT1 GIT1 was amplified with the KB23 & KB24 primers and 
cloned into the EcoRI restriction site of pACT2. 
pACT2-GIT1255-378aa GIT1255-378aa was amplified with the KB81 & KB77 
primers and cloned into the BamHI-EcoRI restriction sites 
of pACT2. 
pACT2-GIT1255-320aa GIT1255-320aa was amplified with the KB81 & KB82 
primers and cloned into the BamHI-EcoRI restriction sites 
of pACT2. 
pACT2-αPIX αPIX was amplified with the KB19 & KB20 primers and 
cloned into the EcoRI-XhoI restriction sites of pACT2. 
pACT2-βPIX (rat) βPIX was amplified with the KB67 & KB64 primers and 
cloned into the EcoRI restriction site of pACT2 
pACT2-IQGAP1 IQGAP1 was amplified with the KB26 & KB27 primers 
and cloned into the XhoI restriction site of pACT2. 
pACT2-scribble Scribble was amplified with the KB16 & KB18 primers 
and cloned into the BamHI-EcoRI restriction sites of 
pACT2. 
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Tab. 2.6 Other plasmids.  
The plasmids listed in the table contain sequences of human genes, unless otherwise stated. 
 
Plasmid Kindly provided by 
pEF6A-HA-wtRhoJ, pEF6A-HA-daRhoJ(Q79L),       
pEF6A-HA-dnRhoJ(T35N),   
pEF6A-flag-wtRhoJ, pEF6A-flag-daRhoJ(Q79L),     
pEF6A-flag-dnRhoJ(T35N), pEF6A 
Dr Victoria Heath 
University of Birmingham, UK 
(unpublished) 
pGBT9, pACT2 
Dr Victoria Heath 
(Heath, Shaw et al. 2004) 
pEGFPC2-wtRhoJ 
Dr Phillipe Fort 
CNRS, Montpellier, France 
(Vignal, De Toledo et al. 2000) 
pRK5-HA-wtRac1, 
pRK5-flag-wtCdc42, 
pRK5-myc-daRhoA (G14V) 
Prof L.Machesky 
University of Birmingham, UK 
(unpublished) 
pEF-flag-MRCKA-isob-FL 
Prof Chris J. Marshall 
The Institute of Cancer Research, 
London, UK 
(unpublished) 
pCDEF3-flag-β-Pix (rat) 
pEGFP-N1-wt-β-Pix (rat) 
Prof Arthur Weiss 
UCSF, USA 
(Phee, Abraham et al. 2005) 
pMT2SH-HA-α-Pix 
Dr Georg Rosenberger 
University Hospital,             
Hamburg-Eppendorf, Germany 
(Rosenberger, Gal et al. 2005) 
pEGFP-GIT1 
Dr Alan Horwitz 
University of Virginia, USA 
(Manabe, Kovalenko et al. 2002) 
pEGFP-C1-scribble 
Dr Michael Sebbagh 
CRCM, Marseille, France 
(Audebert, Navarro et al. 2004) 
pEF-BOS-mycIQGAP 
 Prof. John Heath  
 University of Birmingham, UK 
(unpublished) 
Lentiviral plasmids: 
pWPXL, pWPI, psPAX2, pMD2G  
Addgene, Didier Trono Lab 
http://www.addgene.org 
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2.6. siRNA duplexes 
Tab. 2.7 siRNA duplexes.  
All designed siRNA duplexes contain dTdT overhang modifications on sense and antisense 
strands. The base pair numbers of isoforms 1 of βPIX or GIT1 genes that are targeted by 
corresponding duplexes are indicated. However, both βPIX- or GIT1-specific duplexes listed 
here target all isoforms of βPIX or GIT1 genes, respectively. All siRNA duplexes were 
purchased from Eurogentec. 
 
 
siRNA duplex 
name 
 
Targeted gene 
 
Duplex sense strand (5’-3’) 
 
Gene base pairs 
targeted by duplex 
RhoJ-siRNA1 Human RhoJ ccacuguguuugaccacuau 155-174 
RhoJ-siRNA2 Human RhoJ agaaaccucucacuuacgag 455- 474 
βPIX-siRNA1 Human βPIX ggaagaagaugcucagauu 1587-1605 (in isoform 1) 
βPIX-siRNA2 Human βPIX agagacacauggaggauua 728-746 (in isoform 1) 
GIT1-siRNA1 Human GIT1 ccaagaacauucaggaacu 1985-2003 (in isoform 1) 
GIT1-siRNA2 Human GIT1 cgagcugcuuguaguguau 549-567 (in isoform 1) 
Ctrl-siRNA Non-silencing 
control 
Sequence not disclosed by 
Eurogentec;  
(Cat No: OR-0030-Neg05) 
Non-specific to known 
sequences of  human 
genes  
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2.7. Mammalian cell culture 
2.7.1. Mammalian cells and media 
HUVECs were isolated from umbilical veins obtained from Birmingham Women’s Health 
Care NHS Trust; cords were donated with informed consent. HUVECs were grown in M199 
medium (CRUK Central Services or Sigma-Aldrich) supplemented with either bovine brain 
extract (prepared as in (Maciag, Cerundolo et al. 1979)) or with large vessel endothelial 
growth supplements (TCS CellWorks, Buckingham, UK). This medium contained also 90 
μg/ml of heparin, 10 % (v/v) fetal calf serum (FCS) (PAA Cell Culture Co, Ontario, USA), 4 
mM L-glutamine (CRUK Central Services or Sigma-Aldrich), and if required antibiotics 
gentamicin/amphotericin B (TCS CellWorks) and/or penicillin/streptomycin (Invitrogen). 
This medium is referred to as HUVECs medium. The isolation of HUVECs and preparation 
of bovine brain extract was performed by Mr James Beesley (Molecular Angiogenesis Group, 
University of Birmingham). HUVECs were cultured in medium containing antibiotics unless 
the siRNA-mediated knock-down of genes was performed (as in section 2.16). The 
immortalised human microvascular endothelial cell line-1 (HMEC-1) (Ades, Candal et al. 
1992) was maintained in the same conditions as HUVECs. Human embryonic kidney 293T 
cells (HEK 293Ts) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich) supplemented with 10 % (v/v) FCS (PAA Cell Culture Co), 4 mM L-glutamine 
(CRUK Central Services or Sigma-Aldrich) and pen/strep antibiotics (Invitrogen). 
All mammalian cells were grown in sterile plastic culture dishes (Falcon, Becton Dickinson 
Labware, Franklin Lakes, USA) and incubated in a humidified atmosphere with 5 % CO2 
supply at 37 °C (Sanyo CO2 incubator, Sanyo Electric CO, Japan). For culturing HUVECs 
and HMEC-1, plastic dishes were coated additionally with gelatin, prior to use. This was 
performed by covering dishes with 0.1 % (w/v) gelatin (dissolved in PBS and filtered) and 
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incubating for 20 min at 37 °C. After this time, gelatin solution was removed and cells were 
seeded in culture medium. Media for culturing cells were filtered through sterile 0.22 µm pore 
filters (Millipore) before use. PBS (CRUK Central Services or Sigma-Aldrich) for washing 
cells was sterilised by autoclaving prior to use. 
Growth and conditions of mammalian cells in culture were routinely monitored using Leica 
DM IL microscope (Leica Microsystems, Houston, USA). 
2.7.2. Passaging cells 
Cells were split at a ratio of 1:3 once a week (HUVECs and HMEC-1) or at a ratio of 1:10 
twice a week (HEK 293Ts). A confluent monolayer of cells (in a 10 cm-diameter culture dish) 
was washed with 10 ml of PBS, covered with 2.5 ml of trypsin-EDTA solution (CRUK 
Central Services or Sigma-Aldrich) and incubated for 5 min at 37 °C. Afterwards cells were 
collected from a plate with 10 ml of PBS and 10 ml of complete medium. It was important to 
add medium as it contains FCS, which inhibits the enzymatic activity of trypsin. Cells were 
then centrifuged for 5 min (195 x g, room temperature), resuspended in fresh complete 
medium and plated in a volume of 10 ml per one 10 cm-diameter dish. 
2.7.3. Counting cells 
When specified numbers of cells were required in particular experiments, the cells were 
counted before plating. After trypsinisation (section 2.7.2) cells were resuspended in fresh 
complete medium. 5 µl of cell suspension was then mixed with 5 µl of trypan blue to identify 
dead cells and cells were counted using the haemocytometer counting chamber (Neubauer, 
Paul Marienfeld GmbH & CO, Germany) according to manufacturer’s instructions.  
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2.7.4. Freezing and storing cells 
After trypsinisation (section 2.7.2) cells were resuspended in freezing medium containing 10 
% (v/v) dimethyl sulfoxide and 90 % (v/v) FCS (PAA Cell Culture Co). The cell suspension 
was then frozen in the Mr. Frosty freezing container (NalgeneTM, Thermo Fisher Scientific, 
Rochester, USA) for 24 h at -80 °C and subsequently transferred to the liquid nitrogen stores. 
2.8. Bacteria strains, media and antibiotics 
The chemically competent Escherichia coli (E. coli) strains DH5α, BL21(DE3) pLys S 
or XL1-Blue Supercompetent Cells (Stratagene, La Jolla, USA) were used for transformations 
with various plasmids. All bacteria were cultured in Luria Bertani (LB) broth or LB agar 
(both from CRUK Central Services or Fisher Scientific) with addition of appropriate 
antibiotics. Final concentrations of antibiotics were used as follows: 0.1 mg/ml ampicillin 
(Amp), 0.02 mg/ml chloramphenicol (Chloramph) and 0.03 mg/ml kanamycin (Kan). Bacteria 
were grown on LB agar at 37 °C (CellStar incubator, Borolabs Ltd, Basingstoke, UK) and 
when in liquid LB medium bacteria were grown in the orbital shaking incubator 
(Sanyo/Gallenkamp, Loughborough, UK) at 30-37 °C. 
2.9. Manipulation of DNA material 
2.9.1. Cloning 
The cloning process was performed as summarised in Fig. 2.1 and particular steps are 
described in the next sections. Reagents, enzymes and their compatible buffers used in 
cloning were purchased from New England Biolabs (NEB) (Herts, UK), unless otherwise 
stated. 
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DNA gel purification 
Vector 
Restriction digest 
PCR quick DNA purification 
Insert generated by PCR 
Restriction digest 
DNA gel purification 
Ligation of plasmid and insert 
Transformation 
Construct DNA mini-preparation Colony-PCR screen 
Restriction digest screen 
Sequencing 
Fig. 2.1 Cloning process. 
The DNA sequence of interest (insert) was amplified with forward and reverse primers which contained 
specific restriction sites. The insert and vector were then digested with restriction enzymes, resolved by 
agarose gel electrophoresis and purified. The insert was then ligated into specific sites of vector created 
earlier by restriction digest. The vector-insert construct was subsequently introduced into bacteria by 
transformation and bacteria were grown on selective LB agar medium. Colonies positive for cloned 
construct were then identified by PCR screening or diagnostic digest. Plasmids were isolated from 
positive colonies and were finally sequenced to verify the absence of mutations. 
2. MATERIALS AND METHODS 
64 
 
2.9.1.1. Production and purification of plasmids 
Large scale preparation of plasmids was performed from bacterial cultures using the 
GenEluteTM Plasmid Maxiprep Kit or Qiagen Plasmid Maxi Kit (Qiagen, Crawley, UK) 
according to the manufacturer’s protocols. For small-scale plasmid preparations DNA was 
isolated using the GeneJETTM Plasmid Miniprep Kit (Fermentas, York, UK). Final DNA 
concentration was measured with the NanoDrop ND-1000 Spectrophotometer (Labtech, 
Ringmer, UK). 
2.9.1.2. Amplification of insert by PCR 
Inserts were prepared by polymerase chain reaction (PCR) using a high fidelity polymerase as 
follows. 100 μl reaction mixes were prepared by adding: 74 μl of water, 20 μl of 5x Phusion 
HF Buffer, 2 μl of 10 mM deoxyribonucleotide triphosphate (dNTP) mix (Bioline, London, 
UK), 1 μl of each 100 μM primer (Eurogentec) and 1 μl of PhusionTM High-Fidelity DNA 
Polymerase (Finnzymes, Espoo, Finland). Finally 500 ng of template DNA was added. The 
PCR reaction involved an initial denaturation (98 ºC, 30 s), then 24 cycles of denaturation (98 
ºC, 10 s), annealing (55 ºC, 30 s) and elongation (72 ºC, 1 min/kb of amplicon). A final DNA 
elongation step of 72 ºC for 10 min was included. 
2.9.1.3. PCR quick DNA purification 
Inserts generated by PCR reaction were purified with QIAquick Purification Kit (Qiagen) to 
remove nucleotides and salts prior to restriction digest. 
2.9.1.4. Digestion of DNA with restriction enzymes 
Large scale preparative restriction digests of insert and vector DNA for cloning were 
performed as follows. Purified PCR product (from a 100 μl reaction) or 5 μg of plasmid were 
incubated in 50 μl of digestion solution containing: 5 μl of 10x NEBuffer compatible with the 
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appropriate restriction enzymes, 5 μl of 10x bovine serum albumin (BSA) (if necessary), 2.5 
μl of each restriction enzyme (20000 U/ml) and water. Digestion was carried out for 2 h in the 
temperature required for each enzyme. Restriction digests for diagnostic purposes only were 
scaled down appropriately to 10 μl volumes. 
2.9.1.5. DNA gel electrophoresis 
DNA agarose-gel electrophoresis was performed using equipment for horizontal 
electrophoresis (Jencons Scientific Ltd, a VWR Division, East Grinstead, UK). Gels were 
prepared by dissolving 0.8 – 1.5 % (w/v) agarose (VWR International, Lutterworth, UK or 
Sigma-Aldrich) in TAE buffer (CRUK Central Services) and stained with SYBR Safe 
(Invitrogen). Gels were visualised and imaged using Gene Genius Bio Imaging System 
(Syngene, Cambridge, UK). 
2.9.1.6. DNA gel purification 
DNA bands were cut from the gel and DNA was extracted using QIAEX II Agarose Gel 
Extraction Kit (Qiagen) or GeneJETTM Gel Extraction Kit (Fermentas) according to the 
manufacturer’s instructions. 
2.9.1.7. DNA ligations 
Inserts were ligated with appropriate plasmids using T4 Ligase as follows. 2 μl of 400000 
U/ml T4 Ligase enzyme and 2 μl of T4 Ligase Buffer were added to the 16 μl of insert:vector 
mixture prepared in a ratio of 3:1. Ligations were performed at room temperature for 1 h. 
2.9.1.8. Heat-shock transformation of bacteria 
Chemically competent E. coli (20-50 μl) were mixed with 5 µl of ligation mix or 50-500 pg of 
plasmid and incubated on ice for 30 min. Afterwards, bacteria were heat shocked at 42 ºC for 
90 s and incubated on ice for further 2 min. The transformation mix was diluted into 250 µl of 
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pre-warmed antibiotic-free LB-broth and allowed to recover for 1 h in an orbital shaker 
incubator at 37 ºC. Subsequently bacteria were plated on LB-agar plates (containing 
appropriate antibiotics) for overnight incubation at 37 ºC. 
2.9.1.9. Colony- PCR screen 
Colony PCR was used to screen for successful ligation of vector and insert. A 20 µl PCR 
reaction was prepared per colony screened by adding: 16 µl of water, 0.4 µl of 10 mM dNTPs 
(Bioline), 2 µl of 10x NH4 buffer (Bioline), 1 µl of 50 mM MgCl2 (Bioline), 0.2 µl of each 
100 μM primer (Eurogentec), 0.2 µl of Taq polymerase (Bioline) and bacterial colony sample. 
Prior to mixing with the PCR mix, a replica plate was set up containing samples of each 
colony screened. The PCR reaction was performed as follows: initial denaturation (94 ºC, 2 
min), then 30 cycles of denaturation (94 ºC, 30 s), annealing (55 ºC, 30 s) and elongation (72 
ºC, 1 min/ 1kb of amplicon). A final DNA elongation step of 72 ºC for 5 min was included. 
PCR products were visualised by DNA gel electrophoresis. Colonies which gave positive 
results were used for small or large scale plasmid preparations as described above. 
2.9.1.10. Sequencing and storing of plasmids 
All constructed plasmids were verified by sequencing by the Functional Genomics and 
Proteomics Laboratory (School of Biosciences, University of Birmingham, UK). All 
constructs were stored as glycerol stocks at -80 ºC. These were prepared by mixing the 
saturated bacterial cultures with an equal volume of 30 % (v/v) glycerol (CRUK Central 
Services). 
2.9.2. Site-directed mutagenesis  
The nucleotide free dominant negative RhoJ mutant was created using the QuickChange® II 
Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s method. Briefly, 
2. MATERIALS AND METHODS 
67 
 
a PCR reaction with pGEX-4T2-wtRhoJ plasmid as a template and primers (KB1 and KB2) 
was performed. These primers encoded a single amino acid change (G33A) and additionally 
contained single nucleotide changes, which created a restriction site for NarI, a RhoJ-non-
cutting enzyme, without affecting the amino acid sequence. The PCR reaction mixture was 
then treated with DpnI, which digested methylated parental plasmid. Then 1 μl of DpnI-
treated solution was transformed into 50 μl of XL1-Blue Supercompetent Cells by heat-shock 
(30 min on ice, then 45 sec at 42 ºC and back on ice for 2 min). Subsequently cells were 
recovered by incubation in 250 µl of pre-warmed antibiotic-free LB medium and plated on 
LB-agar plate containing Amp. Colonies were screened by colony PCR followed by 
restriction digest with NarI. Successful mutagenesis was confirmed by DNA sequencing. 
2.10. Analysis of proteins 
2.10.1. Protein production and purification 
Plasmids encoding fusion proteins were transformed into chemically competent BL21(DE3) 
pLys S E. coli strain by heat shock (method 2.9.1.8) and plated on LB-agar plates containing 
appropriate antibiotics (Amp or Kan with Chloramph). Colonies were inoculated in LB-broth 
(Amp or Kan and Chloramph), incubated over night at 37 ºC with shaking and then diluted 
100-fold into LB-broth (Amp or Kan and Chloramph). Then bacteria were cultured at 30 ºC 
until they reached the mid-log phase growth, when they were induced with 0.3 mM iso-
propyl-β-D-thiogalactopyranoside (IPTG) (Melford Laboratories, Suffolk, UK) for 2.5 h. 
After induction, bacteria were centrifuged (10 min, 4435 x g, 4 ºC), washed with E. coli 
washing buffer and centrifuged again. Bacterial pellets were frozen at -80 ºC prior to lysis. 
Subsequently, bacteria were thawed on ice, lysed with ice-cold E. coli lysis buffer (2 ml of 
lysis buffer per bacterial pellet from 100 ml of culture) and ultra-sonicated for 3 min 
(Ultrasonicator Vibra CellTM, Sonics & Materials, Newtown, USA). For purification of 
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proteins other than RhoJ fusions, Triton-X-100 (Sigma-aldrich) was added to a final 
concentration of 1% (v/v) and bacterial lysates were left on ice for 30 min. After sonication 
and optional incubation with Triton-X-100, lysates were clarified by centrifugation (10 min, 
21910 x g, 4 ºC), the supernatant collected and mixed with an equal volume of glycerol 
(CRUK Central Services) to give a final concentration of 50% (v/v). Protein lysates were 
stored at -20 ºC.  
Fusion proteins were purified from bacterial lysates by pull-down with appropriate beads. 
Glutathione-agarose beads were used to pull-down/purify proteins fused to GST and amylose 
beads (NEB) were used to pull-down/purify proteins fused to maltose binding protein (MBP). 
Firstly the amount of fusion protein in bacterial lysate was assessed as follows. Different 
volumes of bacterial lysate (e.g. 25, 50, 100 and 200 µl) were diluted with E. coli lysis buffer 
up to 1 ml and incubated with 12.5 µl of packed beads for 45-60 min at 4 ºC on a rotating 
wheel. The beads were then washed 3 times with E. coli lysis buffer and finally resuspended 
in equal volume of 2x SDS sample-loading buffer. These samples along with 1, 5 and 10 µg 
of BSA samples were loaded on a polyacrylamide gel and subjected to sodium dodecyl 
sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) (as described in section 2.10.4). 
The proteins were then stained in gel by Coomassie dye (as described in section 2.10.4) and 
the amount of pulled-down fusion proteins was determined by comparison to BSA markers.  
In order to purify approximately 5-15 µg of fusion protein from bacterial lysate 12.5 µl of 
packed glutathione-agarose or amylose beads were used. Fusion proteins on beads were then 
used for various assays or alternatively beads with proteins were resuspended in equal volume 
of 2x SDS sample-loading buffer and analysed by SDS-PAGE/western blotting (sections 
2.10.4-2.10.5).  
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MBP-wtRhoJ-CAAX protein used as antigen for production of polyclonal RhoJ antibodies in 
rabbits was produced as above and purified from bacterial lysate using amylose beads. To 
elute MBP-wtRhoJ-CAAX from amylose beads 10 mM maltose (made in 20 mM Tris-Cl pH 
7.5, 200 mM NaCl, 1mM EDTA, 10 mM 2-mercaptomethanol) was used and the 
concentration of the fusion protein was assesd with the Bio-Rad assay (as in section 2.10.3).  
2.10.2. Preparation of mammalian cell lysates 
Unless specified otherwise, the procedure described in this section was used to obtain 
mammalian cellular lysates. Confluent plates (10 cm diameter) of HUVECs, HMEC-1 or 
HEK 293Ts were washed with PBS and lysed on plates by adding 200 µl (for HUVECs and 
HMEC-1) or 1 ml (for HEK 293Ts) of Rho-assay lysis buffer (supplemented with protease 
inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF). Cells were scraped quickly with a cell 
scraper (Fisher Scientific) and transferred into 1.5 ml microfuge tubes. The cells were lysed 
for 10 min on ice and centrifuged for another 10 min (21910 x g, 4 ºC). The supernatant was 
used directly in different assays or stored at -80 ºC in 10 % (v/v) glycerol. Alternatively, for 
further SDS-PAGE (section 2.10.4) mammalian cell lysates were mixed with equal volumes 
of 2x SDS sample-loading buffer. 
2.10.3. Protein quantification 
The amount of proteins present in mammalian cellular lysates was measured using Bio-Rad 
DC Protein Assay (Bio-Rad Laboratories, Hemel Hempstead, UK) according to the 
manufacturer’s instructions. This was performed in a 96-well plate (C96 Maxisorp, Thermo 
Fisher Scientific). Briefly, 5 µl of lysate was mixed in well with 25 µl of Bio-Rad mixture 
(made by combining of 20 µl reagent S with 1 ml reagent A) and with 200 µl reagent B. In 
parallel, samples containing known amount of BSA (0, 2, 4, 8, 1.6 mg/ml) were mixed with 
the same Bio-Rad reagents in separate wells. After 15 min incubation at room temperature the 
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colour in protein samples had developed and absorbance was measured at 750 nm wavelength 
using Versamax microplate reader spectrophotometer (Molecular Devices). Based on the 
absorbance values obtained for known BSA concentrations the protein standard curve was 
created using Microsoft Excel Software and the concentration of proteins in lysate samples 
was determined. When possible, the protein samples were measured in triplicate to obtain 
more accurate values.   
2.10.4. SDS-PAGE 
Protein samples (mixed previously with 2x SDS sample-loading buffer) were boiled for 5 
min, collected by centrifugation for 10 s and loaded on a polyacrylamide gel. Polyacrylamide 
gels were prepared according to Sambrook and Russel (Sambrook and Russel 2001). The 
polyacrylamide used to make these gels (Protogel) was from National Diagnostics (Hessle 
Hull, UK) and contained 30 % w/v Acrylamide : 0.8 % (w/v) Bis-Acrylamide in a proportion 
of 5:1. SDS-PAGE was carried-out using the X cell II™ Mini cell and X cell sure lock™ 
system (Invitrogen). Electrophoresis was performed in SDS-PAGE running buffer at 100 V 
until the dye front had reached the resolving buffer at which point the voltage was increased 
to 160 V. When electrophoresis was finished the gel was stained with Coomassie dye. This 
was performed by immersing gel in Coomassie staining buffer and rocking for at least 1 h at 
room temperature. The gel was then de-stained at room temperature using Coomassie de-
staining buffer. Alternatively, after SDS-PAGE the gel with proteins was subjected to western 
blotting (2.10.5). 
2.10.5. Western blotting 
The Immobilon-P polyvinylidene fluoride (PVDF) membrane with 0.45 μm pores (Millipore) 
was activated by pre-wetting in methanol for 30 s and then placed in transfer buffer. The 
polyacrylamide gel with protein samples (after SDS-PAGE), blotting paper and blotting pads 
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were also soaked in transfer buffer for 10 min prior to assembling the transfer apparatus in the 
X cell II™ Mini cell, X cell II™ Blot Module and X cell sure lock™ (Invitrogen). Wet 
transfer was performed at 30 V for 1-2 h at 4 ºC. Proteins transferred onto the membrane were 
stained with Ponceau S dye to check for successful transfer. The membrane was then blocked 
with 5 % dried milk (prepared in TBST buffer) for 1 h at room temperature. Subsequently, the 
membrane was incubated overnight with an appropriate primary antibody (diluted in solution 
containing 3 % (w/v) BSA, 3 mM NaN3 and TBST) at 4 ºC. The membrane was then washed 
for 30 min in TBST with 6 buffer changes and placed in secondary antibody conjugated with 
horseradish peroxidase (HRP). After 1 h of incubation at room temperature, the membrane 
was washed for 30 min as above and developed with ECL Western Blotting 
Detection Reagents (GE Healthcare) for 1 minute. Finally, results were visualised on 
Hyperfilm ECL (GE Healthcare) which was exposed to the membrane for different times. 
When required, densitometry of protein bands on western blotting films was performed using 
ImageJ software which measured the mean grey values of protein bands.  
Primary and secondary antibodies used in western blotting (and their working concentrations) 
are listed in Tables 2.2 and 2.3, respectively (section 2.3). 
2.10.6. Comparing the protein levels of endogenous Rho GTPases 
in HUVECs 
A comparison of endogenous protein levels of RhoJ, Cdc42 and Rac1 in HUVECs was 
performed by western blotting. This is described below using the example of comparing RhoJ 
with Cdc42. 
Firstly, HEK 293Ts were transfected with plasmids to express flag-tagged versions of RhoJ 
and Cdc42 proteins (calcium-phosphate transfection method, section 2.14.1) and their lysates 
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were prepared (section 2.10.2). These and HUVEC lysates were subjected to SDS-PAGE 
(2.10.4) and western blotting (2.10.5) with flag-, RhoJ- and Cdc42-specific antibodies (3 
membrane replicates were made with a separate membrane for each antibody). The western 
blotting protocol was followed as described in section 2.10.5 until the step when the ECL 
reagents were added. Here, the membranes were incubated with the Supersignal detection 
reagent (Pierce, Thermo Fisher Scientific, Cramlington, UK) instead of the incubation with 
ECL Western Blotting Detection Reagents. After 1 min of incubation, membranes were 
scanned with the GeneGnome HR scanner (Syngene), which measures the real time 
chemiluminescent signal. 
The intensity values of flag-RhoJ bands obtained with RhoJ- or flag-specific antibodies were 
compared with the intensity values of flag-Cdc42 bands obtained with Cdc42- or flag-specific 
antibodies. Using the flag-RhoJ and flag-Cdc42 protein, and the flag-specific antibody 
allowed the calculation of the relative efficacies of the RhoJ and Cdc42-specific antibodies 
and so enabled relative expression levels of RhoJ and Cdc42 in HUVECs to be determined. 
The formulas shown in boxes below were used in these calculations (abbreviations: WB, 
western blotting; α, anti).  
 
A similar approach was used to compare relative expression levels of RhoJ and Rac1 in 
HUVECs using the HA tag and the HA-specific antibody as a common reference.  
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2.11. Pull-down and identification of RhoJ-binding partners 
2.11.1. Pull-down of RhoJ-binding partners from cellular lysates 
Dominant active RhoJ (daRhoJ, Q79L) and dominant negative RhoJ (dnRhoJ, G33A) fusions 
of GST proteins were bound to glutathione agarose beads and used to pull-down potential 
RhoJ-binding proteins from cellular lysates.  
Before lysis, HUVECs, HEK 293Ts and HMEC-1 were washed in ice-cold HBS, scraped in 
0.5 ml of ice-cold HBS per plate and collected. Cells were then collected by centrifugation (1 
min, 2000 x g, 4 ºC) and lysed in Rho-assay lysis buffer (supplemented with protease 
inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF). 100 μl of lysis buffer per pellet from one 
10 cm-diameter dish of HUVECs and 200 μl of lysis buffer per pellet from one 10 cm-
diameter dish of HEK 293Ts or HMEC-1 were used. Then for each pull-down condition the 
amount of cellular lysates was used as follows: 10 x 100 μl of HUVECs lysate, 7 x 200 μl of 
HMEC-1 lysate and 3.3 x 200 μl of HEK 293Ts lysate. Lysates were firstly precleared with 
10 μg of GST bound to 25 µl of packed glutathione-agarose beads by rotation on wheel for 10 
min at 4 ºC. The beads were then washed 3 times in 1 ml of Rho-assay lysis buffer 
(supplemented with protease inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF) and washes 
were pooled with the precleared lysate. Next, the precleared lysates were incubated with 
glutathione-agarose beads loaded with 10 μg of GST, GST-daRhoJ or GST-dnRhoJ for 1 h at 
4 ºC on a rotating wheel. Then the beads were washed 5 times with 1 ml Rho-assay lysis 
buffer (supplemented with protease inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF) and 
mixed with 40 μl of 2x SDS sample loading buffer. Samples were then subjected to SDS-
PAGE (2.10.4) and mass spectrometry analysis (2.11.2-2.11.3) or western blotting (2.10.5). 
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2.11.2. Preparation of samples for mass spectrometry 
In preparation for mass spectrometry sequencing most of the steps (when possible) were 
carried out in a sterile hood to avoid contamination of the samples.  
Pull-down samples obtained in section 2.11.1 were run in SDS-PAGE as follows. Samples 
were loaded on gradient gels (4-12 % gradient NuPAGE® Novex® Bis-Tris Mini gels, 
Invitrogen) and electrophoresis was carried-out for 50 min at 200 V (constant) using 
NuPAGE® MOPS SDS Running Buffer (Invitrogen). Proteins in gels were visualised with 
ProtoBlue Safe colloidal Coomassie reagent (National Diagnostics) according to the 
manufacturer’s instructions and gels were placed on a clean glass plate. The gel fragments 
containing protein bands, which were present in the GST-daRhoJ or GST-dnRhoJ pull-down 
lanes, and which did not have corresponding bands in the GST pull-down lane, were excised 
with a sterile scalpel blade and placed in 1.5 ml microfuge tubes. These tubes were washed 
with 0.1 % (w/v) formic acid / 50 % (v/v) acetonitrile solution prior to use. Gel slices in tubes 
were then washed twice with 100 μl of 50 % (v/v) acetonitrile / 50 mM ammonium 
bicarbonate solution for 45 min at 37 ºC (with agitation) and subsequently were dried in a 
speed vacuum. The dried gel slices were then covered with 50 μl of 50 mM DTT (made in 10 
% (v/v) acetonitrile / 50 mM ammonium bicarbonate solution) and incubated at 56 ºC for 1 h. 
Subsequently, the supernatant was discarded and gel slices were covered with 50 μl of 100 
mM iodoacetamide (made in 10 % (v/v) acetonitrile / 50 mM ammonium bicarbonate 
solution) for 30 min incubation at room temperature in the dark. This solution was then 
removed and the gel slices were washed 3 times with 100 μl of 10 % (v/v) acetonitrile / 40 
mM ammonium bicarbonate solution for 15 min, and dried down in a speed vacuum. 
Afterwards, samples were covered in 1.5 x gel volume of 12.5 μg/ml sequencing grade 
modified trypsin (Promega, Southampton, UK) diluted in 10 % (v/v) acetonitrile / 40 mM 
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ammonium bicarbonate and incubated for 1 h at room temperature. Then 20 μl more of 10 % 
(w/v) acetonitrile / 40 mM ammonium bicarbonate was added and samples were incubated 
overnight at 37 ºC. The next day the supernatant was collected, 30 μl of 3 % (w/v) formic acid 
was added to the gel samples and incubated for 1 h at 37 ºC. Then this supernatant was pooled 
with the previous one. This procedure was repeated with another 30 μl of 3 % (w/v) formic 
acid and again the supernatant was pooled with the previous ones. The collected solutions 
(approximately 70 – 90 μl) containing digested proteins were stored in -80 ºC until their 
analysis by mass spectrometry. 
2.11.3. Mass spectrometry 
The samples prepared in section 2.11.2 were then used in liquid chromatography and mass 
spectrometry (LC-MS), which was performed by Dr Cleidi Zampronio in collaboration with 
Prof. John Heath (School of Biosciences, University of Birmingham, Functional Genomics 
and Proteomics Unit). The LC-MS procedure was described by Dr Cleidi Zampronio and 
permission was given to copy the method description in this thesis: 
“Samples were injected using online Micro AS autosampler and Surveyor MS pump (Thermo 
Fisher Scientific, Germany). A 75 µm (internal diameter) Integrafrit (New Objective, USA) 
C8 resolving column (length 10 cm) was used and peptides were separated using a binary 
solvent system consisting of (A) water (J.T.Baker, Holland) and 0.1% formic acid and (B) 
acetonitrile (J.T.Baker, Holland) and 0.1% formic acid. A linear 40 min gradient increasing 
the composition of (B) from 5% to 40% was used. The Triversa Nanospray source (Advion 
Biosciences, NY) was used to spray the peptide eluted in a flow rate of approximately 300 nL 
min-1 into the mass spectrometer. The nanoelectrospray voltage was typically +1.7 kV.  
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A 7-T LTQ FT mass spectrometer (Thermo Fisher Scientific, Germany) was used to perform 
a data-dependent scanning. Data acquisition was controlled by Xcalibur 2.0 software. The 
mass spectrometer alternated between a full FT-MS scan (m/z 380 – 2000) and subsequent 
Collision-Induced Dissociation (CID) MS/MS scans of the three most abundant ions. Survey 
scans were acquired in the ICR cell with a resolution of 100 000 at m/z 400. Precursor ions 
were isolated and subjected to CID in the linear ion trap, which the product ion was acquired 
with a resolution of 25 000 at m/z 400. Collision activation for the experiment was performed 
in the linear trap using helium gas at collision energy normalised to precursor m/z of 35% and 
qexcite = 0.25. The width of the precursor isolation window was m/z 2 and only multiply 
charged precursor ions were selected for MS/MS.” 
Identification of proteins encompassing detected peptide sequences was performed by Dr 
Cleidi Zampronio who used the TurboSEQUEST search algorithm (Eng, McCormack et al. 
1994).  
2.12. Yeast-two-hybrid 
2.12.1. Yeast strain and media 
For Y2H experiments the PJ69-4A yeast strain was used (genotype: MATa, trp1-901, leu2-
3,112, ura3-52, his3-200, gal4Δ, gal80Δ, GAL2-ADE2, LYS2::GAL1-HIS3, met2::GAL7-
lacZ).  
For routine yeast growth, yeast-peptone-dextrose (YPD) full medium was used, which 
contained 1 % (w/v) bacto-yeast extract, 2 % (w/v) bacto-peptone, 2 % (w/v) dextrose, 2 % 
(w/v) bacto-agar (required for solid medium only) and 0.01 % (w/v) tryptophan (trp).  
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For selective yeast growth, special synthetic complete dextrose (SCD) medium was used that 
contained 0.67 % (w/v) yeast nitrogen base without amino acids, 2 % (w/v) dextrose, 2 % 
(w/v) bacto-agar (required for solid medium only) and 0.14 % (w/v) yeast synthetic drop-out 
media supplement lacking histidine (his), leucine (leu), uracil (ura) and trp. When necessary, 
SCD medium was supplemented with 100 mg/L trp, 50 mg/L leu, 40 mg/L his or 20 mg/L 
ura. 
Most of stock solutions for making Y2H media were autoclaved prior to use except of trp, 
which was sterilised by filtering through 0.22 µm-pore filters (Millipore). All Y2H 
procedures, such as preparing media, transforming and plating yeast were carried out using 
aseptic technique. 
2.12.2. Yeast-two-hybrid method 
Y2H analyses were used to test the interactions of RhoJ with its candidate binding proteins 
identified earlier by mass spectrometry (section 2.11). Wild type RhoJ (wt) as well as its 
dominant active (da, Q79L) and dominant negative (dn, T35N) mutants were fused with the 
DNA binding domain (DBD) of Gal4p (pGBT9 constructs, selected on SCD media lacking 
trp) and RhoJ-binding candidate proteins were fused with the activation domain (AD) of 
Gal4p (pACT2, selected on media lacking leu). These constructs were sequentially 
transformed into the PJ69-4A yeast strain which contains Gal1 promoter-HIS3 reporter gene 
(as described in section 2.12.3). Interaction of RhoJ with the candidate proteins was then 
tested in a spot assay. For this purpose, yeast colonies with both pGBT9 and pACT2 
constructs were grown in SCD medium (lacking leu and trp) and diluted to optical density 
(OD) at 600 nm of 0.5. A five five-fold dilution series of yeast were prepared and spotted onto 
SCD agar plates lacking leu and trp (SCD-leu-trp) and onto SCD agar plates lacking leu, trp 
and his (SCD-leu-trp-his). The plates were then incubated at 30 ºC for 3-5 days. Growth of 
2. MATERIALS AND METHODS 
78 
 
yeast on SCD-leu-trp-his indicated an interaction of RhoJ with candidate protein tested. To 
eliminate false positive interactions, plates with SCD-leu-trp-his were additionally 
supplemented with 3 mM 3-Amino-1,2,4-triazole (3AT). 3AT competitively inhibits 
imidazoleglycerol-phosphate dehydratase, which participates in the production of histidine 
(Bartel, Chien et al. 1993). 
2.12.3. Yeast transformation 
Yeast transformation was performed according to the lithium acetate / single stranded carrier 
DNA / polyethylene glycol method (Gietz and Woods 2002) with some changes. Briefly, 
yeast grown overnight in YPD or SCD media as appropriate, were diluted to optical density 
(OD) at 600 nm of 0.25 and grown for another two generations up to OD600 of 0.5-1. Then 
2x108 yeast (yeast solution with OD600 of 1 contains approximately 2x107 yeast/ml) were 
centrifuged (2 min, 5000 x g, room temp.), washed with 1 ml of sterile water and centrifuged 
again as above. The yeast pellet was resuspended with transformation reagents in the 
following order: 240 µl of 50 % (w/v) polyethylene glycol (PEG, molecular weight of 3350 
g), 36 µl of 1 M lithium acetate, 10 µl of 10 mg/ml single-stranded-carried DNA from salmon 
sperm (previously boiled for 5 min and chilled on ice, Invitrogen) and 34 µl of plasmid DNA 
diluted with water (0.1 to 1 µg of DNA). Yeast resuspended in these transformation reagents 
were incubated with agitation for 30 min at 30 ºC and heat shocked at 42 ºC for 15 min. Then 
yeast were centrifuged (1 min, 5000 x g, room temp.), washed with 1 ml of water, centrifuged 
again (2 min, 5000 x g, room temp.) and plated onto appropriate SCD medium-agar plates. 
Plates with transformed yeast were incubated at 30 ºC for 3-5 days. 
2. MATERIALS AND METHODS 
79 
 
2.13. Development of RhoJ polyclonal antibodies  
2.13.1. Production of polyclonal RhoJ antibodies in rabbits 
To make polyclonal anti-RhoJ antibodies, recombinant RhoJ protein fused to MBP was 
produced and used as the immunogen. Firstly, pMAL-2CE plasmid containing wild type (wt) 
RhoJ without the region encoding the CAAX box (pMAL-2CE-wtRhoJ-CAAX) was 
transformed into BL21 (DE3) pLys S E. coli. MBP-wtRhoJ-CAAX protein was produced in 
these bacteria and purified according to the protocol described in section 2.10.1. 
Immunisation of 2 rabbits with purified MBP-wtRhoJ-CAAX was performed by Harlan Sera 
Lab (CRUK Central Services). Rabbits were given 6 injections as follows. The primary 
immunisation required 400 μg immunogen in complete Freund’s adjuvant. The following 5 
injections were given every two weeks thereafter and contained 100 μg of immunogen in 
incomplete Freund’s adjuvant. The rabbits were terminally bled one week after the 6th 
injection.  
2.13.2. Purification of polyclonal RhoJ antibodies from rabbit 
antiserum 
Purification of RhoJ antiserum included removal of the MBP-specific antibodies by MBP-
amylose beads, purifying RhoJ-specific antibodies by GST-wtRhoJ-CAAX bound to PVDF 
membrane, and elution of RhoJ-specific antibodies by low pH glycine.  
A batch of RhoJ antibody was purified at a time from 3 mls of RhoJ antiserum divided into 6x 
0.5 ml aliquots. Firstly, RhoJ antiserum was depleted of MBP-specific antibodies. For this 
purpose, 6 aliquots of 15 μg MBP protein purified from bacterial lysate and bound to 25 μl 
packed amylose beads (NEB) (as in section 2.10.1) were blocked in 3 % (w/v) BSA (diluted 
in TBST) for 1 h at 4 °C. Each aliquot of beads was then collected by centrifugation, 
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resuspended in 0.5 ml of MBP-RhoJ antiserum and incubated on a rotating wheel for 1 h at 4 
°C. The beads were then collected by centrifugation, pre-cleared antiserum collected and 
beads were washed 4 times with 1 ml of TBST. These washes were pooled with precleared 
antiserum and the total volume of each precleared aliquot of RhoJ antiserum was then 
adjusted to 5 ml with TBST and supplemented with 3 mM NaN3. 
In the meantime, binding of the GST-wtRhoJ-CAAX protein to PVDF membrane was 
performed. Firstly, the GST-wtRhoJ-CAAX protein was produced and purified from bacteria 
as described in section 2.10.1. Then 10 μg of GST-wtRhoJ-CAAX was loaded in each well of 
6 polyacrylamide gels (12%) and SDS-PAGE was carried out (as in section 2.10.4). 
Subsequently, proteins were transferred from gels to PVDF membranes as in the standard 
western blotting procedure (section 2.10.5). After the transfer, the membranes were stained 
with Ponceau S dye to visualise the GST-wtRhoJ-CAAX protein bands, which were then cut 
out as strips (one membrane strip containing the GST-wtRhoJ-CAAX bands was excised from 
each membrane). These strips were then blocked in 3 % (w/v) BSA (diluted in TBST) for 1 h 
at room temperature. Subsequently, each of the 6 membrane strips was placed in a separate 50 
ml tube containing 5 ml of pre-cleared RhoJ antiserum/TBST/ NaN3 solution and incubated 
overnight on a rotating wheel at 4 °C. The next day membrane strips were washed with ice-
cold solutions of TBST (3 x 10 min), high salt TBST (1 x 10 min) and finally TBS (3 x 10 
min). All 6 membrane strips were then placed in one fresh 50 ml tube and covered with 3 ml 
of ice-cold 100 mM glycine (pH 2.5). This caused the elution of antibody from the 
membranes and was carried out for 7 min by gentle tilting of the tube with strips (at 4 °C). 
Then glycine/RhoJ antibody solution was transferred into a fresh tube and neutralised 
immediately by adding 1 M Tris-Cl (pH 9.5) in 50 µl aliquots until the pH of antibody 
solution was approximately 7.0; usually 150-200 µl of Tris-Cl was enough to neutralise 3 ml 
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of antibody. In the meantime, the membranes were incubated with another 3 ml of 100 mM 
glycine (pH 2.5) for 5 min and the stripping/neutralisation of the antibody was repeated as 
above. Purified antibodies were stored at 4 °C supplemented with 3mM NaN3 and 4 % (w/v) 
BSA. 
The quality of the purified antiserum was then tested in western blotting (as in section 2.10.5) 
and in immunofluorescence (as in section 2.18). The purified RhoJ antiserum was used as a 
primary antibody in western blotting (diluted 1:25) or in immunofluorescence (diluted 1:3).  
2.14. Plasmid transfections of mammalian cells 
2.14.1. Calcium-phosphate transfection of HEK 293Ts 
3 x 106 cells were plated in sterile culture dishes (10 cm diameter) and the next day the 
transfection was performed as follows. 5 µg of DNA plasmid was mixed with 450 µl distilled 
water and 63 µl 2M calcium chloride (CaCl2x6H2O) in a 5 ml tube. Then 500 µl of 2x HBS-
based buffer (containing 1.6 % (w/v) NaCl, 0.074 % (w/v) KCl, 0.027 % (w/v) 
Na2HPO4x2H2O, 0.2 % (w/v) dextrose, 1.0 % (w/v) HEPES; pH adjusted to 7.05 and 
sterilised by passing through a 0.22 µm-pore filter) was added dropwise with shaking and 
allowed to precipitate for 15 min. The media of the plated HEK 293Ts was replaced with the 
fresh media and transfection mixture was added. Cells were then incubated in a humidified 
atmosphere with 5% CO2 at 37 °C and the next day transfection medium was replaced with 
fresh medium. 24 hours later cells were used in various assays. 
2.14.2. TransPass D2 transfection of HUVECs 
106 of HUVECs were seeded on gelatin-coated plates (10 cm diameter) and the next day 
transfection was performed as follows. 4 μg of plasmid was mixed with 12 μl of TransPass 
D2 reagent (NEB) in 1 ml of OptiMEM medium (Invitrogen) and incubated for 20 min at 
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room temperature. In the meantime, cells were washed with 10 ml OptiMEM and covered 
with 3 ml of OptiMEM. The transfection mix was added and cells were incubated for 2 hours 
in a humidified atmosphere with 5% CO2 at 37 °C. After this time the transfection mixture 
was replaced with 10 ml HUVEC complete medium without antibiotics and cells were used in 
assays 24 h after transfection. For immunofluorescence staining, cells were seeded on gelatin-
coated glass coverslips (13 mm diameter) placed in a 24-well culture plate and the 
transfection reaction was scaled down appropriately. 
2.15. Lentivirus infections of HUVECs 
2.15.1. Production of lentivirus 
Lentivirus was produced in HEK 293Ts. 2.5x106 cells were plated in sterile culture dishes (10 
cm diameter) and the next day calcium-phosphate transfection was performed similarly as in 
section 2.14.1. 20 µg transfer vector (pWPXL-wtRhoJ, pWPXL-daRhoJ(Q79L) or pWPI), 15 
µg packaging vector (psPAX2) and 6 µg envelope vector (pMD2G) were used per plate. After 
addition of the transfection mix cells were incubated in a humidified atmosphere with 5% 
CO2 at 37 °C for 8 hours when the transfection mixture was removed and 5 ml of fresh 
medium was added. After 48 hours of incubation, the medium with virus was collected, 
centrifuged for 5 min at 1100 rpm, cleared through 0.45 µm-pore syringe filters (Corning 
Incorporated, Germany) and stored at -80 °C. Lentivirus was frozen/thawed only once before 
infection. 
2.15.2. Infection of HUVECs 
106 HUVECs were seeded on gelatin-coated culture dishes (10 cm diameter) and the next day 
HUVEC medium was replaced with 7.5 ml of lentivirus supernatant supplemented with 8 
µg/ml polybrene, bovine brain extract and 90 µg/ml heparin. 24 h after infection the lentivirus 
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supernatant was replaced with fresh complete HUVEC medium and cells were left to grow for 
another 2 days. Then GFP-positive cells were sorted by FACS (MoFlo Cytomation 
fluorescence activated cell sorter). Lentivirus infection according to this procedure yielded 
typically in 90 % of GFP-expressing and 40-60 % of GFP-wtRhoJ or GFP-daRhoJ-expressing 
HUVECs. 
2.16. Knock-down of genes using siRNA 
106 HUVECs were seeded on gelatin-coated culture dishes (10 cm diameter) and the next day 
transfection was performed with 10-25 nM siRNA duplexes and 0.3 % (v/v) lipofectamineTM 
RNAiMAX (Invitrogen). All siRNA duplexes used are listed in Table 2.7 (section 2.6). Per 
transfection of a 10 cm HUVEC plate, duplex (or water for mock transfection) was diluted 
with OptiMEM in one tube to give a final volume of 680 µl, and 12 μl of RNAiMAX 
lipofectamineTM was diluted with 108 μl of OptiMEM medium in another tube. Both solutions 
were mixed gently and incubated for 10 min at room temperature. The mixtures were then 
combined, mixed gently and incubated for another 10 min at room temperature. In the 
meantime, cells were washed twice with PBS and 3200 μl of OptiMEM medium was added 
per plate. Then the transfection mixture was added, the plates were gently tilted for mixing 
and incubated for 4 h at 37 ºC. Afterwards the transfection mix was replaced with complete 
HUVEC medium (without antibiotics) and 48 h after transfection cells were used in various 
assays. 
2.17. Endocytosis assays 
2.17.1. Trafficking of transferrin receptor in HUVECs 
The up-take and release of fluorescently labelled Tf was tested in HUVECs with siRNA-
silenced RhoJ. 24 h after the siRNA RhoJ knock-down (10 nM siRNA duplexes used, section 
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2.16), 105 HUVECs were seeded on gelatin-coated wells of a 12-well plate and incubated 
overnight in complete HUVEC medium. Afterwards, cells were incubated first in starving 
medium (M199, 4 mM L-glutamine) for 1 h and then for another hour in complete HUVEC 
medium containing 5 µg/ml Alexa-488 labelled Tf (Invitrogen). Subsequently, cells were 
washed with PBS and complete HUVEC medium with 50 µg/ml of unlabelled Tf was added 
and cells were incubated at 37 °C for different time periods (0-30 min). Cells were then 
washed quickly with PBS, covered with 0.75 ml trypsin-EDTA and incubated for 2 min at 37 
°C. Then 0.25 ml of 4 % (w/v) paraformaldehyde (PFA, prepared in PBS) was added and 
cells were immediately transferred into FACS tubes. Fixation with PFA was performed for 15 
min at room temperature in the dark. The amount of fluorescently labelled Tf in HUVECs 
was measured with FACS-Becton Dickson FACSCalibur cell sorter (Becton and Dickson, 
USA) in FL-1. At least 103 cells were counted in each condition and the geometric mean 
fluorescence levels were determined. To plot the results of the Tf uptake, the mean for each 
condition (with or without RhoJ knock-down) from 3 experiments was depicted as bar chart 
with standard errors. To present the results of Tf release firstly the geometric mean of cell 
fluorescence before the incubation with unlabelled Tf (0 min release) was averaged from 3 
experiments and considered as 100 %. The subsequent time points for Tf release (5, 15, 30 
min) were then plotted as a percentage in relation to 100 %.  
2.17.2. Testing the surface levels of VEGFR2 in HUVECs 
The amount of VEGFR2 present at the cell surface was tested in HUVECs with siRNA-
silenced RhoJ. 24 h after the siRNA RhoJ knock-down (25 nM siRNA duplexes used, section 
2.16), 105 HUVECs were seeded on gelatin-coated wells of a 12-well plate and incubated 
overnight in complete HUVEC medium. Cells were then treated in three different ways. In the 
first condition cells were starved for 1 h in HUVECs starving medium (M199, 4 mM L-
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glutamine). In the second condition cells were starved for 1 h in HUVEC starving medium 
and then stimulated for 30 min by 10 ng/ml VEGF-A (PeproTech, Rocky Hill, USA), which 
was diluted in HUVEC starving medium. In the third condition cells were left in complete 
HUVEC medium without any treatment. After applying these conditions cells were washed 
with PBS and 0.75 ml of non-enzymatic cell dissociation solution was added to each well and 
incubated for 5 min at 37 °C. Cells in this solution were then transferred into 1.5 ml 
microfuge tubes containing 0.25 ml of 4 % (w/v) PFA (prepared in PBS) and incubated for 15 
min at room temperature. Cells were then centrifuged (195 x g, 5 min, room temperature), the 
supernatant removed and blocking performed for 30 min in 4 % (w/v) BSA (prepared in 
PBS). Cells were then centrifuged as above and incubated with 2 µg/ml goat anti-VEGFR2 
antibody (diluted in blocking buffer) for 1 h. This was followed by 2 washes with PBS and 30 
min incubation with 15 µg/ml anti-goat FITC-conjugated secondary antibody diluted in 
blocking buffer. Cells were then washed twice and diluted in PBS. Subsequently FACS 
analysis was performed using FACS-Becton Dickson FACSCalibur cell sorter. At least 103 
cells were counted for each condition and the geometric mean fluorescence levels were 
determined. The results were shown in a form of bar chart with standard errors, containing 
means for each condition from 3 experiments. 
2.18. Immunofluorescence 
For immunofluorescence, cells were grown on glass coverslips (13 mm diameter, VWR 
International). Prior to use, coverslips were immersed in 1 M HCl for 10 min, then washed 5 
times with sterile distilled water and stored in 70 % ethanol (Fisher Scientific). Before each 
experiment, coverslips were placed in wells of a 24-well culture plate and were washed 5 
times with sterile distilled water in a sterile hood to remove residual ethanol. Coverslips were 
then coated with gelatin or with Matrigel (BD Biosciences, Oxford, UK). For gelatin coating, 
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coverslips were covered with 0.1 % (w/v) gelatin and left for 20 min at 37 °C. After this time 
gelatin solution was removed. For Matrigel coating, an aliquot of Matrigel was firstly thawed 
on ice at 4 °C for several hours. 100 % (v/v) Matrigel was then spread on coverslips with a 
pipette tip and its excess was immediately aspirated leaving only a very thin coating. 
Coverslips were then allowed to dry out prior to seeding HUVECs. For analysis of sparse 
cells, HUVECs were seeded at the concentration of 2 x 104 cells/well at least 4 h prior to 
fixation. To obtain a confluent monolayer of cells, HUVECs were seeded at the concentration 
of 7.5 x 104 cells/well the day before fixation. A general staining procedure (except 
endogenous RhoJ staining, please see below) was carried out as follows at room temperature. 
HUVECs were gently washed with PBS and fixed in 4 % (w/v) PFA (in PBS) for 15 min. The 
cells were then washed once in PBS and permeabilised with 0.1 % (v/v) Triton-X-100 (in 
PBS) for 4 min. Afterwards cells were washed again with PBS and left in blocking buffer (3% 
(w/v) BSA, 10% (v/v) FCS, 0.1% (v/v) tween-20, 0.01% (w/v) NaN3 in PBS) for 30-60 min. 
The cells were then incubated with a primary antibody diluted in blocking buffer for 1 h and 
then were washed 3 times with PBS. Subsequently a secondary antibody diluted in blocking 
buffer was added and after 30-60 min of incubation cells were washed 3 times with PBS and 
once with distilled water. Antibodies and their concentrations used are described in Tables 2.2 
and 2.3 (section 2.3). Coverslips with cells were then mounted on slides (Menzel-Glaser 
GmbH, Braunschweig, Germany) using 6 µl ProLong Gold Antifade reagent with DAPI 
(Invitrogen) per one coverslip. The mounting reagent was warmed up for 30 min at room 
temperature prior to use. 
In order to immunostain endogenous RhoJ with the polyclonal rabbit RhoJ antibody 
(developed and purified in section 2.13), cells were fixed and permeabilised with ice-cold 100 
% methanol for 5 min. This was followed by one wash in PBS and 1 hour blocking in 4 % 
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(w/v) BSA at room temperature. Subsequently cells were incubated with RhoJ antibody 
diluted in 4 % (w/v) BSA for 2 hours and this was followed by 2 x 5 min washes in PBST. 
Incubation with a secondary antibody diluted in 4 % BSA was carried out for 45 min and was 
followed by 3 x 5 min washes in PBST and one wash in distilled water. Cells were then 
mounted as described in the general procedure above. 
Images of immunofluorescently stained cells were acquired using the Axiovert 100M 
confocal microscope and LSM 510 software (Zeiss). LSM Image Browser software (Zeiss) 
was used to export images, which were then cropped in Microsoft Office Power Point 
program.   
2.19. Testing the functions of endothelial cells expressing 
dominant active RhoJ 
HUVECs were infected with lentivirus to express GFP or GFP-daRhoJ (section 2.12.2) and 
were FACS-sorted for GFP-positive cells. Cells were then expanded in complete HUVECs 
medium supplemented with pen/strep antibiotics and were used in the assays described below. 
2.19.1. Scratch wound assay 
3.6 x 105 HUVECs expressing either GFP or GFP-daRhoJ were seeded on gelatin-coated 
wells of a 6-well plate in complete medium and left at 37 °C. The next day scratches were 
made with 200 µl sterile pipette tips, cells were then washed twice with PBS and fresh 
medium supplemented with 2.5 µg/ml mitomycin C was added. Pen marks perpendicular to 
the scratches were made and pictures were taken in the same scratch places at 0, 4, 8 and 12 
hours using USB 2.0 2M Xli camera connected to the Leica DM IL microscope (Leica, 
Milton Keynes, UK). The wound areas were measured with ImageJ software. To compare the 
speed of a wound closure between GFP and GFP-daRhoJ expressing cells, the wound areas 
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measured at different time-points were compared to the wound areas at 0 hours. Wound sizes 
at 0 hours were considered as 100 %, thus plotted graphs were representing the % of 
remaining wound areas. 
2.19.2. Analysis of focal adhesions and stress fibres 
To analyse the number of FAs and SFs in migrating HUVECs a scratch wound assay was 
performed on cells cultured on coverlips. 7.5 x 104 HUVECs expressing either GFP or GFP-
daRhoJ were plated on gelatin-coated coverslips in a 24-well plate. 24 h later the monolayers 
of cells were scratched with 10 µl sterile pipette tip, washed twice with PBS and covered with 
fresh complete medium supplemented with 2.5 µg/ml mitomycin C. Cells were allowed to 
migrate for 2-4 h before the opposite edges of wounds started to merge. Then coverslips were 
washed gently with PBS, cells were fixed with 4 % PFA and stained according to the 
procedure described in section 2.18. A vinculin-specific antibody was used to visualise FAs 
and actin was stained with 50 µg/ml phalloidin-TRITC (Invitrogen). Images of cells within a 
monolayer and at the edge of a monolayer were acquired using the Axiovert 100M confocal 
microscope and LSM 510 software (Zeiss). FAs were counted manually using the cell counter 
plug-in tool of ImageJ. The mean fluorescent intensity of F-actin per cell was determined 
from acquired images using the LSM 510 software. 
2.19.3. Organotypic tube forming assay 
HUVECs stably expressing GFP or GFP-daRhoJ were sent to Dr Georgia Mavria’s 
Laboratory (Leeds Institute of Molecular Medicine, St James’s University Hospital, Leeds, 
UK), where Margherita Scarcia and Sabu Abraham used them to perform an organotypic 
angiogenesis assay. The permission was given to present the data in this thesis (Fig. 3.10 B 
and C). The results of this experiment were also published in Kaur et al. (2011), where the 
full experimental procedure is included. 
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2.20. Examining the localisation of RhoJ, GIT1 and βPIX to focal 
adhesions 
RhoJ, GIT1 and βPIX were knocked-down in HUVECs using 25 nM siRNA duplexes as 
described in section 2.16. 48 hours after siRNA transfection cells were sparsely plated on 
gelatin-coated coverslips and left for 4 hours to adhere. The cells were then fixed and stained 
with RhoJ-, GIT1- or βPIX-specific antibodies as described in section 2.18. These cells were 
also counter-stained with vinculin-specific antibody to visualise FAs. The cell images were 
acquired using the Axiovert 100M confocal microscope and LSM 510 software (Zeiss) and 
FAs in each cell were counted manually using the cell counter plug-in tool of ImageJ. The 
total number of FAs per cell was determined by counting vinculin-positive FA-like regions. 
The number of RhoJ, GIT1 or βPIX-positive FAs was then determined and presented as a 
percentage of total FAs per cell. 
2.21. RhoJ activation assay 
2.21.1. Optimisation of RhoJ-GTP pull-down 
2.21.1.1. Preparation of cellular lysate for GTP/GDP loading on Rho 
GTPases 
Confluent monolayers of HUVECs or HMEC-1 (in 10 cm plates) were washed with PBS, 
covered with 2 ml of non-enzymatic cell dissociation solution and incubated at 37 ºC for 10 
min. Afterwards cells were collected in two washes of 10 ml PBS and centrifuged (5 min, 195 
x g, room temperature). The pellet of cells from one plate was then lysed in 180 μl of 
nucleotide-loading lysis buffer (supplemented with protease inhibitor cocktail, 2 mM NaVO3 
and 10 mM NaF) for 10 min on ice. Subsequently the lysate was centrifuged for 10 min 
(21910 x g, 4 ºC), the supernatant collected and mixed with 20 μl of glycerol to make its final 
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concentration 10 % (v/v). Lysates were stored at -80 ºC. The lysates of HEK 293Ts 
ectopically expressing wt-, da- or dnRhoJ were prepared in a similar way with only difference 
in the amount of lysis buffer used, which was 5 times higher than that used for lysis of 
HUVECs or HMEC-1. 
2.21.1.2. Preparation of GST-CRIB beads 
In order to pull-down active RhoJ, Cdc42 or Rac1 from cellular lysates the CRIB domains of 
PAK (1-254 amino acids of rat PAK1) or WASP (228-268 amino acids of human WASP) 
proteins fused with GST were produced and loaded on glutathione-agarose beads as described 
in section 2.10.1. For each pull-down condition 5 μg of GST-CRIB was bound to 12.5 μl of 
packed glutathione-agarose beads, which were then washed 3 x with 1 ml nucleotide-loading 
lysis buffer (supplemented with protease inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF) 
and finally diluted with this buffer to give a 50 % slurry. The beads were then left on ice 
ready for pull-down. 
2.21.1.3. GTP/GDP loading on Rho GTPases and pull-down 
200 μl of HUVECs or HMEC-1 lysate (made from one confluent plate) was used to perform 
one nucleotide-loading condition. When the HEK 293Ts lysate was used for nucleotide 
loading, the original lysate (prepared as in section 2.21.1.1) was diluted 10 times to give a 
final volume of 200 μl. Initially this experiment was carried out according to the protocol 
adapted from commercially available “Rac1/Cdc42 Activation Assay Kit” (Upstate Cell 
Signalling Solutions, 17-441, Temecula, USA). However, since the loading of nucleotides on 
RhoJ was not successful, the method was slightly changed, according to the protocol used by 
Erasmus and Braga, which measured active Cdc42 and Rac1 (Erasmus and Braga 2006). 
Briefly, 200 µl of cellular lysate was mixed with EDTA (final concentration 10 mM) and 
GTPγS (a stable analogue of GTP) or GDP (final concentration of nucleotides 1 mM). After 
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incubation for 10 min at room temperature, MgCl2 was increased to a final concentration of 
30 mM, and then these samples were mixed with GST-CRIB fusion protein bound earlier to 
glutathione-agarose beads. The pull-down was performed for 45 min at 4 ºC on a rotating 
wheel. After the pull-down the beads were washed 3 times with 1 ml of Rho-assay lysis buffer 
(supplemented with protease inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF) and 
resuspended in 30 μl of 2x SDS sample-loading buffer. Pull-down and lysate samples were 
then subjected to the SDS-PAGE (2.10.4) and western blotting (2.10.5) with RhoJ-, Cdc42- or 
Rac1-specific antibodies.  
2.21.2. Measuring RhoJ activation after VEGFA, FGF-2 and 
thrombin stimulation 
The day before treatment 106 HUVECs were seeded on gelatin-coated 10 cm plates in 
HUVEC medium. Prior to the treatment with various stimuli, cells were washed with PBS and 
rested for 1 h in starving medium (M199, 4 mM L-glutamine). Subsequently the starving 
medium was replaced with 5 ml of stimuli (diluted in fresh starving medium) and cells were 
incubated for 1, 15, 30 and 60 min. The concentration of stimuli used was as follows: 10 
ng/ml VEGFA (Peprotech), 10 ng/ml FGF-2 (kindly provided by Prof. John Heath, School of 
Biosciences, University of Birmingham, UK) or 2.5 U/ml thrombin. FGF-2 stimulus was 
supplemented with 10 µg/ml heparin. After treatment medium was quickly removed, the 
plates were placed on ice and 200 μl of 2x Rho-assay lysis buffer (supplemented with 2x 
protease inhibitor cocktail, 4 mM NaVO3 and 20 mM NaF) was added. One plate of cells was 
lysed straight after 1 h of resting without treatment and was considered as 0 min. Cells were 
scraped in lysis buffer, collected in 1.5 ml eppendorf tubes and incubated on ice for 10 min. 
The lysates were then clarified by centrifugation (5 min, 21910 x g, 4 ºC). 20 μl of each lysate 
sample was mixed with equal amount of 2x SDS sample-loading buffer and the rest was 
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mixed with GST-CRIB bound to glutathione-agarose beads (CRIB domain of PAK was used, 
prepared as in section 2.21.1.2). Samples were placed on the rotating wheel and pull-down 
was performed for 45 min at 4 ºC. Then beads were washed 3 times with Rho-assay lysis 
buffer (supplemented with protease inhibitor cocktail, 2 mM NaVO3 and 10 mM NaF) and 
resuspended in 30 μl of 2x SDS sample-loading buffer.  Samples were finally subjected to 
SDS-PAGE and western blotting with RhoJ- or Cdc42-specific antibodies (as in sections 
2.10.4 and 2.10.5). 
2.22. Statistical analyses 
Results were plotted as the mean of at least 3 experiments with standard errors (except of Fig. 
3.1). Where possible, the statistical significance of results was analysed using the GraphPad 
Prism 4.03 software and was denoted as follows: *** for p<0.001, ** for 0.001<p<0.01, * for 
0.01<p<0.05 and ns for non-significant. The Wilcoxon signed-rank test was used to analyse 
significance of RhoJ and Cdc42 activation by VEGF. The Mann Witney test was used to 
analyse statistical difference in the amount of FAs and in the fluorescent intensity of F-actin 
staining in pairs of GFP and GFP-daRhoJ-expressing cells. 
2.23. Preparation of figures 
Calculations were performed and graphs were plotted using the Microsoft Office Excel 
software. Graphs with data displayed as a box and whisker plot were created using the 
GraphPad Prism 4.03 software. Some pictures were rotated and cropped using GIMP 2.4.5 
GNU Image Manipulation Program before they were inserted into Microsoft Office Power 
Point program. All graphs and pictures were finally assembled into figures and edited using 
the Microsoft Office Power Point program. 
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3.1. Intra-cellular localisation, expression and known functions of 
RhoJ 
RhoJ is a member of the Cdc42-like sub-family that belongs to the larger family of small Rho 
GTPases and is also called TCL or TC10-like due to its high similarity to TC10 GTPase 
(Vignal, De Toledo et al. 2000). Many Rho GTPases, including RhoJ, cycle between an active 
GTP-bound and an inactive GDP-bound state. Once activated, these proteins act as molecular 
switches that regulate a variety of cellular processes, such as cytoskeletal reorganisation, cell 
migration, endocytosis and cell proliferation (Hall 1998; Jaffe and Hall 2005). 
In initial studies ectopically expressed tagged RhoJ localised to the dorsal cell membrane and 
was associated with large intra-cytoplasmic vesicles in REF-52 fibroblasts (Vignal, De 
Toledo et al. 2000). In these cells, an active mutant of RhoJ caused the production of dynamic 
F-actin ruffles on the dorsal membrane. This phenotype was blocked by dominant negative 
Rac1 and Cdc42 mutants, which suggested that these three GTPases may share similar GEFs.  
In another study, constitutively active RhoJ caused the formation of lamellipodia and FA-like 
assemblies at the cell periphery of porcine aortic ECs stably expressing the human platelet-
derived growth factor β-receptor (Aspenstrom, Fransson et al. 2004). Lamellipodia are sheet-
like protrusions extended by migrating cells (Small, Stradal et al. 2002), while FAs are 
dynamic, multiprotein complexes, which connect the intracellular cytoskeleton with the ECM 
(Dubash, Menold et al. 2009). 
Some other studies showed that RhoJ played a role in endocytosis and localised to the plasma 
membrane and intracellular vesicles in HeLa cells (de Toledo et al. 2003). These studies 
revealed that RhoJ mostly localised to the EE/ES and played a role in the clathrin-dependent 
endocytosis, since its knock-down by siRNA perturbed the Tf release by HeLa cells. 
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Overexpression of the constitutively active RhoJ promoted an accumulation of Tf in the 
EE/ES and blocked its movement to the perinuclear recycling endosomes, resulting in Tf 
recycling to the plasma membrane straight from the EE/ES (de Toledo et al. 2003). 
More recent work performed by members of our laboratory revealed that RhoJ is 
predominantly expressed in ECs (Herbert, Stekel et al. 2008; Kaur, Leszczynska et al. 2011). 
These cells are very important in the maintenance of the healthy state of the whole organism 
as they line the inner wall of blood and lymphatic vessels (Adams and Alitalo 2007). ECs are 
also crucial in the process of angiogenesis, when new blood vessels sprout from the pre-
existing vasculature, and many Rho GTPases play an important role in this process (Bryan 
and D'Amore 2007). Initially, using a bioinformatic method, RhoJ was found to be present 
only in endothelial expression libraries but not in those from other cell types (Herbert, Stekel 
et al. 2008). This finding was supported by discovering high mRNA levels of RhoJ in ECs but 
not in some non-EC types tested (Herbert, Stekel et al. 2008). More recently, in situ 
hybridisation studies in both the developing mouse embryo at embryonic day 9.5 (when 
angiogenesis occurs) and in various human tissue sections have shown that the RhoJ gene was 
expressed in the blood vessels (Kaur, Leszczynska et al. 2011). The presence of RhoJ in 
human smooth muscle cells and pericytes was also detected (both RNA and protein) but 
appeared to be very low in comparison to ECs (Kaur, Leszczynska et al. 2011). 
Since RhoJ was endogenously expressed in endothelium, a series of experiments were 
performed to determine its function in this tissue (Kaur, Leszczynska et al. 2011). Firstly, a 
set of experiments tested the role of RhoJ in tubulogenesis in vitro. ECs may be induced to 
form a 2-dimensional network of tubes when cultured on Matrigel, which is a solubilised 
basement extract (Passaniti, Taylor et al. 1992). ECs will also form a 3-dimensional network 
of tubes with lumens when cultured on a monolayer of fibroblasts and in the presence of pro-
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angiogenic growth factors VEGF and FGF-2 (Bishop, Bell et al. 1999). Knock-down of RhoJ 
impaired tubule formation in both of these systems.  
One of the important steps in angiogenesis is EC migration (Carmeliet 2003). This strongly 
depends on a constant turnover of the actomyosin cytoskeleton and FAs (Raftopoulou and 
Hall 2004). Kaur et al. discovered that silencing of RhoJ using siRNA significantly decreased 
EC migration. This was tested in chemotaxis and chemokinesis assays. In the former RhoJ 
knock-down significantly impaired the movement of cells towards the serum and FGF-2. In 
the latter silencing of RhoJ slowed down the migration of cells in a scratch wound assay. 
Subsequently, Sukhbir Kaur showed that RhoJ knock-down increased numbers of FAs and 
SFs in migrating ECs. These cells also had increased levels of pMLC and were able to 
strongly contract the type I collagen gel. Importantly, indirect inhibition of MLC 
phosphorylation by adding a pharmacological inhibitor of ROCK (Y27632), or its direct 
inhibition by blebbistatin, improved the migration of RhoJ-silenced cells and also decreased 
the contractility in these cells. Thus, findings by Kaur et al. showed that RhoJ plays an 
important role in EC migration, proliferation and in vitro tubulogenesis as well as in 
modulating actomyosin contractility and FA numbers in ECs (Kaur, Leszczynska et al. 2011). 
The work described in this chapter aimed to determine the endogenous localisation of RhoJ in 
ECs and to further investigate its function in these cells. Firstly, the protein levels of RhoJ and 
other crucial Rho GTPases were compared in ECs. Secondly, a polyclonal rabbit RhoJ 
antibody was made, validated and used to study the localisation of endogenous RhoJ in ECs. 
In addition, the localisation of overexpressed RhoJ in these cells was determined. Thirdly, a 
dominant active mutant of RhoJ was used to verify the role of RhoJ in EC migration, tubule 
formation and its influence on FAs and SFs in these cells. Fourthly, the potential role of RhoJ 
in endocytosis in ECs was investigated. 
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3.2. Comparison of RhoJ, Cdc42 and Rac1 proteins in HUVECs 
RhoJ is a Rho GTPase that is expressed in ECs, where it regulates processes such as cell 
migration and proliferation (Kaur, Leszczynska et al. 2011). However, it is well established 
that other Rho GTPases are expressed abundantly in ECs and are very important for their 
proper functioning (Bryan and D'Amore 2007). Therefore it was important to compare the 
levels of RhoJ protein with some of the other key Rho GTPases expressed in ECs. 
The relative quantitation of RhoJ and Cdc42 proteins in HUVECs was performed by western 
blotting. Firstly, HEK 293Ts were transfected with plasmids to express flag-tagged versions 
of these proteins and their lysates were prepared. These and HUVECs lysates were used in 
western blotting with flag, RhoJ and Cdc42 specific antibodies (Fig. 3.1 A). The intensity 
values of flag-RhoJ bands obtained with RhoJ- or flag-specific antibodies were compared 
with the intensity values of flag-Cdc42 bands obtained with Cdc42- or flag-specific 
antibodies. This allowed the calculation of relative efficacies of RhoJ and Cdc42-specific 
antibodies and so enabled relative expression levels of RhoJ and Cdc42 in HUVECs to be 
determined. The chemiluminescence intensity of specific bands was acquired using 
GeneGnome HR scanner, which measures the real time chemiluminescent signal.  
A similar approach was used to compare relative expression levels of RhoJ and Rac1 in 
HUVECs using the HA tag and the HA-specific antibody as a common reference. It was 
found that HUVECs contain 3.5 times more Rac1 and 11 times more Cdc42 than RhoJ 
proteins respectively (Fig. 3.1 B). 
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Fig. 3.1 Quantitation of RhoJ, Cdc42 and Rac1 protein levels in HUVEC. 
A, HEK 293Ts were transfected with plasmids encoding flag-RhoJ, flag-Cdc42, HA-RhoJ and HA-
Rac1 and lysates were prepared. These and HUVEC lysates were compared in western blotting with 
indicated antibodies and chemiluminescent intensities of particular bands (stated under each lane) 
were measured using GeneGnome HR scanner. B, the bar chart shows calculated relative RhoJ, Cdc42 
and Rac1 protein levels in HUVECs. 
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3.3. Production and purification of RhoJ polyclonal antibodies 
Initial experiments showed that the commercially available mouse monoclonal RhoJ antibody 
(Ab57584 from Abcam) was suitable for western blotting but did not detect RhoJ by 
immunofluorescence. To enable the localisation of endogenous RhoJ there was a need to 
generate alternative RhoJ-specific antibodies and these were developed in rabbits. 
To create reagents for production and purification of RhoJ antibodies, recombinant RhoJ 
proteins were made as the c-terminal fusions with GST or MBP proteins. Both constructs 
were designed to have the last five amino acids of RhoJ missing (-CCSII, known as CCAAX 
box). The CCAAX box undergoes posttranslational lipidation and anchors proteins in cellular 
membranes. It was removed to avoid potential difficulties in protein production and 
purification from bacteria.  
MBP-RhoJ recombinant fusion protein was used to immunise two rabbits as described in the 
methods and materials. Antiserum from the terminal bleed was firstly depleted of MBP-
specific antibodies and then RhoJ-specific antibodies were affinity purified with GST-RhoJ 
protein attached to the PVDF membranes.  
3.3.1. Testing the specificity of RhoJ antibodies in western blotting 
The quality of the purified antibody was firstly assessed by western blotting (Fig. 3.2). Since 
the antibody was raised using the full-length RhoJ protein (-CCAAX box), it was crucial to 
check that it would not recognise other Rho GTPases that share some sequence homology 
with RhoJ. To test this HEK 293Ts were transfected with plasmids to express epitope tagged 
RhoJ, RhoA, Cdc42 and Rac1. Lysates were prepared and used in western blotting to test the 
specificity of the RhoJ mouse monoclonal antibody (Abcam) and the purified RhoJ rabbit 
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Fig. 3.2 Testing the specificity of RhoJ antibodies and siRNA duplexes.   
A, HEK 293Ts were transfected with plasmids encoding epitope tagged RhoJ, RhoA, Cdc42 and 
Rac1; lysates were prepared and subjected to SDS-PAGE and western blotting with antibodies as 
indicated. Neither of the RhoJ antibodies detected RhoA, Cdc42 or Rac1. B and C, HUVECs were 
transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2 and Ctrl-siRNA duplexes or were mock 
transfected. 48 h later cells were lysed and the protein amount adjusted to be equal between the 
samples. B, Western blot showing the specificity of the purified anti-RhoJ polyclonal antibody that 
detects a single RhoJ band. C, Western blot (representative of 3 experiments) showing that RhoJ 
siRNA knock-down does not affect the levels of RhoA, Rac1 and Cdc42 proteins in HUVECs. 
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 polyclonal antisera (Fig. 3.2 A). Both the commercially available RhoJ mouse monoclonal 
antibody and the purified RhoJ rabbit polyclonal antisera recognised only RhoJ protein. The 
other Rho GTPases tested were not detected by any of the RhoJ antibodies.  
In order to further validate the specificity of the purified polyclonal RhoJ antibody, it was 
tested in western blotting on lysates from cells that had RhoJ silenced with siRNA. HUVECs 
were transfected with two different RhoJ-specific siRNAs (RhoJ-siRNA1 and RhoJ-siRNA2), 
control non-specific siRNA (Ctrl-siRNA) or were mock transfected (no siRNA). The Ctrl-
siRNA has no homology to known human sequences. Lysates from these cells were used in 
western blotting with the purified polyclonal RhoJ antibody. Only one band was detected of 
the correct size (~25 kDa) and this was absent in the lanes containing lysates from the RhoJ 
knocked-down cells (Fig. 3.2 B). Western blotting showed that RhoJ silencing had no effect 
on the levels of RhoA, Rac1 and Cdc42 proteins (Fig. 3.2 C), thus demonstrating the 
specificity of the siRNA duplexes for RhoJ. This also showed that there was no up-regulation 
of these Rho GTPases to compensate for the loss of RhoJ. 
3.3.2. Testing the purified polyclonal rabbit RhoJ antibody for 
immunofluorescence  
The purified polyclonal RhoJ antibody was tested to determine if it would detect RhoJ protein 
by immunofluorescence (Fig. 3.3). HEK 293Ts transfected with myc-RhoJ encoding plasmids 
were fixed and co-stained with purified anti-RhoJ polyclonal antisera, anti-myc antibody and 
DAPI reagent to mark nuclei. RhoJ- and myc-specific antibodies gave a similar staining 
pattern in myc-RhoJ transfected cells, while in the mock transfected cells only a weak 
background signal was detected (Fig. 3.3 A). The expression of myc-RhoJ in HEK 293Ts was 
confirmed by western blotting with the RhoJ-specific monoclonal antibody (Abcam) (Fig. 3.3 
C). 
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Fig. 3.3 Testing the purified polyclonal RhoJ antibody in immunofluorescence. 
A, HEK 293Ts were transfected with myc-RhoJ encoding plasmids or were mock transfected. 48 h 
later cells were fixed and co-stained with myc and purified polyclonal RhoJ antibodies. Regions 
marked in the white boxes are expanded to give a more detailed view of the staining. B, HUVECs 
were transfected with 10 nM RhoJ-siRNA1, RhoJ-siRNA2 and Ctrl-siRNA duplexes or were mock 
transfected. 48 h later cells were fixed and stained with the purified polyclonal RhoJ antibody. RhoJ 
knock-down significantly reduced the peripheral punctate staining pattern. DAPI was used to visualise 
nuclei. All scale bars: 10 µm. Western blots showing the expression of myc-RhoJ (C) or RhoJ knock-
down (D). 
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The purified polyclonal RhoJ antibody also detected endogenous RhoJ in HUVECs (Fig. 3.3 
B). These cells were transfected with RhoJ-specific siRNAs (RhoJ-siRNA1 and RhoJ-
siRNA2), control non-specific siRNA (Ctrl-siRNA) or were mock transfected (no siRNA). 
Staining with the polyclonal RhoJ antibody gave a peripheral punctate pattern that was 
significantly reduced in the RhoJ siRNA silenced cells. The RhoJ staining pattern was clearer 
when cells were fixed using the ice-cold methanol (Fig. 3.3 B) in comparison to 4% 
paraformaldehyde fixed cells (data not shown). The efficiency of RhoJ knock-down in stained 
cells was tested by western blotting with the RhoJ-specific monoclonal antibody (Abcam) 
(Fig. 3.3 D). 
These experiments validate the specificity of the RhoJ monoclonal and polyclonal antibodies. 
In all further experiments the RhoJ monoclonal antibody from Abcam will be used for 
western blotting and the purified rabbit RhoJ polyclonal antibody will be used for 
immunofluorescent staining. 
3.4. Localisation of endogenous RhoJ to FAs 
In order to determine endogenous localisation of RhoJ in ECs, HUVECs were stained with the 
purified polyclonal RhoJ antisera. These initial experiments showed punctate, peripheral 
localisation of RhoJ reminiscent of FAs (Fig. 3.3 B), which are dynamic multiprotein 
complexes that via integrins connect the intracellular cytoskeleton with the ECM (Dubash, 
Menold et al. 2009).  
To more precisely test this hypothesis, RhoJ co-localisation with FA markers was verified by 
immunofluorescence. This was done in HUVECs cultured on gelatin or Matrigel substrates. 
In standard HUVECs culturing conditions gelatin is used to facilitate the adhesion of cells to 
the plate. Matrigel, on the other hand, is a richer substrate for ECs as it contains collagen, 
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Fig. 3.4 RhoJ localises to focal adhesions, co-localising with vinculin, talin and pFAK in 
HUVECs cultured on gelatin-coated coverslips. 
HUVECs were seeded on glass coverslips that were previously coated with gelatin. After 24 h cells 
were fixed with ice-cold methanol, blocked in BSA and co-stained with the indicated antibodies. 
DAPI was used to visualise nuclei. Regions marked in the white boxes are expanded in the bottom 
panel. RhoJ co-localised with vinculin (A), talin (B) and pFAK (C) as indicated with arrows. Scale 
bars: 10 µm. 
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Fig. 3.5 RhoJ localises to focal adhesions, co-localising with vinculin, talin and pFAK in 
HUVECs cultured on Matrigel-coated coverslips. 
HUVECs were seeded on glass coverslips that were previously coated with a thin layer of Matrigel. 
After 24 h cells were fixed with ice-cold methanol, blocked in BSA and co-stained with the indicated 
antibodies. DAPI was used to stain nuclei. Regions marked in the white boxes are expanded in the 
bottom panel. RhoJ co-localised with vinculin (A), talin (B) and pFAK (C) as indicated with arrows. 
Scale bars: 10 µm. 
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laminin, growth factors and other components such as these present in a basement membrane, 
which surrounds blood vessels, and this substrate induces tubule formation by ECs (Kubota, 
Kleinman et al. 1988; Passaniti, Taylor et al. 1992).  
HUVECs plated on these substrates were co-stained with antibodies specific to RhoJ and to 
the FA proteins vinculin, talin and phosphorylated FAK (pFAK).  RhoJ co-localised with all 
of these FA markers in cells cultured on both substrates (Fig. 3.4 and 3.5). Very often this co-
localisation was adjacent but not completely overlapping. This suggests that RhoJ, although 
present in these same FAs, might localise in different regions of the FA. The presence of 
Matrigel did not increase the localisation of RhoJ to FAs.  
3.5. Localisation of overexpressed RhoJ to vesicles and FAs 
The localisation of endogenous RhoJ in HUVECs to FAs was contradictory to that reported in 
HeLa cells, where ectopically expressed myc-RhoJ was found in the early endosomal 
compartment (de Toledo et al. 2003). Therefore to verify the localisation of overexpressed 
RhoJ, HUVECs were transiently transfected with GFP-RhoJ and myc-RhoJ encoding 
plasmids. Cells were then fixed and stained with a myc-specific antibody (for myc-RhoJ 
expressing cells) and antibodies against the early/sorting endosomal markers EEA1 and Rab5, 
the recycling endosomal marker Rab11 and the lysosomal marker Lamp1. The expression 
efficiency was very low with only a few cells highly overexpressing tagged RhoJ. In these 
cells both GFP-RhoJ (Fig. 3.6) and myc-RhoJ (Fig. 3.7) clearly localised to the early/sorting 
endosomes positive for EEA1 but not for Rab5, there was localisation of a small amount of 
RhoJ to the Rab11 positive recycling endosomes. In addition RhoJ was clearly present in the 
lysosomes stained for Lamp1. 
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Fig. 3.6 Overexpressed GFP-RhoJ localises to endosomes and lysosomes in HUVECs. 
HUVECs were cultured on gelatin-coated glass coverslips and 24 h later were transfected with GFP-
RhoJ encoding plasmids using the TransPass D2 transfection reagent. 48 h later cells were fixed with 
PFA and immunofluorescent staining was performed with the indicated antibodies. DAPI was used to 
stain nuclei. Regions marked in the white boxes are expanded in the bottom panel. GFP-RhoJ clearly 
co-localised with the early/endosomal marker EEA1 (A) but not with the Rab5 (B). Some co-
localisation was observed with the recycling endosomal marker Rab11 (C) and with the lysosomal 
marker Lamp1 (D). Scale bars: 10 µm. 
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Fig. 3.7 Overexpressed myc-RhoJ localises to endosomes and lysosomes in HUVECs. 
HUVECs were cultured on gelatin-coated glass coverslips and 24 h later were transfected with myc-
RhoJ encoding plasmids using the TransPass D2 transfection reagent. 48 h later cells were fixed with 
PFA and immunostaining was performed with the indicated antibodies. DAPI was used to stain nuclei. 
Regions marked in the white boxes are expanded in the bottom panel. Myc-RhoJ clearly co-localised 
with the early/endosomal marker EEA1 (A) but not with the Rab5 (B). Some co-localisation was 
observed with the recycling endosomal marker Rab11 (C) and with the lysosomal marker Lamp1 (D). 
Scale bars: 10 µm. 
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However, this transient HUVECs transfection resulted in only a few cells expressing very 
high levels of tagged RhoJ. Thus an alternative approach was used to introduce tagged wild 
type and active mutant RhoJ into a higher proportion of cells. HUVECs were transduced with 
the lentivirus to express GFP-wtRhoJ (wild type RhoJ), GFP-daRhoJ (Q79L dominant active 
RhoJ mutant), GFP-dnRhoJ (T35N dominant negative RhoJ mutant) or GFP proteins. GFP-
positive cells were then purified by flow cytometry. 
The lentivirus infection efficiency reached approximately 90 % for GFP control cells and 40-
60 % for GFP-wtRhoJ and GFP-daRhoJ expressing cells. No protein expression was observed 
in HUVECs infected with GFP-dnRhoJ lentivirus. It is possible that the dominant negative 
RhoJ mutant sequesters GEFs essential for other related Rho GTPases resulting in the down-
regulation of many crucial signalling pathways and cell lethality. The expression of proteins 
in GFP-positive sorted cells was confirmed by western blotting (Fig. 3.8). Confocal 
microscopy showed that in these cells both GFP-wtRhoJ and GFP-daRhoJ localised to the 
plasma membrane in addition to FAs which positively stained for vinculin (marked by white 
arrows, Fig. 3.9). GFP-RhoJ was also observed in the intracellular vesicles (marked by yellow 
arrows, Fig. 3.9). 
These results suggest that endogenous RhoJ localises mainly to FAs in HUVECs, and when 
overexpressed it also localises to intracellular vesicles. 
3.6. Testing the role of dominant active RhoJ in endothelial cell motility 
Studies performed by other members in our laboratory showed that silencing of RhoJ with 
siRNA significantly impaired EC migration, proliferation and tube formation. It was shown 
that this motility defect was accompanied by increased FA numbers and cell contractility  
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Fig. 3.8 Stable expression of GFP-wtRhoJ and GFP-daRhoJ in HUVECs. 
HUVECs were infected with lentivirus to express GFP, GFP-wtRhoJ or GFP-daRhoJ proteins. GFP-
positive cells were sorted using flow cytometry. Subsequently lysates were prepared from the same 
number of cells for each infection. Western blotting was performed with GFP, RhoJ and tubulin-
specific antibodies as indicated. 
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Fig. 3.9 Lentivirally transduced GFP-RhoJ localises to vesicles and focal adhesions in HUVECs. 
HUVECs were transduced with lentivirus to stably express GFP, GFP-wtRhoJ or GFP-daRhoJ, and 
were sorted for GFP-positive cells using flow cytometry. Cells were then cultured on gelatin-coated 
coverslips and immunofluorescent staining was performed with the vinculin-specific antibody. DAPI 
was used to visualise nuclei. Regions marked in the white boxes are expanded in the bottom panel. 
Both GFP-wtRhoJ and GFP-daRhoJ localised to the membrane, focal adhesions (white arrows) and 
intracellular vesicles (yellow arrows). Scale bars: 10 µm. 
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(Kaur, Leszczynska et al. 2011). Since RhoJ function had only been probed by determining 
the effect of silencing RhoJ, it was important to establish the effect of expressing a dominant 
active mutant form of RhoJ in various cell motility and tube formation assays. In order to do 
this, HUVECs were transduced with lentivirus to stably express GFP or GFP-daRhoJ, and 
GFP-positive cells were sorted by flow cytometry. These cells were expanded by passaging 
and tested in various assays described in the subsequent sections. The expression of GFP and 
GFP-daRhoJ in the flow cytometry-sorted HUVECs was confirmed by western blotting (Fig. 
3.8). It was determined that these cells were expressing approximately 15-20 times more 
GFP-daRhoJ than endogenous RhoJ. 
3.6.1. Dominant active RhoJ promotes endothelial cell tube branching 
It was noticed that all HUVECs donors stably expressing GFP-daRhoJ had a different 
morphology from GFP-expressing cells when cultured in standard gelatin-coated petri dishes. 
Unlike the GFP control cells, HUVECs with GFP-daRhoJ very often had an arched elongated 
shape with numerous protrusions (indicated by arrows in Fig. 3.10 A). 
In order to verify the potential role of active RhoJ in the tubule formation, these cells were 
used in an organotypic angiogenesis assay. This was performed in collaboration with 
Margherita Scarcia and Sabu Abraham in Dr Georgia Mavria’s Laboratory (Leeds Institute of 
Molecular Medicine, St James’s University Hospital, Leeds, UK; permission given to present 
the data). In this assay they seeded HUVECs on a monolayer of human dermal fibroblasts, 
which produce ECM and secrete VEGF. These conditions and exogenously added FGF-2 
stimulate ECs to form tubules with lumens that are highly reminiscent of the in vivo 
microvasculature (Bishop, Bell et al. 1999; Donovan, Brown et al. 2001). After 5 days of co-
culture assay cells were stained with the CD31-specific antibody to visualise HUVECs (Fig. 
3.10 B). More tubules were formed by GFP-daRhoJ-expressing HUVECs in comparison to  
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Fig. 3.10 Dominant active RhoJ changes HUVECs morphology and promotes endothelial tube 
branching. 
HUVECs were transduced with lentivirus to express either GFP or GFP-daRhoJ and were sorted for 
GFP-positive cells by flow cytometry. A, The GFP-daRhoJ expressing HUVECs had a distinct 
morphology with arched elongated protrusive shapes (indicated with arrows) as compared to GFP 
control cells. B, GFP and GFP-daRhoJ cells were used by Margherita Scarcia and Sabu Abraham in 
co-culture assay with human dermal fibroblasts (permission given to re-print the data). After 5 days of 
co-culture endothelial tubules were visualised by staining with CD31-specific antibody. Numbers of 
junctions, tubules, total and mean tubule lengths were quantified using the Angiosys software (C). 
Statistically significant differences between GFP and GFP-daRhoJ containing tubes were determined 
with the Mann Whitney test (*** for p < 0.001; ** for 0.001 < p < 0.01 and * for 0.01 < p < 0.05.)  All 
scale bars: 100 µm. 
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GFP-expressing cells. In addition, GFP-daRhoJ-containig tubes were shorter and had more 
branches (Fig. 3.10C). This result supports the hypothesis that active RhoJ may play a role in 
promoting tubule formation. 
3.6.2. Dominant active RhoJ increases cell migration 
In order to test the role of RhoJ in cell migration, a scratch wound assay was performed. 
Monolayers of HUVECs expressing either GFP or GFP-daRhoJ were scratched with a pipette 
tip and then incubated in complete HUVEC medium to allow the wound closure. During this 
incubation mitomycin C was added, which inhibits cell proliferation. Therefore in such 
conditions wound closure rates are affected by cell motility alone. It was found that HUVECs 
expressing GFP-daRhoJ migrated faster to close the wound in comparison to GFP control 
cells (Fig. 3.11). Combining data from three different HUVECs isolates did not give a 
statistically significant increase in the speed of wound closure by GFP-daRhoJ expressing 
cells compared to the GFP control cells. However GFP-daRhoJ expressing cells migrated 
consistently faster than GFP expressing cells in at least 3 different HUVECs isolates. The 
presence of a dominant active form of RhoJ induced an opposite phenotype to that seen in 
cells where RhoJ was silenced with siRNA (Kaur, Leszczynska et al. 2011). Both data 
indicate that RhoJ plays important role in the regulation of EC migration. 
3.6.3. Dominant active RhoJ decreases the numbers of FAs and SFs in 
migrating cells 
Experiments performed by Sukhbir Kaur in our laboratory showed that RhoJ-siRNA silencing 
caused an increase in the number of FAs and SFs (Kaur, Leszczynska et al. 2011). This was 
observed in sparsely plated cells or in cells that were at the edge of a migrating monolayer but 
not in cells that were within a monolayer. This suggested that RhoJ was affecting FAs and  
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Fig. 3.11 Dominant active RhoJ promotes HUVECs migration in the scratch wound assay. 
HUVECs were transduced with lentivirus to express either GFP or GFP-daRhoJ and were sorted for 
GFP-positive cells by flow cytometry. Cells were then grown to a monolayer, scratched with a pipette 
tip and the wound closure was monitored (A). The scale bar: 200 µm. B, Graph showing the 
quantitation of remaining wound area for different time points. The means from 3 different 
experiments and standard errors are plotted. Although the difference in the speed of a wound closure 
between the GFP and GFP-daRhoJ expressing cells is not statistically significant, accelerated wound 
closure as a result of GFP-daRhoJ expression was observed in 3 different HUVEC isolates. 
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Fig. 3.12 Dominant active RhoJ decreases the numbers of focal adhesions and stress fibres in 
migrating endothelial cells. 
HUVECs were transduced with lentivirus to express either GFP or GFP-daRhoJ and were sorted for 
GFP-positive cells by FACS. A, These were sparsely plated and 4 h later fixed and stained with 
vinculin-specific antibody. B and C, Monolayers of HUVECs expressing either GFP or GFP-daRhoJ 
were scratched with a pipette tip and cells were allowed to migrate. 2-3 h later cells were fixed and 
stained with vinculin-specific antibody (B) or with phalloidin (C). Focal adhesions were counted and 
actin fluorescence measured per cell in at least 32 cells from 3 experiments. The graphs show box and 
whisker plots indicating the maximum, minimum, 25th and 75th percentiles and median values (*** 
for p<0.001, a Mann-Whitney test used). Scale bars: 20 µm. 
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SFs particularly in motile cells. Therefore the effect of dominant active RhoJ was tested in 
these same assays. Firstly, in sparsely plated HUVECs, GFP-daRhoJ significantly decreased 
the number of FAs (Fig. 3.12 A). SFs, stained for F-actin, were also decreased, but only in 
two HUVEC isolates out of three isolates tested (data not shown). Secondly, GFP-daRhoJ 
expressing cells, which were at the wound edge of a migrating monolayer, had decreased 
numbers of FAs (Fig. 3.12 B) and SFs (Fig. 3.12 C) in comparison to GFP-expressing cells. A 
difference in the FA numbers was not observed in HUVECs that were within a monolayer. In 
addition, there were no consistent differences in the intensity of the SF staining between 
different HUVECs isolates transduced with GFP or GFP-daRhoJ which were situated within a 
monolayer. 
It was concluded that active RhoJ significantly reduced FAs and SFs in the migrating cells. 
This result, together with effect of silencing of RhoJ, suggests that this small Rho GTPase 
plays a crucial role in cell motility via the regulation of FA turnover and cell contractility. 
3.7. The role of RhoJ in an endocytosis of transferrin receptor in 
endothelial cells 
Previous studies indicated that ectopically expressed RhoJ localised to endosomes and played 
a role in an early endocytosis in HeLa cells, whereas silencing of RhoJ caused a delay in 
recycling of Tf receptor (de Toledo, Senic-Matuglia et al. 2003). We compared the levels of 
endogenous RhoJ proteins in HeLa cells and HUVECs and we were not able to detect it in 
HeLa cell lysates (Fig. 3.13 A). However other isolates of HeLa might express RhoJ. Since, 
we also showed that overexpressed RhoJ localised to intracellular vesicles including 
endosomes and lysosomes in HUVECs (Fig. 3.6, 3.7 and 3.9), it was important to test the  
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Fig. 3.13 RhoJ siRNA silencing delays Tf release in HUVECs. 
A, Western blotting showing comparison of the RhoJ protein levels in HUVECs and HeLa lysates. B 
and C, HUVECs were transfected with 10 nM RhoJ-siRNA1, RhoJ-siRNA2 and Ctrl-siRNA duplexes 
or were mock transfected. 48 h later cells were depleted of endogenous Tf by serum starvation for 1 h 
and then were incubated with 5 µg/ml of Alexa 488-conjugated Tf for another hour (B). Cells were 
then washed and incubated with 50 µg/ml of un-labelled Tf for the indicated time periods (C). The 
plots represent the geometric mean fluorescence of the cells (analysed by FACS) which gives an 
indication of the Tf uptake (B), or that remaining in the cells (C). The 0 time point in C shows the 
mean cell fluorescence of the cells prior to incubation with unlabelled Tf. This was considered to be 
100 % and subsequent time points are plotted as a percentage. Although not statistically significant, 
RhoJ siRNA silencing caused a slight but reproducible delay in the Tf release in 3 different HUVEC 
isolates. 
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effect of RhoJ silencing on the uptake and recycling of the Tf receptor in ECs, which express 
RhoJ abundantly. In order to measure an uptake of Tf, HUVECs with siRNA-silenced RhoJ 
as well as control cells were loaded with a fluorescently labelled Tf and then analysed by flow 
cytometry. Similarly to the study on HeLa cells (de Toledo, Senic-Matuglia et al. 2003), RhoJ 
knock-down did not affect the levels of Tf taken up in HUVECs (Fig. 3.13 B).  
In the next step Tf release was measured. Medium with a fluorescently labelled Tf was 
removed from the cells and fresh media with an excess of un-labelled Tf was added. Cells 
were then incubated for different time periods and FACS analysis was performed to measure 
the amount of fluorescent Tf remaining in these cells. It was found that RhoJ silencing caused 
a slight but reproducible delay in the Tf release (Fig. 3.13 C). Although a statistically 
significant difference was not observed between RhoJ-knocked-down or RhoJ-expressing 
cells, the trend in the delay of Tf release caused by RhoJ knock-down was consistent for 3 
different HUVEC isolates. 
3.8. Testing an influence of RhoJ knock-down on the surface levels of 
VEGFR2 in HUVECs 
VEGFR2 is a major receptor that responds to VEGFA, a very potent mediator of angiogenesis 
(Gerhardt, Golding et al. 2003; Olsson, Dimberg et al. 2006). VEGFR2 traffics between the 
plasma membrane, endosomes and degradative cellular compartments, and this is regulated by 
the presence of VEGFA ligand (Ewan, Jopling et al. 2006; Gampel, Moss et al. 2006). Since 
RhoJ loss had only a slight effect on the Tf release in HUVECs it was important to examine 
whether it plays a role in the trafficking of VEGFR2. This was tested by looking at VEGFR2 
surface levels in the RhoJ siRNA-silenced cells.  
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Fig. 3.14 RhoJ siRNA silencing does not affect the VEGFR2 surface distribution in HUVECs. 
Cells were transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2 and Ctrl-siRNA duplexes or were 
mock transfected. 48 h later HUVECs were serum starved and then VEGF-A (10 ng/ml) stimulated. 
One group of cells was not starved but was left untreated in complete medium, as indicated. Cells 
were then harvested with non-enzymatic dissociation solution and fixed with PFA. Since they were 
not permeabilised the immunofluorescent staining with VEGFR2-specific antibody detected only 
VEGFR2 present on the cell surface. FACS analysis showed that RhoJ siRNA silencing did not affect 
surface levels of VEGFR2. The graph shows the means and standard errors for combined 3 
experiments. 
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HUVECs with RhoJ knock-down were tested for the presence of VEGFR2 at a cell surface by 
immunofluorescent staining with VEGFR2-specific antibody. This was done in cells that were 
fixed with PFA but not permeabilised with any detergent to prevent staining of intracellular 
VEGFR2. Since receptor trafficking is regulated by the availability of VEGA, cells treated in 
three different conditions were tested: starved cells, VEGF stimulated cells or cells left in 
complete HUVEC medium. FACS analyses did not reveal any significant differences in 
VEGFR2 levels between RhoJ-silenced and control cells under any of these conditions (Fig. 
3.14). These studies did not include thorough analysis of co-localisation of VEGFR2 with 
particular endosomal markers in the presence or absence of RhoJ. Nonetheless it was 
concluded that RhoJ was not important in regulating the surface levels of VEGFR2. 
3.9. Discussion 
ECs are critical for the formation of new blood vessels, a process known as angiogenesis 
(Carmeliet 2003). Our group has shown that RhoJ, a small Rho GTPase, is expressed 
predominantly in ECs where it plays a critical role in many processes important during 
angiogenesis. These include the regulation of EC migration, tube formation, FA numbers and 
actomyosin contractility (Kaur, Leszczynska et al. 2011). All these findings were based on the 
observations of the effects of RhoJ siRNA silencing in HUVECs. Work described in this 
chapter was first to show the intracellular localisation of endogenous RhoJ in ECs. 
Overexpression of dominant active RhoJ promoted endothelial tube formation and migration, 
the converse to that seen with RhoJ knock-down, and thus reinforcing our conclusions about 
the role of RhoJ in endothelial motility and tubulogenesis. Additionally, the potential role of 
RhoJ in endocytosis in ECs was investigated. 
The first group that characterised RhoJ (Vignal, De Toledo et al. 2000) showed in subsequent 
studies that ectopically expressed tagged RhoJ was present on the plasma membrane and 
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EE/ES in HeLa cells (de Toledo, Senic-Matuglia et al. 2003). Nonetheless, none of the 
published data so far have indicated the localisation of endogenous RhoJ. Thus knowing that 
this protein is abundantly expressed in ECs it was important to determine its intracellular 
localisation in these cells, as this would enable a better understanding of its function. 
Polyclonal RhoJ antibodies were made in rabbits, purified and validated for 
immunofluorescence. Using these antibodies, it was established that endogenous RhoJ 
localised to FAs in ECs as shown by co-localisation with vinculin, pFAK and talin. Since FAs 
play a critical role in the regulation of cell motility (Dubash, Menold et al. 2009; Parsons, 
Horwitz et al. 2010), this finding was consistent with the role our group have discovered for 
RhoJ in EC motility. In addition, when the localisation of overexpressed myc- and GFP-
tagged RhoJ in ECs was tested, it was found that transient and high overexpression of tagged 
RhoJ in ECs drove its localisation not only to endosomes, as seen by de Toledo et al. in HeLa 
cells (de Toledo, Senic-Matuglia et al. 2003), but also to lysosomes. However, in ECs 
transduced with lentivirus to moderately and stably express GFP-tagged RhoJ (both wild type 
and dominant active mutant forms), its localisation was observed in intracellular vesicles as 
well as in FAs.   
Previously, our laboratory showed that silencing of RhoJ with siRNA in HUVECs impaired 
cell motility and tubule formation and this was accompanied by an increase in the number of 
FAs and SFs in migrating cells (Kaur, Leszczynska et al. 2011). During migration cells 
polarise and extend protrusions such as spike-like filopodia and sheet-like lamellipodia 
towards the pro-migratory factors. These protrusions are built on the actin cytoskeleton and 
stabilised by nascent FAs, which connect the actin filaments with the ECM. Attached to the 
underlying surface, cells use the actomyosin contractility to move forwards and subsequently 
FAs at the rear are disassembled. Thus a constant turnover of FAs and actomyosin 
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cytoskeleton is very important in cell migration (Raftopoulou and Hall 2004; Parsons, 
Horwitz et al. 2010). Importantly, RhoJ knock-down increased the numbers of FAs and SFs 
only in sparsely plated cells or in these present at the edge of a migrating monolayer, but not 
within a monolayer. Thus this suggested that RhoJ played a role in highly motile cells, while 
in cells within a monolayer cell-cell contacts might have induced signalling pathways that 
compensated for the loss of RhoJ. To more thoroughly test the function of RhoJ in ECs, a 
constitutively active RhoJ mutant was used. As expected, active RhoJ increased the EC 
migration in a scratch wound assay. Its role was also profound in the formation of tubes by 
ECs, as observed by excessive sprouting by these cells. Finally, active RhoJ decreased the 
number of FAs and SFs in the migrating cells. Together, the effects of RhoJ knock-down and 
overexpression of its active form led to the conclusion that RhoJ is a critical player in the 
regulation of EC motility, as it controls the turnover of FAs and SFs in migrating cells.  
Other Rho GTPases such as RhoA, Rac1 and Cdc42 are known to drive the formation of FAs 
and rearrange the cytoskeleton: Cdc42 induces peripheral focal complexes associated with 
filopodia, Rac1 drives formation of focal complexes in lamellipodia, and RhoA induces SF-
associated FAs (Nobes and Hall 1995). RhoJ knock-down did not affect the expression levels 
of these Rho GTPases, which are also present in HUVECs (Fig. 3.2 C). Since RhoJ is 
expressed predominantly in ECs and its knock-down phenotype is not rescued by the presence 
of other Rho GTPases such as RhoA, Rac1 and Cdc42, it was concluded that RhoJ plays a 
distinct role in ECs. 
De Toledo and colleagues demonstrated that ectopically expressed myc-RhoJ localised to  
EE/ES where it played a role in the early endocytosis of Tf receptor in HeLa cells (de Toledo, 
Senic-Matuglia et al. 2003). Work described in this chapter also showed that in ECs 
overexpressed RhoJ was partially localising to endosomes and other intracellular vesicles. 
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Therefore, it was important to examine the role of RhoJ in endocytosis of ECs and this was 
initially tested by investigating the trafficking of Tf. Whereas no difference was observed in 
the Tf uptake, the RhoJ knock-down caused a slight delay in the Tf release and this was 
consistent with the previous observation by de Toledo et al. (2003).  
The major role of Tf is delivering iron ions to the cells and this process takes place in various 
tissues (Macedo and de Sousa 2008). Since RhoJ knock-down only slightly affected this 
endocytosis pathway common to many cell types, it was hypothesised that RhoJ may regulate 
trafficking of molecules which are more specific to ECs. VEGFR2, a key receptor in ECs 
which responds to the pro-migratory and pro-angiogenic factor, VEGF, is constantly 
endocytosed and recycled to the plasma membrane, and this is regulated via stimulation by its 
ligand (Ewan, Jopling et al. 2006; Gampel, Moss et al. 2006; Gerhardt 2008). Thus the role of 
RhoJ in distribution of this receptor to the plasma membrane was investigated but no change 
was observed in RhoJ-knocked-down ECs. Additionally, a single experiment was performed 
to investigate the endocytosis via scavenger receptors in HUVECs. This was done by 
measuring the uptake of acetylated low-density-lipoprotein fluorescently labelled with 1,1’-
dioctadecyl-3,3,3’3’-tetramethyl-indocarbocyanine perchlorate (DiI-Ac-LDL). The uptake of 
this chemically modified lipoprotein is specific to ECs end macrophages and is mediated by 
the family of scavenger receptors (Voyta, Via et al. 1984; Adachi and Tsujimoto 2006). 
Again, RhoJ-siRNA silenced cells were able to normally uptake the DiI-Ac-LDL as analysed 
by FACS or fluorescent microscopy (data not shown). Given that RhoJ did not play a role in 
the VEGFR2 trafficking or uptake of DiI-Ac-LDL and the role of RhoJ in Tf recycling was 
not major, other endocytosis pathways would need to be investigated to explore the role of 
RhoJ present in the intracellular vesicles. Existing evidence shows that during FA turnover 
some components of FAs such as paxillin are endocytosed and then recycled to the new focal 
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complexes (Di Cesare, Paris et al. 2000; Matafora, Paris et al. 2001; Rosenberger and Kutsche 
2006). Since it was shown here that active RhoJ decreased the number of FAs, it is possible 
that it might regulate the endocytosis of their components. However, future studies would be 
required to test this hypothesis.  
In conclusion, work presented in this chapter was first to show the localisation of endogenous 
RhoJ to FAs. Overexpression of a dominant active RhoJ mutant in ECs showed that RhoJ 
promotes EC migration, tubulogenesis and decreases the numbers of FAs and SFs in 
migrating cells. This supported previous findings by Sukhbir Kaur where RhoJ knock-down 
caused opposite effects. Combining these data, the evidence suggests that RhoJ plays a critical 
role in EC biology as it regulates EC migration, tubulogenesis, FA turnover and actomyosin 
contractility, and therefore it might be an important player in angiogenesis. 
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4.1. RhoJ binding partners 
RhoJ belongs to the Cdc42-like subfamily of Rho GTPases as structurally it is most similar to 
TC10 and Cdc42. Vignal et al. showed that active RhoJ, like active TC10 and Cdc42, 
interacts with the CRIB domain present in PAK and WASP; this was demonstrated by both 
GST-CRIB pull-down and Y2H assays (Vignal, De Toledo et al. 2000). This was also 
subsequently observed by Aspenstrom et al. who additionally demonstrated a weak 
interaction of active RhoJ with rhotekin (Aspenstrom, Fransson et al. 2004). This group also 
performed a Y2H study in which they tested interactions of the dominant active RhoJ mutant 
with known Cdc42 effectors; positive interactions were found for WASP, N-WASP, Cdc42-
interacting protein 4 (CIP4), partitioning defective 6 (Par6), p50RhoGAP, PAK1B and PAK4 
(Aspenstrom, Fransson et al. 2004). However, no further studies have been published that 
show the physiological relevance of these interactions in mammalian cells.  
Chiang et al. identified and characterised TC10β and TC10βLong, which are the mouse 
orthologs of RhoJ. They found that TC10β when transfected into murine 3T3L1 adipocytes 
localised to lipid rafts and was activated by insulin stimulation, this was dependent on 
Cbl/CAP (Chiang, Hou et al. 2002). Cbl/CAP is a complex which regulates the glucose up-
take by mobilisation of the glucose transporter GLUT4 from the intracellular storage sites to 
the cell surface. Upon insulin stimulation the Cbl/CAP complex becomes phosphorylated by 
the insulin receptor. Then Cbl/CAP translocates to lipid rafts via interaction with flotillin, and 
recruits CrkII along with C3G. C3G is a guanine nucleotide exchange factor that has been 
shown to activate human TC10 (Chiang, Baumann et al. 2001). The activation of TC10β by 
insulin was inhibited by a dominant negative mutant of CAP which does not localise to the 
lipid rafts, thus it was possible that TC10β activation was mediated by the C3G GEF recruited 
to lipid rafts by the Cbl/CAP/CrkII complex (Chiang, Hou et al. 2002).   
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Since it was established that RhoJ is expressed in ECs (Herbert, Stekel et al. 2008; Kaur, 
Leszczynska et al. 2011), one of the main aims of these PhD studies was to determine the 
binding partners of RhoJ in these cells. It was anticipated that the most likely candidates 
would be found among proteins containing a CRIB domain. Some of the known effectors of 
Cdc42 which contain the CRIB motif and were shown to play a role in ECs, include PAK, 
myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK), WASP and N-WASP 
(Groeger and Nobes 2007; Galan Moya, Le Guelte et al. 2009; Sheldon, Andre et al. 2009; 
Kang, Wang et al. 2010). These proteins regulate processes such as cytoskeletal 
rearrangements, actin polymerisation, actomyosin contractility, FA dynamics (Bishop and 
Hall 2000). FAs are multiprotein dynamic complexes, which connect the intracellular 
cytoskeleton with the ECM. Their constant turnover along with protrusion and retraction of 
the actomyosin filaments are important in the cell migration (Parsons, Horwitz et al. 2010). 
RhoJ is likely to interact with the components of FAs as work described in the previous 
chapter established that RhoJ localises to FAs and when activated it decreases the number of 
FAs, SFs and promotes EC migration.  
The PIX and GIT proteins form a complex which localises to FAs via the C-terminal domain 
of GIT1, which binds to paxillin (Bagrodia, Bailey et al. 1999; Turner, Brown et al. 1999). 
The interaction of GIT1 with paxillin was shown to promote FA disassembly and cell 
migration (Zhao, Manser et al. 2000; Feng, Baird et al. 2010). Moreover, PIX and GIT have 
multiple domains and can serve as scaffolds which interact with and bring together a number 
of proteins including PAK, Cdc42, Rac1, paxillin, pFAK (Frank and Hansen 2008). PIX 
serves as a GEF for Cdc42 and Rac1, and concomitantly it binds to their effector – PAK, 
which was shown to promote FA disassembly (Manser, Huang et al. 1997; Bagrodia, Taylor 
et al. 1998; Manser, Loo et al. 1998).  
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The aim of the work described in this chapter was to identify the proteins that interact with 
RhoJ in ECs, and thus help to elucidate the mechanism through which RhoJ functions. RhoJ-
binding candidates were pulled-down from cellular lysates using GST-RhoJ fusion proteins 
and identified by mass spectrometry. The most interesting candidates such as those involved 
in cell migration, FA turnover, potential GAPs, GEFs or CRIB domain containing proteins 
were shortlisted and their interactions with RhoJ were tested in a Y2H assay. This experiment 
revealed that RhoJ interacted directly with GIT1 and MRCKA. Thus further studies focused 
on examining the interaction of RhoJ with the GIT1/βPIX complex in ECs. Firstly, 
immunofluorescence was used to verify the co-localisation of RhoJ with this complex. 
Secondly, the single components of the hypothetical βPIX/GIT1/RhoJ complex were 
knocked-down to test how their loss would affect the localisation of these proteins to FAs. 
4.2. Pull-down of RhoJ binding partners and their identification by mass 
spectrometry 
In order to look for GAPs, GEFs and other RhoJ-interacting proteins, pull-down assays were 
performed according to the method described by Garcia-Mata and colleagues (Garcia-Mata, 
Wennerberg et al. 2006). This used GST-daRhoJ (Q79L, GTP-bound) and GST-dnRhoJ 
(G33A, nucleotide-free) fusion proteins, which were loaded on glutathione-agarose beads and 
incubated with various cellular lysates (HUVECs, HMEC-1 or HEK 293Ts). The dominant 
active RhoJ mutant should bind GAPs and effector proteins and the dominant negative RhoJ 
mutant should sequester GEFs (Garcia-Mata, Wennerberg et al. 2006). Mixtures of protein 
samples from pull-down experiments were firstly resolved by SDS-PAGE and then visualised 
in gels by Coomassie staining (Fig. 4.1). Some of the interesting protein bands (as indicated in 
the Fig. 4.1) which appeared only in the GST-RhoJ but not in the GST control pull-downs  
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Fig. 4.1 Pull-down of GAPs, GEFs and effectors of RhoJ. 
HUVECs, HMEC-1 and HEK 293Ts were grown in appropriate complete medium and lysed. 
Subsequently their lysates were firstly precleared with GST-glutathione agarose beads and then 
incubated with GST-daRhoJ, GST-dnRhoJ or GST control proteins bound to the glutathione agarose 
beads as indicated. After the pull-downs the beads were washed and resuspended in 2x SDS sample-
loading buffer. Samples were subjected to SDS-PAGE and stained with the Coomassie dye. The 
protein bands that were visible in GST-RhoJ pull-down lanes (marked with the white numbers) but not 
in GST alone pull-down control lanes were excised, processed and analysed by mass spectrometry. 
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Tab. 4.1 Mass spectrometry results showing potential RhoJ-binding proteins. 
The table indicates the gene symbol, name and the sample number that corresponds to the 
digested gel fragment as labelled in Fig. 4.1. 
 
Gene 
symbol 
Name Sample No 
from MS 
 
Potential GAPs or GEFs 
 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor 6 (αPIX) 3 
ARHGEF7 PAK-interacting exchange factor beta isoform b (βPIX) 3 
IQGAP1 IQ motif containing GTPase activating protein 1 1, 2, 9, 7 
GIT1 G protein-coupled receptor kinase-interacting target 1 3 
GNL3 guanine nucleotide binding protein-like 3 isoform 1 10 
GUF1 GUF1 GTPase homolog 4 
G3BP1 Ras-GTPase-activating protein SH3-domain-binding protein 13 
OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF isoform a 
14 
 
CRIB-domain containing 
 
CDC42BPA 
CDC42-binding protein kinase alpha, also called myotonic 
dystrophy kinase-related cell division cycle 42-binding 
kinase alpha (MRCKA) 
1, 2 
CDC42BPB 
CDC42-binding protein kinase beta,  also called myotonic 
dystrophy kinase-related cell division cycle 42-binding 
kinase beta (MRCKB) 
1, 2 
 
Cytoskeletal-related proteins 
 
FLNA filamin A, alpha isoform 2 1,6,9 
FLNB filamin B, beta (actin binding protein 278) 6 
CEP250 centrosomal protein 2 isoform 1 6,7,12,11 
TUBA1B tubulin, alpha, ubiquitous 14 
TUBA1C tubulin alpha 6 14 
TUBA3D tubulin, alpha 3d 14 
TUBA4A tubulin, alpha 4a 14 
TUBAL3 tubulin, alpha-like 3 14 
TUBB tubulin, beta 14 
TUBB2A tubulin, beta 2 14 
TUBB2C tubulin, beta, 2 14 
TUBB4 tubulin, beta 4 14 
TUBB4Q tubulin, beta polypeptide 4, member Q 14 
TLN1 talin 1 9 
SCRIB scribble isoform b 13 
MYO1B myosin IB isoform 2 5, 8 
MYO1C myosin IC isoform c 7 
4. IDENTIFICATION OF RHOJ BINDING PARTNERS IN ECS 
132 
 
 
MYO1D myosin ID 7 
MYH9 myosin, heavy polypeptide 9, non-muscle 1, 6 
MYH11 smooth muscle myosin heavy chain 11 isoform SM1A 1, 6 
MYH14 myosin, heavy chain 14 isoform 2 1, 6 
 
Other miscellaneous hits 
 
IKIP IKK interacting protein isoform 1 5,8 
THBS1 thrombospondin 1 precursor 7 
TRAP1 TNF receptor-associated protein 1 3 
CUL5 Vasopressin-activated calcium-mobilising receptor-1 11 
TSGA10 testis specific, 10 2 
SLC4A2 solute carrier family 4, anion exchanger, member 2 
(erythrocyte membrane protein band 3-like 1) 
4 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 5 
EEF1B2 eukaryotic translation elongation factor 1 beta 2 5 
EEF1G eukaryotic translation elongation factor 1 gamma 5 
ZBTB37 zinc finger and BTB domain containing 37 isoform b 5 
 various heat shock proteins  
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lanes were digested with trypsin and analysed by mass spectrometry. Protein sequencing was 
performed by Dr Cleidiane Zampronio using liquid chromatography and mass spectrometry 
(LS-MS) (in collaboration with Prof. John Heath, School of Biosciences, University of 
Birmingham, Functional Genomics and Proteomics Unit). The results revealed many 
interesting candidates for RhoJ-binding proteins, which were grouped into the following 
categories: GAPs, GEFs, CRIB domain-containing proteins, cytoskeleton-related proteins and 
other miscellaneous hits (Tab. 4.1). 
4.3. Confirmation of the interactions between RhoJ and pulled-down 
proteins 
Having identified candidates for RhoJ-binding proteins (Tab. 4.1), the next step was to 
confirm these interactions by another method; here a Y2H assay was used. The most 
interesting RhoJ-binding candidates important in cell motility-related processes, potential 
GAPs, GEFs or CRIB domain containing proteins (shortlisted and briefly described in the 
Table 4.2) were cloned into the pACT2 vector to generate fusion proteins with the activating 
domain (AD) of the Gal4 transcription factor. The wild type RhoJ or its mutant versions 
(GTP-bound dominant active (Q79L) and GDP-bound dominant negative (T35N) forms) were 
cloned into the pGBT9 vector to generate fusion proteins with the DNA-binding domain 
(DBD) of the Gal4 transcription factor.  
Various combinations of pGBT9 and pACT2 constructs were transformed into pJ69-4A yeast 
strain, which is auxotropic for histidine and contains the Gal1 promoter-HIS3 reporter gene. 
The interaction of candidate proteins with RhoJ or its mutants should result in the expression 
of HIS3 gene and allow yeast to grow on a histidine-free medium. Thus, yeast were spotted 
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Tab. 4.2 RhoJ-binding protein candidates tested in the Y2H assay. 
The table shows the list of proteins tested for the interaction with RhoJ in the Y2H assay and 
indicates their known functions. 
 
Protein Known functions Key references 
MRCKA Contains CRIB domain; effector of Cdc42; mediates 
Cdc42-induced filopodia formation; phosphorylates 
MLC; regulates the nuclear repositioning during cell 
polarisation and migration; modulates the lamellar 
actomyosin retrograde flow during cell protrusion and 
migration.  
(Gomes, Jani et al. 
2005; Zhao and 
Manser 2005; Tan, 
Yong et al. 2008) 
GIT1 GAP for Arf GTPases; trafficks between cytoplasmic 
complexes, FAs and cell periphery; participates in the 
internalisation of GPCRs; interacts with mitogen-
activated protein kinases (MAPK) and phospholipase 
Cγ; interacts with PAK, PIX and paxillin in the 
regulation of FA turnover; participates in the formation 
of podosomes; required for pulmonary vascular 
development. 
(Hoefen and Berk 
2006; Frank and 
Hansen 2008; Pang, 
Hoefen et al. 2009; 
Wang, Taba et al. 
2009) 
αPIX GEF for Rac1 and Cdc42, regulates the actin 
cytoskeleton and FA through the interactions with PAK, 
Rho GTPases, GIT, β-Parvin and calpain; forms homo- 
or heterodimers with βPIX. 
(Rosenberger and 
Kutsche 2006; Frank 
and Hansen 2008) 
βPIX Displays a weak GEF activity towards Rac1 and Cdc42, 
forms homo- or heterodimers with αPIX; together with 
GIT1 and PAK localises to FA and plays a role in FA 
turnover and cell migration; regulates formation of 
podosomes; interacts with scribble and shank in the cell 
polarisation process. 
(Rosenberger and 
Kutsche 2006; Frank 
and Hansen 2008) 
IQGAP1 Involved in calcium/calmodulin signalling, MAPK 
signalling, regulation of the cytoskeleton, cell-cell 
contacts, cell adhesion and cell motility, EC 
proliferation; potential oncogene.  
(Brown and Sacks 
2006; Johnson, 
Sharma et al. 2009) 
Scribble Regulates cell polarity and proliferation, binds to βPIX 
and interacts with βPIX/PAK/GIT1 complex 
(Iden and Collard 
2008; Etienne-
Manneville 2009) 
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Fig. 4.2 Comparison of the interactions between RhoJ and candidate proteins. 
A yeast strain (PJ69-4A) containing a Gal1 promoter - HIS3 reporter gene was transformed with 
combinations of pGBT9 and pACT2 plasmids. pGBT9 plasmids encoded Gal4 DNA-binding domain 
(DBD) fusions of RhoJ (wild type, da or dn mutants) and pACT2 encoded Gal4 activation domain 
(AD) fusions of RhoJ-binding candidates as indicated. Five fivefold serial dilutions starting with an 
OD600 of  0.5 (left column) for each culture were prepared and spotted on to synthetic media either 
containing (+HIS) or lacking (-HIS) histidine. Yeast were grown for 3-5 days at 30 °C. 
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and grown as dilution series on a synthetic medium containing or lacking histidine. It was 
found that among all proteins tested, RhoJ (in its wild type or dominant active forms) 
interacted only with MRCKA and GIT1 (Fig. 4.2). A positive interaction between the 
dominant active RhoJ and the CRIB domain acted as a positive control for this assay (Vignal, 
De Toledo et al. 2000). Although α- and βPIX did not bind to RhoJ in the Y2H experiment, 
these proteins were clearly pulled-down by GST-daRhoJ from HUVEC lysate. PIX proteins 
strongly bind to GIT1 (Hoefen and Berk 2006) and possibly in the GST-daRhoJ pull-down 
they were precipitated via their binding to GIT1. Thus a potential interaction of RhoJ with 
PIX proteins in ECs, in particular βPIX, was considered in the subsequent experiments. 
Due to the availability of GIT1- and βPIX-specific antibodies the pull-down and mass 
spectrometry results for these hits were verified by western blotting. GST and GST-daRhoJ 
pull-downs were repeated from HUVEC lysates and western blotting with anti-βPIX and anti-
GIT1 antibodies was performed. The GIT1 and βPIX bands were detected in the GST-daRhoJ 
but not in the GST alone pull-down lanes (Fig. 4.3). This and Y2H results together suggested 
that RhoJ binds to the GIT1/βPIX complex via direct interaction with GIT1. Interestingly, the 
GIT1/βPIX complex plays a very important role in FA turnover (Rosenberger and Kutsche 
2006) and in the previous chapter it was shown that RhoJ localises to FAs where it regulates 
the FA numbers. Thus subsequent experiments were focused on the closer characterisation of 
this RhoJ and GIT1/βPIX complex interaction and then on the verification of its physiological 
relevance in ECs. Due to the time limit of these PhD studies, no further characterisation of the 
interaction of RhoJ and MRCKA was performed. 
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Fig. 4.3 Western blot confirming the pull-down of GIT1 and βPix with GST-daRhoJ. 
HUVECs were grown in complete medium and lysed. Subsequently their lysates were firstly 
precleared with GST-glutathione agarose beads and then incubated with either GST-daRhoJ or GST 
control protein bound to the glutathione agarose beads, as indicated. After the pull-downs the beads 
were washed and resuspended in 2x SDS sample-loading buffer. Samples were subjected to SDS-
PAGE and western blotting with anti-βPIX and anti-GIT1 antibodies. 
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4.4.  Further investigation of RhoJ interactions with GIT1 and 
βPix proteins 
4.4.1. Mapping the GIT1 domain that interacts with RhoJ 
GIT1 contains several domains which mediate its binding to various proteins (described in the 
Fig. 4.4 A). In order to better understand the context of the RhoJ and GIT1 interaction, the 
domain of GIT1 which binds to RhoJ was determined. Francesca Edelmann in our laboratory 
made a series of C-terminal truncation mutants of GIT1 as shown in the Fig. 4.4 B. These 
were fused with the AD domain of GAL4, co-expressed with wild type or dominant active 
RhoJ fused to the DBD domain of GAL4 and screened using a Y2H assay as described above 
(Francesca Edelmann, unpublished data). Binding of GIT1 to dominant active RhoJ was lost 
upon truncation of the SHD domain, suggesting that this domain is necessary for RhoJ 
interaction.  
In order to identify the exact region of SHD domain which interacts with RhoJ, further Y2H 
studies were undertaken. The SHD domain comprises two homology repeats (Premont, Perry 
et al. 2004). These and the whole SHD were cloned again to generate fusions with the AD 
domain of GAL4 and were tested for the interaction with RhoJ fused to the DBD of GAL4 
(Fig. 4.4 C). No yeast growth was observed on the histidine-lacking selective medium which 
suggested that the SHD domain appeared to be critical but not sufficient for binding with 
RhoJ, providing this fusion was correctly expressed in the yeast. Possibly other domains of 
GIT1 are required to enable this interaction. 
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Fig. 4.4 Mapping of the GIT1 domain that interacts with RhoJ. 
A, The scheme shows domains of GIT1. GAP, a GTPase activating domain for Arf  GTPases; PBS, a 
minor interaction site with paxillin; ANK, ankyrin repeats, interact with C-terminus of GIT1 and are 
involved in its localisation to endosomes; SHD, yeast Spa2 homology domain, interacts with many 
proteins including MEK, αPIX, βPIX, FAK; CC, coiled-coil region with a leucine zipper motif, 
involved in homo- and heterodimerisation of GIT1; FAH, focal adhesion targeting homology domain, 
includes major paxillin binding site (PBS2); SLD, synaptic localisation domain, targets  GIT1 to 
dendritic protrusions. Domains were described as reviewed by Frank and Hansen (2008). B, 
Truncation mutants of GIT1 cloned and tested for RhoJ interactions in Y2H system (Francesca 
Edelmann, unpublished data). C, Testing the SHD domain for interaction with RhoJ. A yeast strain 
(PJ69-4A) containing the Gal1 promoter - HIS3 reporter gene was transformed with combinations of 
plasmids to express Gal4 DBD fusions of RhoJ (wild type or its da mutant) and Gal4 AD fusions of 
GIT1 fragments. Five fivefold serial dilutions starting with an OD600 of  0.5 (left column) for each 
culture were prepared and spotted on to synthetic media either containing (+HIS) or lacking (-HIS) 
histidine. Yeast were grown for 3-5 days at 30 °C. 
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4.4.2. Testing co-localisation of RhoJ with βPix and GIT1 in HUVECs 
If RhoJ interacts with the GIT1/βPIX complex in HUVECs, these proteins should co-localise 
in this cell type. Experiments in chapter 3 demonstrated that RhoJ localised to FA and it is 
well known that the GIT1/βPIX complex can localise to FAs (Zhao, Manser et al. 2000; 
Rosenberger and Kutsche 2006). Available antibodies suitable for immunostaining of RhoJ, 
βPIX and GIT1 were made in rabbits, thus it was not possible to use them for the co-
localisation of endogenous proteins. Therefore GFP, GFP-wtRhoJ and GFP-daRhoJ 
expressing HUVECs were used and stained with βPIX and GIT1-specific antibodies 
separately (Fig. 4.5 and 4.6 respectively). It was found that both βPIX and GIT1 co-localised 
with RhoJ in the cell periphery in regions resembling FAs (as indicated with the yellow 
arrows). Moreover it was evident that there was more βPIX or GIT1 localising to these FAs 
when RhoJ was overexpressed in wild type or activated form (as indicated with the white 
arrows). Subsequently, western blotting was performed to determine the expression levels of 
βPIX, GIT1 and GFP-RhoJ (Fig. 4.7). Each HUVEC isolate overexpressing the activated 
RhoJ mutant contained more βPIX protein than the GFP-expressing controls. This suggested 
that active RhoJ may play a role in the stabilisation of βPIX protein or in the regulation of its 
expression levels. 
4.4.3. Testing the interdependence in the localisation of RhoJ, βPIX and GIT1 
to FAs  
The next step was to assess if the loss of single components of the hypothetical 
βPIX/GIT1/RhoJ complex would affect the localisation of these proteins to FAs. Two 
different siRNA duplexes were designed to knock-down βPIX and GIT1 and they were tested 
in HUVECs at the 25 nM concentration. Firstly it was important to check that these duplexes  
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Fig. 4.5 GFP-RhoJ co-localises with βPix in HUVECs. 
HUVECs were transduced with lentivirus to stably express GFP, GFP-wtRhoJ or GFP-daRhoJ, and 
were sorted for GFP-positive cells using flow cytometry. Cells were then cultured on gelatin-coated 
coverslips and immunofluorescent staining was performed with the βPIX-specific antibody. DAPI was 
used to stain nuclei. Regions marked in the white boxes are expanded in the bottom panel. Both GFP-
wtRhoJ and GFP-daRhoJ co-localised with βPIX as indicated with the yellow arrows. Expression of 
GFP-wtRhoJ or GFP-daRhoJ increased βPIX levels in FAs compared with GFP controls, as indicated 
with the white arrows. Scale bars: 10 µm. 
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Fig. 4.6 GFP-RhoJ co-localises with GIT1 in HUVECs. 
HUVECs were transduced with lentivirus to stably express GFP, GFP-wtRhoJ or GFP-daRhoJ, and 
were sorted for GFP-positive cells using flow cytometry. Cells were then cultured on gelatin-coated 
coverslips and immunofluorescent staining was performed with the GIT1-specific antibody. DAPI was 
used to stain nuclei. Regions marked in the white boxes are expanded in the bottom panel. Both GFP-
wtRhoJ and GFP-daRhoJ co-localised with GIT1 as indicated with the yellow arrows. Expression of 
GFP-wtRhoJ or GFP-daRhoJ increased GIT1 levels in FAs compared with GFP controls, as indicated 
with the white arrows. Scale bars: 10 µm. 
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Fig. 4.7 Dominant active RhoJ increases the level of βPix protein. 
A, HUVECs were infected with lentivirus to stably express GFP, GFP-wtRhoJ or GFP-daRhoJ 
proteins. GFP-positive cells were sorted using flow cytometry. Subsequently lysates were prepared 
from the same number of cells for each condition and these were subjected to western blotting with 
antibodies as indicated. B, Graph showing the densitometry of βPIX protein relative to tubulin, which 
was normalised to 1 for GFP control. The mean and standard errors were plotted for 3 HUVEC 
isolates expressing GFP or GFP-RhoJ. 
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do not induce the interferon response. Interferon is a cytokine which is induced during the 
viral infection with double-stranded RNA. Induced interferon leads to the activation of 
signalling cascade which up-regulates transcriptional activation of hundreds of interferon 
stimulated genes (Haque and Williams 1998) which in turn will affect EC behaviour. Thus a 
quantitative PCR was performed to test the expression of the interferon inducible genes 2',5'-
oligoadenylate synthetase 1 (Clemens 2005) and IFN-Stimulated Gene of 20 kDa (Espert, Rey 
et al. 2004). No significant up-regulation of these genes was observed in the RhoJ-, βPIX- or 
GIT1-siRNA-silenced cells and it was assumed that these duplexes did not induce the 
interferon response at the concentration of duplexes tested (data not shown). Then the 
succesful knock-downs with these duplexes were examined by western blotting, as shown in 
the Fig. 4.8. Duplexes at this concentration of 25 nM were used in all subsequent experiments. 
Firstly the localisation of RhoJ to FAs was examined (Fig. 4.9). HUVECs with siRNA-
silenced RhoJ, βPIX and GIT1 (knock-down of each gene separately) were co-stained with 
vinculin- and RhoJ-specific antibodies (Fig. 4.9 A and B). Vinculin is one of the crucial 
components of FAs (Parsons, Horwitz et al. 2010) and its visualisation allowed monitoring of 
all FAs in each cell. All vinculin-positive FAs per cell were counted and the number of these 
that positively stained for RhoJ was quantified. βPIX knock-down significantly reduced the 
number of FAs positively staining for RhoJ from approximately 60 to 25 % (Fig. 4.9 C). This 
reduction was comparable to the decrease of βPIX in FAs after its knock-down (Fig. 4.10 C). 
GIT1 knock-down caused a more modest but still statistically significant decrease of RhoJ 
localisation to FAs. Moreover RhoJ knock-down caused an increase in total FAs, which was 
consistent with previous findings (Kaur et al. 2010).  
The localisation of βPIX and GIT1 in FAs was assessed in a similar way. It was found that 
βPIX localisation to vinculin-positive FAs was slightly but significantly reduced in either  
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Fig. 4.8 Western blots showing siRNA knock-downs of βPIX, GIT1 and RhoJ. 
HUVECs were transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2, βPIX-siRNA1, βPIX-siRNA2, 
GIT1-siRNA1, GIT1-siRNA2 and Ctrl-siRNA duplexes or were mock transfected. 48 h later cells 
were lysed and lysates subjected to SDS-PAGE and western blotting with antibodies as indicated. 
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Fig. 4.9 The influence of βPIX- or GIT1-siRNA silencing on the localisation of RhoJ to focal 
adhesions. 
A and B, HUVECs were transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2, βPIX-siRNA1, βPIX-
siRNA2, GIT1-siRNA1, GIT1-siRNA2 and Ctrl-siRNA duplexes or were mock transfected. 48 h later 
cells were plated on the gelatin-coated coverslips and allowed to spread for 4 h. Cells were then fixed 
and immunofluorescent staining was performed with antibodies specific to RhoJ and vinculin. Scale 
bars 10 µm. C, Graphs showing the numbers of total FAs positive for vinculin (b) and the percentage 
of vinculin staining FAs also positively staining for RhoJ (a). Counting of FAs was performed with 
ImageJ software in at least 22 cells from 3 different experiments. The box and whisker plots indicate 
the maximum, minimum, 25th and 75th percentiles and median values. The Mann Whitney test was 
used to calculate p values (*** for p<0.001; ** for 0.001<p<0.01; * for 0.01<p<0.05 and ns for non-
significant). 
The figure is presented on the next 3 pages. 
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Fig. 4.9 The influence of βPIX or GIT1 siRNA silencing on the localisation of RhoJ to focal 
adhesions. 
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Fig. 4.9 The influence of βPIX or GIT1 siRNA silencing on the localisation of RhoJ to focal 
adhesions (continued). 
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Fig. 4.9 The influence of βPIX or GIT1 siRNA silencing on the localisation of RhoJ to focal 
adhesions (continued). 
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Fig. 4.10 The influence of RhoJ- or GIT1-siRNA silencing on the localisation of βPIX to focal 
adhesions. 
A and B, HUVECs were transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2, βPIX-siRNA1, βPIX-
siRNA2, GIT1-siRNA1, GIT1-siRNA2 and Ctrl-siRNA duplexes or were mock transfected. 48 h later 
cells were plated on the gelatin-coated coverslips and allowed to spread for 4 h. Cells were then fixed 
and immunofluorescent staining was performed with antibodies specific to βPIX and vinculin. Scale 
bars 10 µm. C, Graphs showing the numbers of total FAs positive for vinculin (b) and the percentage 
of vinculin staining FAs also positively staining for βPIX (a). Counting of FAs was performed with 
ImageJ software in at least 25 cells from 3 different experiments. The box and whisker plots indicate 
the maximum, minimum, 25th and 75th percentiles and median values. The Mann Whitney test was 
used to calculate p values (*** for p<0.001; ** for 0.001<p<0.01; * for 0.01<p<0.05 and ns for a non-
significant). 
The figure is presented on the next 3 pages. 
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Fig. 4.10 The influence of RhoJ or GIT1 siRNA silencing on the localisation of βPIX to focal 
adhesions. 
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Fig. 4.10 The influence of RhoJ or GIT1 siRNA silencing on the localisation of βPIX to focal 
adhesions (continued). 
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Fig. 4.10 The influence of RhoJ or GIT1 siRNA silencing on the localisation of βPIX to focal 
adhesions (continued). 
4. IDENTIFICATION OF RHOJ BINDING PARTNERS IN ECS 
154 
 
 
Fig. 4.11 The influence of RhoJ- or βPIX-siRNA silencing on the localisation of GIT1 to focal 
adhesions. 
A and B, HUVECs were transfected with 25 nM RhoJ-siRNA1, RhoJ-siRNA2, βPIX-siRNA1, βPIX-
siRNA2, GIT1-siRNA1, GIT1-siRNA2 and Ctrl-siRNA duplexes or were mock transfected. 48 h later 
cells were plated on the gelatin-coated coverslips and allowed to spread for 4 h. Cells were then fixed 
and immunofluorescent staining was performed with antibodies specific to GIT1 and vinculin. Scale 
bars 10 µm. C, Graphs showing the numbers of total FAs positive for vinculin (b) and the percentage 
of vinculin staining FAs also positively staining for GIT1 (a). Counting of FAs was performed with 
ImageJ software in at least 17 (for GIT1 knock-down) and at least 23 (all other conditions) cells from 
3 different experiments. The box and whisker plots indicate the maximum, minimum, 25th and 75th 
percentiles and median values. The Mann Whitney test was used to calculate p values (*** for 
p<0.001; ** for 0.001<p<0.01; * for 0.01<p<0.05 and ns for a non-significant). 
The figure is presented on the next 3 pages. 
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Fig. 4.11 The influence of RhoJ or βPIX siRNA silencing on the localisation of GIT1 to focal 
adhesions. 
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Fig. 4.11 The influence of RhoJ or βPIX siRNA silencing on the localisation of GIT1 to focal 
adhesions (continued). 
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Fig. 4.11 The influence of RhoJ or βPIX siRNA silencing on the localisation of GIT1 to focal 
adhesions (continued). 
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RhoJ- or GIT1-siRNA silenced HUVECs (Fig.4.10). The localisation of GIT1 to vinculin-
positive FAs was also decreased after either RhoJ or βPIX knock-down (Fig. 4.11). All results 
from the studies on localisation of RhoJ, βPIX and GIT1 to FAs are summarised in Table 4.3. 
In summary, these findings suggested that RhoJ interacts with the GIT1/βPIX complex in 
HUVECs. Firstly, RhoJ co-localised with GIT1 and βPIX in FAs. Secondly, a presence of 
βPIX was required for localisation of RhoJ to FAs. Thirdly, overexpression of activated RhoJ 
caused an increase of GIT1 and βPIX in FAs and raised the total levels of the βPIX protein in 
HUVECs. 
 
Tab. 4.3 Summary of the effect of RhoJ, βPIX or GIT1 knock-down and overexpression 
of daRhoJ on recruitment of these proteins to FAs. The table summarises results presented 
in the figures 4.5-4.11. In the first three panels arrows indicate an increase (↑) or a decrease 
(↓) in the number of focal adhesions positive (+ve) for the indicated proteins in HUVECs 
treated with RhoJ-, βPIX- or GIT1-specific siRNA. The bottom panel shows the influence of 
daRhoJ on the number of total FAs and amount of βPIX or GIT1 in these FAs.  
 
 
Vinculin +ve FAs 
(total FAs) 
RhoJ +ve FAs 
(%) 
GIT1 +ve FAs 
(%) 
βPIX +ve FAs 
(%) 
RhoJ-siRNA ↑  ↓↓ ↓ 
GIT1-siRNA ↑/= ↓↓  ↓ 
βPIX-siRNA ↑/= ↓↓↓ ↓  
 
Vinculin +ve FAs 
(total FAs) 
 Amount of GIT1 in FAs 
Amount of 
βPIX in FAs 
daRhoJ ↓  ↑↑↑ ↑↑↑ 
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4.5. Discussion  
Rho GTPases are known to regulate cytoskeletal rearrangements and FA formation, processes 
very important for cell migration (Raftopoulou and Hall 2004). Our group showed that RhoJ 
is a small Rho GTPase expressed predominantly in ECs (Herbert, Stekel et al. 2008; Kaur, 
Leszczynska et al. 2011) and studies described in the previous chapter revealed that RhoJ 
localises to FAs, regulates their numbers and facilitates EC motility. In turn, data presented in 
this chapter for the first time identified the RhoJ-binding proteins in ECs and these are known 
to play important role in the regulation of FA turnover and cell motility.  
Firstly RhoJ-binding candidates were pulled-down from the cellular lysates using RhoJ 
mutants locked either in active or inactive states as fusion proteins with GST. It was expected 
that the constitutively active GTP-bound RhoJ mutant should bind GAPs or effector proteins, 
while the dominant negative mutant, which was locked in the nucleotide-free form, should 
sequester GEFs (Garcia-Mata, Wennerberg et al. 2006). Indeed, mass spectrometry analysis 
of pull-down samples revealed that RhoJ bound to many proteins including GAPs, GEFs and 
potential effectors such as those containing CRIB domains or involved in the regulation of 
cell movement, cytoskeletal rearrangements and regulation of FAs. The most interesting 
RhoJ-binding candidates included MRCKA, MRCKB, IQGAP1, αPIX, βPIX, GIT1 and 
scribble (described briefly in the Table 4.2). Among these, of particular interest were GIT1 
and PIX proteins since they form a complex which localises to FAs and regulates their 
disassembly (Zhao, Manser et al. 2000). This complex is targeted to FAs via the c-terminal 
domain of GIT1, which binds to paxillin (Turner, Brown et al. 1999). α- and βPIX on the 
other hand are GEFs for Rac1 and Cdc42. Thus RhoJ may be targeted to FAs via its 
interaction with the GIT1/PIX complex. At first glance it was surprising that α- and βPIX 
GEFs were pulled-down by the dominant active but not the dominant negative RhoJ mutant. 
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However, Baird et al. demonstrated that dimeric αPIX can bind to activated forms of some 
Rho GTPases (Baird, Feng et al. 2005). They showed that binding to Cdc42-GTP enhanced 
the GEF activity of αPIX towards Rac1. On the other hand binding of activated Rac1 to αPIX 
dimers strongly inhibited their GEF activity towards Rac1 and thus provided a negative 
feedback loop. 
The interactions between RhoJ and its shortlisted binding partners were validated in a Y2H 
assay which showed that only MRCKA and GIT1 bound directly to the dominant active and 
wild type RhoJ. However, since both GIT1 and βPIX proteins were detected in the GST-
daRhoJ pull-down samples by western blotting, it was concluded that βPIX most likely was 
precipitated via its binding to GIT1. However, a direct interaction of RhoJ with βPIX while 
not observed in the Y2H assay may still occur in ECs. 
 Based on the Y2H results, attempts were made to map the domain of GIT1 which binds to 
RhoJ. Firstly, Francesca Edelmann in our laboratory made the c-terminal truncation mutants 
of GIT1 and she determined that the SHD domain of GIT1 was required for the GIT1-RhoJ 
interaction (unpublished data). Subsequently, the studies performed here suggested that the 
SHD domain on its own was not sufficient to bind to RhoJ, indicating that other domains may 
be necessary for the GIT1-RhoJ interaction. The region located N terminal to the SHD 
domain contains the Arf GAP domain, a minor paxillin binding site and ankyrin repeats 
(showed in the Figure 4.4 B). Both the GAP domain and the ankyrin repeats are involved in 
the localisation of GIT1 to endosomes and other intracellular vesicles (Di Cesare, Paris et al. 
2000; Manabe, Kovalenko et al. 2002; Paris, Za et al. 2002), and it was shown that the 
paxillin/GIT1/PIX/PAK complex localised to intracellular vesicles after FA disassembly 
(Rosenberger and Kutsche 2006). Since it was demonstrated in the previous chapter that RhoJ 
localised both to the intracellular vesicles and to FAs in ECs, it might be possible that RhoJ 
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could traffick with this complex. However, further studies are required to test this hypothesis 
and to precisely map the domains of GIT1 which bind RhoJ. 
In order to investigate the interaction of RhoJ with the GIT1/βPIX complex in ECs 
immunofluorescence was performed and showed that GFP-RhoJ (both its wild type and 
dominant active forms) co-localised with endogenous GIT1 and βPIX in FA-like regions. 
Interestingly, studies by Loo and colleagues showed that both GIT1 and βPIX co-localised 
with paxillin-positive FAs in an asymmetrical manner, while paxillin and vinculin showed 
complete co-localisation (Loo, Ng et al. 2004). They suggested that proteins which interact 
directly with the GIT1/βPIX complex would show a similarly asymmetrical co-localisation 
with major FA markers. Indeed, this asymmetrical co-localisation pattern was seen for RhoJ 
co-stained with vinculin-, talin- and pFAK-specific antibodies in HUVECs (Fig. 3.4 and 3.5) 
thus supporting the hypothesis that RhoJ interacts with the GIT1/βPIX complex. 
It was previously reported that in fibroblasts and HeLa cells dominant active mutants of 
Cdc42 and Rac1 were driving localisation of one of their effector proteins PAK to FAs, and 
active PAK was then causing a loss of SFs and disassembly of FAs (Manser, Huang et al. 
1997). The subsequent studies by Manser et al. discovered that βPIX was required for 
localisation of PAK to these FAs and dominant active Cdc42 mutant was potentiating the 
amount of βPIX in these structures leading to the Rac1-dependent activation of PAK (Manser, 
Loo et al. 1998). Experiments described in this chapter revealed that overexpression of active 
RhoJ similarly increased the amount βPIX and GIT1 in FAs (Fig. 4.5 and 4.6, respectively) 
and it was previously shown that dominant active RhoJ reduced the number of FAs and SFs in 
migrating ECs (Fig. 3.12). Thus it is possible that signals which activate RhoJ may potentiate 
the recruitment of the βPIX/GIT1 complex to FAs and lead to their disassembly by activation 
of the βPIX/Rac1/PAK pathway. On the other hand the interaction of GIT1 with paxillin can 
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also promote FA disassembly and it was shown that overexpression of GIT1 increased cell 
migration (Zhao, Manser et al. 2000; Manabe, Kovalenko et al. 2002; Feng, Baird et al. 
2010). Thus an alternative hypothesis is that active RhoJ facilitates EC migration by 
increasing the amount of the βPIX/GIT1 complex in FAs. Then increased interactions 
between the βPIX/GIT1 complex and paxillin may promote the FA disassembly. 
However, the exact mechanism of RhoJ recruitment to FAs remains unclear. The Y2H 
experiments indicated that RhoJ binds directly to GIT1. On the other hand, the siRNA knock-
down of GIT1 in HUVECs only partially reduced the number of RhoJ-positive FAs, while 
silencing of βPIX very strongly inhibited localisation of RhoJ to these structures. 
Interestingly, the overexpression of dominant active RhoJ not only potentiated the amount of 
βPIX and GIT1 in FAs, but it also increased the total levels of the βPIX protein in HUVECs, 
suggesting that active RhoJ may stabilise βPIX or positively regulate its expression. Thus it 
seems evident that RhoJ is linked to the GIT1/βPIX complex when it localises to FAs and the 
presence of βPIX is crucial to preserve this localisation of RhoJ, but the mechanism for that 
remains unresolved. 
MRCKA and -B are CRIB domain-containing kinases which promote cytoskeletal 
reorganisation and formation of peripheral focal complexes downstream of Cdc42 (Leung, 
Chen et al. 1998). RhoJ belongs to the Cdc42-like subfamily of Rho GTPases and when 
activated it can bind effector proteins containing the CRIB domain (Vignal, De Toledo et al. 
2000; Aspenstrom, Fransson et al. 2004). MRCKA and -B were among the strongest RhoJ 
binding candidates identified here by mass spectrometry and the interaction of MRCKA with 
RhoJ was later confirmed in the Y2H assay. Interestingly, in the pull-down/mass spectrometry 
assay RhoJ bound to MRCK but not to the other CRIB domain-containing proteins such as 
PAK, WASP, or N-WASP which are also present in ECs (Derry, Ochs et al. 1994; Galan 
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Moya, Le Guelte et al. 2009; Sheldon, Andre et al. 2009; Kang, Wang et al. 2010). Perhaps 
MRCK is a more specific effector of Cdc42-like Rho GTPases since previous data showed 
that MRCK strongly bound to active Cdc42 but less so to active Rac1 (Leung, Chen et al. 
1998). It is necessary to determine if RhoJ and MRCK interact in ECs and if so, then it will be 
critical to define physiological relevance of these interactions. 
In summary, the GST-RhoJ pull-down/mass spectrometry assay resulted in the identification 
of potential RhoJ-binding partners in ECs. Among these, the βPIX/GIT1 complex was shown 
to be important for the localisation of RhoJ to FAs while dominant active RhoJ potentiated the 
amount of βPIX and GIT1 proteins in these structures. Thus, data presented in this chapter 
provided the link between RhoJ and proteins which facilitate the FA turnover and cell 
motility.  
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5.1. RhoJ activation 
RhoJ is a typical Rho GTPase which cycles between active GTP-bound and inactive GDP-
bound states (Vignal, De Toledo et al. 2000). The presence of either a GTP or GDP nucleotide 
in Rho GTPases determines the difference in the conformation of their so-called Switch I and 
Switch II regions (Paduch, Jelen et al. 2001). The activation of Rho GTPases is regulated by 
proteins from the GEF and GAP families, which respond to upstream signals and switch on 
and off these small G proteins, respectively (Schmidt and Hall 2002; Moon and Zheng 2003). 
Effector proteins can then recognise only activated Rho GTPases and propagate signals 
downstream in the cell (Bishop and Hall 2000). 
Assays that allow the measurement of various activated Rho GTPases in cellular extracts have 
been established as summarised by Pellegrin and Mellor (2008). These assays use GST fused 
with the domains of effector proteins that are known to selectively bind the activated forms of 
Rho GTPases. The GST-fused effector domain can be loaded onto the glutathione agarose 
beads and when incubated with cellular extracts should pull-down only active Rho GTPases. 
Vignal et al. showed that active RhoJ can be pulled-down by a CRIB domain from PAK or 
WASP (Vignal, De Toledo et al. 2000). The CRIB domain was also used by other groups to 
detect the active levels of Rac1, Rac2, Cdc42, TC10 and TC10β (Sander, van Delft et al. 
1998; Benard, Bohl et al. 1999; Haddad, Zugaza et al. 2001; Benard and Bokoch 2002; 
Chiang, Hou et al. 2002; Aspenstrom, Fransson et al. 2004; Tong, Liss et al. 2007). Since the 
same effector domain can bind various GTP-bound Rho GTPases, it is crucial that specific 
antibodies are used to detect the active levels of particular small G proteins (Pellegrin and 
Mellor 2008). 
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A range of upstream signals had been found to lead to the activation of Rho GTPases; these 
include cell surface receptors for various cytokines, growth factors, adhesion molecules or 
GPCRs (Schwartz 2004). Chiang et al. showed that mouse RhoJ (TC10β and TC10βLong), 
when overexpressed in adipocytes, was activated upon insulin stimulation (Chiang, Hou et al. 
2002). 
As shown by members of our laboratory, RhoJ is endogenously expressed in ECs (Kaur, 
Leszczynska et al. 2011), and work described in chapter 3 demonstrated that dominant active 
RhoJ promotes EC migration and tubule formation – processes which are very important 
during angiogenesis. Therefore, it was hypothesised that RhoJ might be activated by pro-
angiogenic signals.  
VEGFA is the most potent ligand of VEGFR2 in promoting angiogenesis and its signalling 
regulates processes such as cell survival, migration, proliferation, vascular permeability, actin 
remodelling or FA turnover (Olsson, Dimberg et al. 2006). Another important stimulus, FGF-
2, is present in the ECM of blood vessels (Presta, Dell'Era et al. 2005). When various factors 
activate angiogenesis, the basement membrane is degraded by matrix metallo-proteinases. 
Then the growth factors trapped in the basement membrane (including FGF-2) are secreted to 
stimulate the development of new blood vessels (Adams and Alitalo 2007).  
The layer of ECs that lines blood vessels is a semi-permeable barrier that allows the exchange 
of liquid and plasma proteins between the blood and neighbouring tissue (Vandenbroucke, 
Mehta et al. 2008). The level of permeability of blood vessels can be controlled by various 
factors including thrombin, TNF-α or lipopolysaccharide (Vandenbroucke, Mehta et al. 2008). 
It was shown that the presence of thrombin, which is an agonist of GPCRs, is crucial in the 
regulation of endothelial barrier function and thrombin-induced signalling was shown to 
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mediate the activity of various Rho GTPases (Beckers, van Hinsbergh et al. 2010; Spindler, 
Schlegel et al. 2010). 
The work presented in this chapter aimed to examine the activation of RhoJ in ECs by pro-
angiogenic factors. Firstly, an assay was optimised to detect active RhoJ in ECs and it was 
subsequently used to measure the levels of active RhoJ in ECs treated with VEGFA, FGF-2 
and thrombin. This allowed testing RhoJ activation downstream of two classes of cell-surface 
receptors: RTKs and GPCRs. 
5.2. Optimisation of an assay for the pull-down of active RhoJ in ECs 
An assay was optimised to determine levels of active RhoJ in cellular extracts of ECs. A 
method was adapted from one used for testing the activation of Cdc42 or Rac1 (Erasmus and 
Braga 2006). This used GST tagged CRIB domains from WASP and PAK proteins, which 
previously were shown to bind only active RhoJ (Vignal, De Toledo et al. 2000). 
To test if this assay would work for pulling-down active RhoJ in ECs, an initial experiment 
was performed where HUVEC lysate containing endogenous RhoJ was incubated with 
GTPγS (a stable analogue of GTP) or with GDP, and then RhoJ binding to GST-CRIB was 
examined. The loading of nucleotides onto Rho GTPases in vitro occurs readily in the absence 
of Mg2+. However, to stop this exchange process, a magnesium ion is required, which 
coordinates binding of the nucleotide to the appropriate amino acids in the protein (Paduch, 
Jelen et al. 2001). The amount of magnesium present at the beginning and at the end of 
nucleotide loading process is thus critical, and this was shown in the following experiments. 
Initially, GTP/GDP loading was performed in the presence of EDTA, which chelates the 
positively charged metal ions and therefore reduces the magnesium concentration. However, 
if these conditions were used during the whole experiment, the nucleotides did not remain  
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Fig. 5.1 Optimisation of GTP/GDP loading on RhoJ. 
A, HUVEC lysates were incubated with GTPγS (GTP) or GDP for 30 min at 30 ºC in the presence or 
absence of EDTA, as indicated. Then GST-CRIB (from PAK) bound to glutathione agarose beads was 
added and the pull-down performed for 1 h at 4 ºC. The beads were then washed and resuspended in 
2x SDS sample-loading buffer. Samples were subjected to SDS-PAGE and western blotting with 
RhoJ- and Cdc42-specific antibodies. B, Comparison of GTP/GDP locking on RhoJ in the presence of 
low or high magnesium concentrations. HUVECs lysates were incubated with GTPγS (GTP) or GDP 
in the presence of EDTA for 30 min at 30 ºC (a) or for 10 min at room temperature (b). Then in 
samples from (b) the concentration of magnesium ions was increased to 30 mM. Active RhoJ was then 
pulled-down with GST-CRIB (from WASP) bound to glutathione agarose beads for 1 h at 4 ºC (for a 
and b). The beads were then washed and resuspended in 2x SDS sample-loading buffer. Samples were 
subjected to SDS-PAGE and western blotting with RhoJ-specific antibodies. 
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Fig. 5.2 Comparison of pull-down of GTP-loaded RhoJ, Cdc42 and Rac1 from HUVEC lysates 
by CRIB domains from WASP and PAK. 
HUVEC lysates were incubated with GTPγS (GTP) or GDP in the presence of EDTA for 10 min at 
room temperature. Then the concentration of magnesium ions was increased to 30 mM and pull-downs 
of active Rho GTPases were performed with GST-CRIB (from WASP or PAK, as indicated) or GST 
bound to glutathione agarose beads at 4 ºC for 1 h. The beads were then washed and resuspended in 2x 
SDS sample-loading buffer. Samples were subjected to SDS-PAGE and western blotting with RhoJ, 
Cdc42 and Rac1- specific antibodies, as indicated. 
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Fig. 5.3 GTP/GDP loading on endogenous RhoJ in HMEC-1 and on HA-RhoJ expressed in HEK 
293Ts. 
A, HMEC-1 lysates were incubated with GTPγS (GTP) or GDP in the presence of EDTA for 10 min 
at room temperature. Then the concentration of magnesium ions was increased to 30 mM and the pull-
down of active RhoJ was performed with GST-CRIB (from WASP) bound to glutathione agarose 
beads at 4 ºC for 1 h. The beads were then washed and resuspended in 2x SDS sample-loading buffer. 
Samples were subjected to SDS-PAGE and western blotting with RhoJ- specific antibodies. B, HEK 
293Ts were transfected with plasmids encoding HA-wtRhoJ, HA-daRhoJ or HA-dnRhoJ. Their 
lysates were subjected to GTP/GDP loading as indicated and GST-CRIB pull-downs using the same 
conditions as in A. Western blotting was performed with HA-specific antibodies. 
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bound to RhoJ, and therefore RhoJ was not pulled-down by GST-CRIB (Fig. 5.1 A). In 
contrast, this low level of Mg2+ was enough to keep GTP locked in Cdc42 (Fig. 5.1 A). This is 
likely to be due to the differences in the magnesium ion coordinating regions of various small 
G proteins (Paduch, Jelen et al. 2001). However, when the levels of Mg2+ were raised to 30 
mM after nucleotide loading, this appeared to be sufficient to lock the GTP or GDP in RhoJ 
and was confirmed by pull-down with GST-CRIB (Fig. 5.1 B).  
These conditions of loading GTP or GDP on RhoJ, Cdc42 and Rac1 in HUVEC lysate were 
confirmed by pull-down with two different fusion proteins containing CRIB domains (from 
PAK and WASP) (Fig. 5.2). The pull-down of Cdc42 with GST-CRIB from WASP was not 
specific for the active form of Cdc42 for these conditions, therefore in further studies GST-
CRIB from PAK was used, which specifically pulled-down active RhoJ, Cdc42 and Rac1. 
This assay was also validated for detecting endogenous GTP-loaded RhoJ in HMEC-1 or for 
HA-RhoJ and flag-RhoJ ectopically expressed in HEK 293Ts (Fig. 5.3, for flag-RhoJ data not 
shown).  
In the following experiments, which aimed to determine the active levels of RhoJ, cell lysis 
buffer was used, in which the concentration of Mg2+ was 30 mM. 
5.3. RhoJ activation by pro-angiogenic stimuli 
Having established conditions to pull-down active RhoJ, this assay has been used to measure 
the level of active RhoJ in ECs. The first experiment was to determine whether resting cells, 
by removing serum and growth factors, would reduce the basal levels of active RhoJ in 
unstimulated cells. HUVECs were starved for different time periods in medium which lacked 
growth factors and serum, then cells were harvested and active Rho GTPases were pulled-
down by GST-CRIB. The amount of active RhoJ and Cdc42 did not change significantly after  
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Fig. 5.4 Testing the levels of basal active RhoJ and Cdc42 in HUVECs. 
HUVECs were starved by incubation in M199 medium supplemented only with glutamine for 
different time periods, as indicated. One group of cells starved for 2 h was additionally stimulated for 
10 min with 5x bovine brain extract (indicated by arrow). Cells were then lysed and pull-downs of 
active Rho GTPases were performed with GST-CRIB bound to glutathione agarose beads. Western 
blotting was performed on pull-down (PD) and whole cell lysate (WCL) samples with anti-RhoJ or 
anti-Cdc42 antibodies, as indicated. Densitometry was performed and levels of activated Rho GTPases 
were calculated as PD values relative to WCL values (indicated under western blot images for RhoJ 
and Cdc42).  This experiment was performed only once. 
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1 and 2 hours of starving in comparison to non-starved cells (Fig. 5.4). Not much was known 
at this stage about RhoJ “activators”, but as a potential positive control, one group of the cells 
was starved for 2 h and then stimulated with bovine brain extract which contains large 
amounts of FGF-2 and supports the growth of ECs (Maciag, Cerundolo et al. 1979). In this 
experiment bovine brain extract was used at a 5-fold higher concentration than that used for 
HUVECs culture, and this resulted in increased levels of both active RhoJ and Cdc42. 
Although starving cells for 1 or 2 h did not change the basal levels of active RhoJ and Cdc42, 
it was shown that these Rho GTPases were clearly activated by bovine brain extract after 
starvation. Thus in the subsequent experiments cells were rested in the serum- and growth 
factor-free medium for 1 h prior to stimulation with various factors.  
A series of pull-down assays were then performed to test the activation of RhoJ upon 
stimulation with VEGFA, FGF-2 and thrombin. VEGFA and FGF-2 are very important 
factors which regulate growth, survival and migration of ECs (Presta, Dell'Era et al. 2005; 
Olsson, Dimberg et al. 2006). Thrombin, on the other hand, stimulates vascular permeability 
by inducing reversible loss of adhesion between cell-cell junctions (Vandenbroucke, Mehta et 
al. 2008).   
Stimulation of HUVECs by VEGFA activated both RhoJ and Cdc42, however the kinetics for 
the activation of these Rho GTPases were different (Fig. 5.5). The activation of Cdc42 was 
higher than that seen for RhoJ and peaked at 15 min; this was consistent with another report in 
the literature (Garrett, Van Buul et al. 2007). The activation of RhoJ was more delayed and 
prolonged, starting at 15 min, peaking at 30 min and then slowly declining (it was still 
noticeable at around 60 min after VEGF treatment). Stimulation with VEGF was performed 5 
times and statistical significance for RhoJ activation was seen at 15 min and for Cdc42 at all 
time points when compared to 0 min. 
5. RHOJ ACTIVATION IN ECS 
174 
 
 
Fig. 5.5 Activation of RhoJ and Cdc42 by VEGF-A in HUVECs. 
HUVECs were stimulated with VEGF-A (10 ng/ml) for the times indicated. Active RhoJ (RhoJ-GTP) 
or Cdc42 (Cdc42-GTP) were pulled-down with GST-CRIB (from PAK). Western blotting was 
performed on pull-down (PD) and whole cell lysate (WCL) samples with anti-RhoJ (A) or anti-Cdc42 
(B) antibodies, as indicated. Densitometry was performed to determine RhoJ and Cdc42 activation. 
This was plotted as pulled-down values relative to WCL, where 0 min was normalised to 1; graphs 
include mean and standard errors derived from 5 independent experiments. The Wilcoxon signed-rank 
test was used to determine statistical significance of RhoJ or Cdc42 activation for different time points 
compared with 1 at zero min  (* for p<0.05). 
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Fig. 5.6 Activation of RhoJ and Cdc42 by FGF-2 in HUVECs. 
HUVECs were stimulated with FGF-2 (10 ng/ml) supplemented with 10 µg/ml of heparin for the 
times indicated. Active RhoJ (RhoJ-GTP) or Cdc42 (Cdc42-GTP) were pulled-down with GST-CRIB 
(from PAK). Western blotting was performed on pull-down (PD) and whole cell lysate (WCL) 
samples with RhoJ-specific and Cdc42-specific antibodies, as indicated. The figure shows activation 
of RhoJ and Cdc42 by FGF-2 in 3 different HUVEC isolates. 
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Fig. 5.7 Activation of RhoJ and Cdc42 by thrombin in HUVECs. 
HUVECs were stimulated with thrombin (2.5 U/ml) for the times indicated. Active RhoJ (RhoJ-GTP) 
or Cdc42 (Cdc42-GTP) were pulled-down with GST-CRIB (from PAK). Western blotting was 
performed on pull-down (PD) and whole cell lysate (WCL) samples with RhoJ-specific and Cdc42-
specific antibodies, as indicated. The figure shows activation of RhoJ and Cdc42 by thrombin in 3 
different HUVEC isolates. 
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Stimulation by FGF-2 and thrombin was performed in 3 different HUVEC isolates (Fig. 5.6 
and 5.7, respectively). FGF-2 activated RhoJ in all three experiments, while the activation of 
Cdc42 was clear only in experiments 2 and 3 (Fig. 5.6). On the other hand, stimulation with 
thrombin activated both RhoJ and Cdc42 only in experiments 2 and 3 (Fig. 5.7). The kinetics 
of RhoJ and Cdc42 activation by FGF-2 and thrombin were not consistent between different 
HUVEC isolates. However, the activation kinetics for RhoJ stimulated with FGF-2 and 
thrombin seemed to mirror each other in particular HUVEC donors. Thus it would be 
important to determine whether these stimuli activate RhoJ through the same signalling 
pathway. Moreover, the experiments presented here would need to be repeated several times 
to determine the most commonly observed activation kinetics for RhoJ in HUVECs. The 
results presented in Fig. 5.6 and 5.7 show evidence that FGF-2 and thrombin are likely to act 
upstream of RhoJ-mediated signalling pathways in ECs. 
5.4. Discussion 
It was shown previously that dominant active RhoJ mutant promoted EC migration and in 
vitro tube formation (Fig. 3.11 and 3.10, respectively), and both these processes are very 
important during angiogenesis which occurs in vivo (Adams and Alitalo 2007). Work which is 
described in this chapter established that RhoJ is activated in ECs by the pro-angiogenic 
factor VEGFA. In addition, preliminary experiments indicated that FGF-2 and thrombin are 
also likely to activate RhoJ in these cells.  
Some active Rho GTPases can be pulled-down from cellular lysates and therefore their 
activation by various stimuli can be examined. Here, an assay was optimised to detect levels 
of active RhoJ in ECs using the CRIB motifs from proteins such as WASP and PAK, which 
were shown before to bind to active RhoJ (Vignal, De Toledo et al. 2000). Magnesium ions 
are crucial for maintaining the interaction between Rho GTPases and the guanine nucleotides. 
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The concentration required for this may vary for different family members (Paduch, Jelen et 
al. 2001), thus it was important to determine the level of magnesium in the lysis buffer that 
would preserve the nucleotide-bound RhoJ in cell lysates. It was found that RhoJ requires a 
higher Mg2+ concentration to lock GTPγS or GDP within the protein than Cdc42. This is 
likely to be due to differences in the amino acid sequences between these two Rho GTPases, 
which are responsible for nucleotide binding and magnesium ion coordination (Paduch, Jelen 
et al. 2001). 
Once this assay was optimised it was used to investigate the activation of RhoJ in ECs by pro-
angiogenic factors such as VEGFA, FGF-2 and thrombin. All of these stimuli activated RhoJ, 
however only treatment with VEGFA was repeated enough times to obtain statistical 
significance of this activation. It had been previously reported that VEGFA, which is a potent 
activator of angiogenesis, activates RhoA, Rac1 and Cdc42 in ECs and the kinetics of these 
activations vary (Lamalice, Houle et al. 2004; Garrett, Van Buul et al. 2007; Beckers, van 
Hinsbergh et al. 2010). The activation of Cdc42 and RhoA by VEGFA peaks at around 15 
minutes and declines thereafter. On the other hand, Rac1 activation peaks twice, first at 
around 5 minutes and again at around 30 minutes after VEGFA stimulation. The experiments 
performed here showed that RhoJ activation by VEGFA occurs with the second peak of Rac1 
activation as it is maximal at around 30 min and slowly declines thereafter.  
Interestingly, some studies showed that VEGFA activates Rac1 through its GEF, Vav2, and 
both Vav2 and Rac1 are required for VEGFA-induced EC migration (Soga, Connolly et al. 
2001; Garrett, Van Buul et al. 2007). Although it is not clear through which signalling 
pathway VEGFA activates RhoJ, it was shown that endothelial tubulogenesis is dependent on 
the presence of RhoJ in an organotypic assay (Kaur, Leszczynska et al. 2011), and in this 
assay this process strongly depends on the presence of VEGF and FGF-2 (Bishop, Bell et al. 
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1999). Thus it is possible that endogenous RhoJ is activated by VEGF or by FGF-2 to mediate 
EC migration and tubulogenesis. 
The preliminary experiments indicated that RhoJ can be activated not only downstream of 
RTKs such as VEGFR or FGF receptor but also by thrombin. This agonist binds to GPCRs 
such as PAR-1 and leads to their cleavage. This results in the activation of coupled 
heterotrimeric G-proteins and induction of their down-stream signalling (McLaughlin, Shen et 
al. 2005). It is known that thrombin initially inactivates Rac1 and induces RhoA activity, 
which results in increased cell contractility and permeability of the endothelial wall. However, 
prolonged stimulation with thrombin inhibits RhoA activity and increases levels of active 
Rac1 and Cdc42, which then signal to restore cellular junctions and endothelial barrier 
function (Vandenbroucke, Mehta et al. 2008). Since it was shown that RhoJ negatively 
regulates cell contractility (Kaur, Leszczynska et al. 2011), it is possible that RhoJ might be 
involved in thrombin-mediated recovery of the EC barrier. However, more experiments need 
to be performed, firstly to establish the kinetics of RhoJ activation by thrombin, and secondly 
to determine the physiological relevance of this activation. 
In summary, the data presented in this chapter demonstrated that pro-angiogenic factors such 
as VEGF, FGF-2 and thrombin activate RhoJ in ECs. Thus RhoJ may act downstream of pro-
angiogenic factors to regulate angiogenesis in vivo. 
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ECs are critical for the formation of new blood vessels, a process known as angiogenesis 
(Adams and Alitalo 2007). RhoJ was indicated by our group as a highly endothelial expressed 
Rho GTPase and has been implicated in EC movement, growth and tube formation, all 
processes crucial for angiogenesis (Herbert, Stekel et al. 2008; Kaur, Leszczynska et al. 
2011). Little was then known about the pathways and proteins that interact with RhoJ in ECs. 
Thus, the work presented in this thesis aimed to better understand the role of RhoJ in ECs by 
studying its intracellular localisation and function, determining its binding partners and testing 
the activation of RhoJ by pro-angiogenic stimuli.  
These studies for the first time characterised the localisation of endogenous RhoJ and showed 
that in ECs it is present in FAs. Previously, members of our laboratory had shown that RhoJ 
knock-down by siRNA impaired EC migration, tubulogenesis and increased actomyosin 
contractility and FA numbers (Kaur, Leszczynska et al. 2011). Here, overexpression of the 
dominant active RhoJ mutant resulted in the converse phenotype to that seen with RhoJ 
knock-down, thus reinforcing these roles of RhoJ in EC biology. In addition, it was 
demonstrated that VEGFA, FGF-2 and thrombin activate RhoJ in ECs, suggesting that RhoJ 
signals downstream of various cell surface receptors including RTKs or GPCRs. GIT1 and 
PIX proteins, which are known to regulate cell motility and FA turnover, were identified here 
as RhoJ-binding partners, thus providing a link between the localisation and function of RhoJ 
in ECs. This work focused on studying the relationship between RhoJ, βPIX and GIT1, 
however RhoJ could potentially interact with other members of GIT and PIX protein families 
and this should be taken into consideration in future experiments. The model presented in Fig. 
6.1 places RhoJ among the components of FAs and summarises the current understanding of 
its role in ECs. 
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Fig. 6.1 Localisation and function of RhoJ in ECs. 
A, The localisation of RhoJ to FAs largely depends on the presence of βPIX and partially on GIT1. 
RhoJ may interact with βPIX directly or through the interaction with GIT1 or another protein, e.g. 
PAK. B, The role of RhoJ has been studied via its siRNA knock-down (Sukhbir Kaur) or via 
overexpression of daRhoJ mutant. The loss of RhoJ in ECs caused an increase in actomyosin 
contractility and formation of FAs and SFs. This resulted in inhibited cell migration and tubulogenesis. 
On the other hand, overexpression of daRhoJ resulted in the converse phenotype. The proposed 
mechanism is via recruitment of the GIT1/βPIX complex to FAs, where it promotes FA disassembly 
and cell migration. This, in turn, is likely to negatively regulate actomyosin contractility. 
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The processes of SF formation and FA turnover are closely linked during cell migration. SF 
formation can increase the number and maturation of FAs and, conversely, disassembly of the 
latter can diminish actomyosin contractility. Reciprocal regulation of these two processes is 
crucial during directional cell migration (Parsons, Horwitz et al. 2010), and active RhoJ was 
shown to negatively regulate both FA and SF numbers in migrating ECs. However, the 
precise mechanism of this RhoJ function is not yet fully understood. Localisation to FAs and 
the binding partners, FA proteins GIT1 and βPIX, identified in this study lead to the 
hypothesis that RhoJ is a part of the machinery which regulates the dynamics of FAs, and this 
in turn would affect actomyosin contractility (Fig. 6.1 B). 
GIT1 and βPIX are known to form a tight complex which localises to FAs and promotes FA 
disassembly and cell migration (Manser, Huang et al. 1997; Manser, Loo et al. 1998; Zhao, 
Manser et al. 2000; Manabe, Kovalenko et al. 2002; Loo, Ng et al. 2004; Feng, Baird et al. 
2010). Although the exact mechanism of the interaction between RhoJ and this complex 
remains unresolved, it was demonstrated that RhoJ co-localises with these proteins in ECs and 
the presence of βPIX promotes the localisation of endogenous RhoJ to FAs. In addition, the 
role of RhoJ in the recruitment of GIT1 and βPIX to FAs has been demonstrated, as 
overexpression of daRhoJ increased the amount of these proteins in FAs. Thus, as a next step, 
it will be critical to establish whether the function of RhoJ in ECs is mediated via its 
interaction with the GIT1/βPIX complex. To address this question, ECs expressing daRhoJ 
could be treated with either βPIX- or GIT1-specific siRNAs. If daRhoJ promotes EC 
migration and decreases FA/SF numbers via interaction with the GIT1/βPIX complex, then 
knocking-down either βPIX or GIT1 in these cells should abrogate the effects of daRhoJ. It 
would be also crucial to prove that RhoJ binds directly to GIT1 or βPIX in ECs. This could be 
achieved using a fluorescence resonance energy transfer (FRET) technique, which allows the 
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detection of interactions between two molecules which are in the proximity of up to 10 nm 
(Ciruela 2008).   
Providing that the functions of the GIT1/βPIX complex and RhoJ are interdependent in ECs, 
it would be important to dissect in detail the mechanism and direct consequence of their 
interaction. Some studies indicated that binding of GIT1 to paxillin promotes FA disassembly 
and increases the rate of cell migration (Zhao, Manser et al. 2000; Manabe, Kovalenko et al. 
2002; Feng, Baird et al. 2010), and it was demonstrated here that daRhoJ also decreases FA 
numbers and promotes EC migration. The Y2H experiment showed that RhoJ can physically 
bind to GIT1 and it was hoped that mapping the GIT1 domain which binds RhoJ would help 
to elucidate the context of these interactions. This would also allow the design of a peptide or 
a dominant negative GIT1 mutant, which when introduced to ECs could disrupt the 
interaction between endogenous RhoJ and GIT1. However, the interaction between these 
proteins seems to be more complex in ECs. siRNA studies showed that although GIT1 plays 
some role in RhoJ localisation to FAs, its presence was not critical for this process, as GIT1 
knock-down only partially reduced the localisation of RhoJ to these structures. On the other 
hand, the knock-down of βPIX nearly abolished RhoJ localisation to FAs suggesting that, 
although not seen in a Y2H system, the interaction between RhoJ and βPIX may still occur in 
ECs. 
PIX proteins are known GEFs for Cdc42 and Rac1 (Rosenberger and Kutsche 2006), and 
since the interplay between RhoJ and βPIX was demonstrated in ECs, it is possible that βPIX 
acts as a GEF for RhoJ. A pilot experiment which tested the basal level of active RhoJ in ECs 
after βPIX knock-down was performed, but no decrease in steady state RhoJ activation was 
observed (data not shown). The GEF activity of βPIX can be enhanced by Src-mediated 
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phosphorylation (Feng, Baird et al. 2006), and it would be useful to determine if βPIX 
participates as a GEF in VEGF-, FGF-2- or thrombin-mediated activation of RhoJ.  
The GIT1/βPIX complex acts as a scaffold, which brings various proteins into close proximity 
(Frank and Hansen 2008). GIT1 is recruited to FAs via its c-terminal domain which directly 
binds to paxillin (Turner, Brown et al. 1999; Manabe, Kovalenko et al. 2002). βPIX, being a 
GEF, binds to Cdc42 and Rac1, as well as to their effector, PAK, which is known to promote 
EC motility (Galan Moya, Le Guelte et al. 2009). The interaction between RhoJ and PAK has 
not been investigated in these studies. Nevertheless, evidence suggests that the function of 
both proteins may overlap in ECs and others have demonstrated binding of daRhoJ to PAK in 
a Y2H assay (Vignal, De Toledo et al. 2000; Aspenstrom, Fransson et al. 2004). It was shown 
that the dominant active Cdc42 mutant increases the amount of βPIX in FAs, which then 
recruits PAK and leads to Rac1-dependent activation of PAK and subsequent loss of SFs and 
FAs (Manser, Huang et al. 1997; Manser, Loo et al. 1998). Since daRhoJ similarly potentiates 
the amount of βPIX in FAs, increased migration seen in ECs overexpressing daRhoJ may be 
caused by increased activity of PAK. 
Given that RhoJ was indicated as a component of FA complexes, it may be regulated by 
general signals which modulate the dynamics of these structures. Various factors, including 
integrin clustering or stimulation by growth factors, were shown to activate FAK and Src 
(Rodriguez-Fernandez 1999), and these kinases are crucial for cell migration and FA 
disassembly (Tomar and Schlaepfer 2009). Some studies showed that GIT1 can directly bind 
to FAK (Zhao, Manser et al. 2000), and when phosphorylated in a FAK and Src dependent 
manner GIT1 facilitates FA disassembly (van Nieuw Amerongen, Natarajan et al. 2004). In 
addition, FAK recruits and participates in activation of various GAPs and GEFs, which in turn 
control the activity of RhoA and Rac1, and therefore regulate cell migration (Tomar and 
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Schlaepfer 2009). If GIT1 or PIX bring RhoJ to the close proximity of FAK, conceivably 
RhoJ could be a substrate of FAK-recruited GAPs and GEFs. Thus, it would be important to 
explore a potential interaction of RhoJ with FA components other than βPIX and GIT1. 
The overexpression of RhoJ clearly drives its localisation not only to FAs, but also to the 
plasma membrane and endosomal, lysosomal and other intracellular vesicles. Furthermore, 
the involvement of endogenous RhoJ in Tf recycling to the plasma membrane and its release 
in ECs has been demonstrated, thus indicating that RhoJ might play a role in endocytic 
pathways in ECs. Various studies showed that components of disassembling FAs such as 
paxillin, βPIX, GIT1 and PAK are firstly internalised, and then recycled to the plasma 
membrane, where they eventually join the newly forming FAs (Di Cesare, Paris et al. 2000; 
Matafora, Paris et al. 2001; Manabe, Kovalenko et al. 2002). In some cases, these complexes 
traffick through endosomes (Di Cesare, Paris et al. 2000; Matafora, Paris et al. 2001), while in 
other cases they are recycled through undefined cytoplasmic punctate structures (Manabe, 
Kovalenko et al. 2002). Although the staining of endogenous RhoJ indicated its localisation to 
FAs it cannot be excluded that under certain conditions this protein may also be found in 
intracellular vesicles. It is possible that RhoJ may co-localise with GIT1/βPIX containing 
cytoplasmic complexes and further detailed analyses are required to test this hypothesis. 
Although GIT1 expression is not specific to ECs, some studies indicated its importance in the 
vasculature. The knock-out of this gene in mice caused severe malformation of pulmonary 
vasculature, observed as a pronounced reduction of pulmonary blood vessel numbers and an 
increase of alveolar spaces (Pang, Hoefen et al. 2009). It would be interesting to examine 
whether ECs isolated from GIT1-/- mice would migrate at normal speed and whether 
overexpression of daRhoJ would affect migration and FA/SF dynamics in these cells. This 
would additionally test interdependence between RhoJ and GIT1 function. 
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Another study by Wang and colleagues showed that GIT1 mediates VEGF-induced formation 
of podosomes in ECs (Wang, Taba et al. 2009). These actin-rich structures are a distinct type 
of adhesions, important in highly motile cells (Albiges-Rizo, Destaing et al. 2009). 
Interestingly, Billottet et al. tested the influence of activated Rho GTPases on podosome 
formation in ECs and found that overexpression of the daRhoJ mutant induced development 
of these adhesion structures (Billottet, Rottiers et al. 2008). Since VEGF was shown to 
activate RhoJ in ECs it would be important to verify if RhoJ participates in VEGF/GIT1 
mediated podosome formation. Wang et al. (2009) also demonstrated that GIT1 knock-down 
strongly inhibited EC migration in a scratch wound assay, and a similar effect was seen with 
RhoJ knock-down (Kaur, Leszczynska et al. 2011). This supports the hypothesis that RhoJ 
and GIT1 may be involved in the same signalling pathway in ECs. 
RhoJ knock-down and overexpression of daRhoJ indicated that this Rho GTPase negatively 
regulates EC contractility (Kaur, Leszczynska et al. 2011). As mentioned before, this might be 
a consequence of reduced FA numbers. Alternatively, RhoJ may directly regulate a signalling 
pathway which controls actomyosin contractile forces. Nishizuka and colleagues (2003) 
screened for genes which were up-regulated in NIH-3T3 mouse fibroblasts stably 
overexpressing RhoJ. They found that overexpression of RhoJ increased the level of another 
Rho GTPase, RhoE, and RhoE is known to negatively regulate SFs and cell contractility by 
activating p190RhoGAP, which inactivates RhoA (Wennerberg, Forget et al. 2003) or by 
directly binding to and inhibiting the RhoA effector ROCK I (Riento, Guasch et al. 2003). If, 
similarly, RhoJ up-regulates RhoE expression in ECs, then it may negatively regulate 
actomyosin contractility and therefore facilitate EC migration via RhoE. Nonetheless, RhoJ 
may reduce cell contractility through various signalling pathways and its exact role in this 
mechanism needs to be determined. 
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So far, the importance of RhoJ function was elucidated in ECs in vitro, however its role in 
vivo remains uncertain. It has been demonstrated that daRhoJ enhanced EC sprouting in an 
organotypic assay (Kaur, Leszczynska et al. 2011). Furthermore, active RhoJ down-regulated 
the number of SFs and FAs particularly in highly motile ECs situated at the leading edge of a 
scratch. These observations suggest that RhoJ may play a particular role in the tip cells of 
sprouting capillaries. Generation of RhoJ knock-out mouse model would help to identify in 
vivo function of RhoJ. 
RhoJ is also expressed in ECs of already established blood vessels, as shown by in situ 
hybridisation on human tissue sections (Kaur, Leszczynska et al. 2011). Quiescent ECs lining 
the wall of blood vessel, provide a semi-permeable barrier which allows the exchange of 
various metabolites or trespassing of other cells to the adjacent tissues (Bogatcheva and Verin 
2008). The integrity of the endothelial wall is maintained by the cortical actin, which forms a 
ring of filaments connecting cell-cell adhesions and FAs. The induction of cell permeability 
causes RhoA-mediated formation of SFs and temporary disorganisation of cortical actin and 
cell-cell junctions (Bogatcheva and Verin 2008). It was shown that GIT1 is recruited to FAs 
and reverses thrombin-induced and RhoA-dependent contractility of ECs, suggesting that it 
plays a role in the recovery of the endothelial barrier function (van Nieuw Amerongen, 
Natarajan et al. 2004). It was demonstrated here that thrombin can activate RhoJ in ECs and 
that the daRhoJ mutant both enhances the localisation of GIT1 to FAs and negatively 
regulates EC contractility. Thus, it might be possible that these proteins act together to 
regulate the permeability of established blood vessels, but the link between RhoJ and GIT1 in 
this process needs to be examined. 
In summary, the work presented in this thesis provides information on endogenous 
localisation, function, and binding partners of RhoJ in ECs. These data support the hypothesis 
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that RhoJ is an important player in ECs. They demonstrate its activation by pro-angiogenic 
stimuli. They also demonstrate FA localisation, a role in FA turnover and actomyosin 
contractility and interaction with the FA proteins GIT1 and βPIX, proteins also involved in 
FA turnover. These findings form the basis for a potential mechanism of RhoJ action in EC 
migration. They contribute to our fundamental understanding of EC behaviour and biology 
and form the basis for future studies which will more precisely determine the mechanism of 
RhoJ function. 
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